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Macrolide antibiotics are clinically important drugs widely used to treat 
the infections caused by gram-positive bacteria.  They consist of a macrolactone 
aglycone unit and one or more deoxy sugar component(s).  The presence of an at 
least one deoxy sugar moiety in the structure of macrolides is essential for their 
antimicrobial activity.  Modifications of the deoxy sugar substituent hold promise 
as a valuable approach towards generating new macrolide antibiotics with 
improved biological properties.  The development of new antimicrobial drugs is 
essential to combat the growing problem of the pathogen resistance to the existing 
antibiotics. 
This thesis describes a part of our ongoing effort to investigate the 
mechanistic details of the biosynthetic pathway to D-desosamine, an amino deoxy 
 xi
sugar component of macrolide antibiotics methymycin, neomethymycin, 
pikromycin, and narbomycin produced by Streptomyces venezuelae.  D-
Desosamine also exists in many other clinically important macrolides, e.g. 
erythromycin, clarithromycin, and oleandomycin.  In particular, the gene 
knockout technique was used to explore the functions of the desI, desII, and 
desVIII genes of the D-desosamine biosynthetic gene cluster.  The analysis of the 
macrolides produced by the resulting S. venezuelae mutants has led to the revision 
of the originally proposed pathway to desosamine.  A new mechanism for the C-4 
deoxygenation step was also envisioned.  Four new macrolides were isolated in 
these studies, which established the relaxed substrate specificity of the glycosyl-
transferase DesVII involved in the coupling of TDP-sugar derivatives to the 
aglycone in the pathway. 
To further explore the potential of DesVII to couple various sugar and 
aglycone substrates, desVII was expressed in E. coli and the recombinant DesVII 
protein was used to study the in vitro glycosyltransferase activity.  Our results 
demonstrate that DesVII requires an additional protein component, DesVIII, to 
perform the catalysis, and the activity is optimal at pH 9.  These conditions, 
unusual for the known glycosyl transfer reactions, may prove to be the general 
requirements for other macrolide glycosyltransferases.  The preliminary study of 
the substrate specificity of the DesVII/DesVIII catalytic pair was conducted in 
vitro and showed the potential for their application to glycosylation in 
combinatorial biosynthesis. 
 xii
The mechanism of the self-resistance in S. venezuelae via glycosylation-
deglycosylation was also studied.  The gene encoding the resistance glycosyl-
transferase DesG was identified in the genome of S. venezuelae.  It was later 
expressed in E. coli and the DesG protein was purified.  The substrate specificity 
of DesG was found to be relatively relaxed. 
Overall, this study provides significant insights into the biosynthesis of 
macrolides by Streptomyces.  It has also demonstrated the feasibility of preparing 
novel compounds using genetic manipulations of the biosynthetic machinery.  
The discovery of DesVIII as an essential component in the glycosyl transfer 
catalyzed by DesVII resulted in the first successful reconstitution of a macrolide 
glycosyltransferase activity in vitro.  This work is an important step towards the 
creation of tailored macrolide antibiotics using “unnatural” sugar substrates and 
glycosyltransferases. 
 xiii
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 1
Chapter 1: Introduction: Macrolide Antibiotics 
1.1 MACROLIDE ANTIBIOTICS: THEIR ORIGIN AND MODE OF ACTION 
The term “macrolide” was first introduced by Woodward1 to define 
natural products which contain a 12- to 16-membered macrocyclic lactone ring.  
The macrolactone ring of a macrolide has been referred to as aglycone and is 
often decorated with one or more deoxy and/or amino sugars.  While the original 
term “macrolide” is reserved for compounds containing no nitrogen atoms as part 
of the macrolactone ring, it has now been broadened to include semisynthetic 
nitrogen-containing antibiotics, such as azithromycin (10, Figure 1-1), and 
polyene and streptogramin antibiotics.  A few representatives of macrolide 
antibiotics are shown in Figures 1-1 and 1-2.  The vast majority of macrolide 
antibiotics are produced by various species of Streptomyces, but examples are 
known that are generated by other actinomycetes, such as Micromonospora 
megalomicea (megalomycins).  There are also cases in which the same antibiotic 
is produced by different Streptomyces species.  Macrolide antibiotics are 
preferentially active against gram-positive bacteria, such as Staphylococcus and 
Streptococcus.  They possess only limited activity against gram-negative bacteria, 
mainly gram-negative cocci, such as Neisseria gonorroheae and Haemophilus 
influenzae.   
The first macrolide antibiotic isolated and partially chemically 
characterized is pikromycin (4).2  The isolation of methymycin (1) was reported 
in 1954.3  It became the first macrolide for which the structure was determined.4  
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Macrolides are classified according to the size of the lactone ring.  Methymycin 
(1), together with neomethymycin (2) and 10-deoxymethymycin (3, or YC-17), 
are the only naturally occurring 12-membered ring macrolides known, but they 
have not been used clinically.  In contrast, the more prevalent 14- and 16-
membered ring macrolides have been widely used and extensively studied.  Of 
particular interest are the antibiotics of the erythromycin family.  Erythromycin A 
(6) is the first clinically used macrolide which was launched as a drug in 1952.5  It 
is still being used for treatment of bacterial infections because of its low cost, 
effectiveness, and low toxicity.  A number of semisynthetic macrolides derived 
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Figure 1-1: Examples of 12-, 14-, and 15-membered ring macrolides. 
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developed, such as clarithromycin (7), roxithromycin (8), and the 15-membered 
ring azithromycin (10).  Other clinically useful antibiotics include oleandomycin 
(9), midecamycin A1 (11), and spiramycin (12).  Tylosin (13) is widely used in 
the veterinary field. 
Macrolide antibiotics selectively inhibit protein synthesis in prokaryotes.  
The observed selectivity is due to the differences in the eukaryotic and 


















































































Figure 1-2: Examples of 16-memberd ring macrolide antibiotics. 
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peptide exit tunnel, preventing the extension of the nascent peptide from the 
peptidyl transferase center.  The general location of the macrolide binding site on 
the large ribosomal subunit 50S was initially determined using biochemical and 
genetic methods.6-8 
Recently, results obtained from several crystal structure studies have 
provided more details of the macrolide-ribosome interactions.9, 10  These include 
the complexes of the 50S ribosomal subunit of the eubacterium (Deinococcus 
radiodurans) with 14-membered erythromycin (6) and its analogs, clarithromycin 
(7) and roxithromycin (8).9  The structures of the 50S ribosomal subunit of the 
archaeon (Haloarcula marismortui) with 15-membered azithromycin (10) and 16-
membered spiramycin (12), tylosin (13), and carbomycin A (14) were also 
solved.10  These structures are generally similar, and clearly reveal that the 
binding of macrolides to the polypeptide exit tunnel of the 50S subunit occurs 
predominantly through the contact with the 23S ribosomal RNA.  In the case of 
the 16-membered macrolides, a covalent bond is formed between the aldehyde 
moiety and the 6-N of A2103 (H. marismortui, corresponds to A2062 in 
Escherichia coli).10  These studies also showed that most of the binding 
interactions of macrolides with a ribosome arise from the contacts of their sugar 
substituents.10  It should be noted that all seven macrolides used in the crystal 
studies contain a dimethylamino hexose (desosamine or mycaminose) at the C-5 
position of each aglycone.  The mycaminose is further glycosylated with 
mycarose in the 16-membered macrolides shown in Figure 1-2.  Additional deoxy 
sugar residues are present at C-3 of erythromycin, clarithromycin, roxithromycin, 
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and azithromycin (cladinose), at C-9 of spiramycin (dimethylforosamine), and at 
C-14 of tylosin (mycinose).  These sugars are important for the biological activity 
of each macrolide.11-15  Particularly, the dimethylamino hexose moiety in each 
structure is indispensable for the antibacterial activity of the parent compound, 
although the neutral deoxy sugars, e.g. cladinose in erythromycin, are less 
essential.16 
The conserved feature of the crystal structures of all seven macrolide-
ribosome complexes is a hydrogen bonding interaction between the 2´-OH of 
desosamine, or that of mycaminose, and N-1 of A2058 (the E. coli numbering 
system).9, 10  The complexes with D. radiodurans 23S rRNA have additional 
hydrogen bonds between 2´-OH of desosamine and the 6-NH2 of A2058 and the 
6-NH2 of A2059.9  Modifications of these rRNA residues have been implicated in 
resistance mechanisms (see below).  Hydrophobic and hydrogen bonding 
interactions are also observed between the mycinose sugar of tylosin and the 
dimethylforosamine of spiramycin and ribosomal proteins L22 and L4, providing 
some structural evidence for an alternative resistance mechanism which has been 
suggested through mutations of these proteins.10 
Interestingly, the X-ray crystal structures also show that the disaccharide 
moiety at C-5 of the 16-membered macrolides extends further into the exit tunnel 
toward the peptidyl transferase center than the monosaccharide appendage 
attached at the same position of other macrolides.10  In fact, the length of this 
saccharide (di or mono) side chain directly correlates with the length of the short 
peptides generated by a ribosome in the presence of macrolides: the more the 
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sugar chain extends into the exit tunnel, the shorter the peptide that is produced by 
the ribosome.10  Thus, the analysis of the crystal structure data has provided 
significant insight into not only the macrolides’ mode of action, but also the 
resistance mechanisms developed by pathogens to neutralize the effects of these 
clinically useful drugs. 
1.2 RESISTANCE TO MACROLIDE ANTIBIOTICS 
 After a new antibiotic is introduced, sooner or later the targeted organisms 
will develop a resistance to it.  Recent efforts to combat the emergence of 
antibiotic-resistant bacteria mark a new level of humans’ struggle with infectious 
diseases.17, 18  It has been demonstrated that bacterial antibiotic resistance arises 
under the evolutionary pressure for survival, and once it appears in one strain, it 
can quickly spread to others.5  This is because the resistance determinants 
(resistance genes) found in pathogens are predominantly located in plasmids, 
which are easily transferred from one bacterium to another, as well as between 
strains.19   
 Three major resistance mechanisms have been identified in pathogenic 
bacteria: (i) drug efflux from the cell, (ii) target modification, and (iii) inactivation 
of the antibiotic.  Mechanisms (i) and (ii) are the most common strategies adapted 
by gram-positive pathogens to fight against macrolide antibiotics.20  In fact, most 
antibiotic-producing species utilize one or more of these mechanisms to protect 
themselves from intoxication from their own metabolites.  It has been suggested 
that antibiotic producing species might be the source of at least some of the 
resistance determinants found in the pathogens with an acquired resistance.21   
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1.2.1 Drug Efflux 
Since the protein biosynthetic machinery is located in the cytoplasm, 
macrolides have to pass through the cell membrane in order to reach their target.  
A sufficient amount of the macrolide also needs to accumulate within the cell to 
achieve its effective concentration.  Drug efflux can prevent the buildup of the 
intracellular concentration of the antibiotic, rendering the compound ineffective 
against its target.22  Efflux pumps are found in all kinds of bacteria and are used to 
transport molecules through the membrane into and out of the cell.  An active 
efflux using ATP-binding cassette (ABC) transporters has been reported as an 
effective means for self-resistance by the tylosin producer Streptomyces fradiae,23, 
24 the oleandomycin producer Streptomyces antibioticus,25, 26 and a number of 
other antibiotic-producing organisms.27  Several pathogens exploit efflux pumps 
to confer resistance to multiple antibacterials, including macrolides.28  Recently, 
the resistance to 14- and 15-membered macrolides was found to be based on the 
ABC transporter system in Staphylococcus aureus.29  An important macrolide 
resistance mechanism in a number of Streptococcus pneumoniae strains relies on 
the efflux pumps of a major facilitator superfamily (MFS).30 
1.2.2 Target Modification 
Perhaps the best-studied mechanism of macrolide resistance is the 
modification of drug binding sites in the ribosome.  The mono- or dimethylation 
at the C-6 amino group of A2058 of 23S rRNA by a dedicated N-
methyltransferase (Erm, erythromycin resistance methylase) is the “defense of 
choice” for a growing number of bacteria.31  The first clinical isolates of 
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macrolide-resistant staphylococci, found shortly after the introduction of 
erythromycin, exhibited drug resistance based on such a post-translational 
modification of rRNA.32  Interestingly, the macrolide antibiotics bind to the same 
target site on the ribosome as the structurally distinct antibiotics of lincosamide 
and streptogramin B families.  Therefore, a site-specific methylation of rRNA 
usually confers cross-resistance to these three classes of drugs, and is often 
referred to as MLSB resistance. 
Examining the crystal structure of the 50S ribosomal subunit showed that 
the residue modified by Erm is located in close proximity to the peptidyl 
transferase loop.33  This finding links the mutation, causing the macrolide 
resistance, to the action of the antibiotic as an inhibitor to block the early steps in 
protein synthesis.  As mentioned before, the crystal structure of the complexes of 
the 50S ribosomal subunit with several macrolides also revealed that the 6-N of 
A2058 is involved in hydrogen bonding with the desosamine moiety of 
macrolides.9.  Thus, dimethylation of the 6-N group not only adds a bulky 
substituents causing steric hindrance for the binding, but also prevents the 
formation of hydrogen bonds to the 2´-OH group of desosamine.9 
 The methylation of rRNA has also been shown to confer cellular self-
protection to the producers of erythromycin (Saccharopolyspora erythraea),34, 35 
tylosin (S. fradiae),36, 37 and carbomycin (Streptomyces thermotolerans).38  The 
species employing this strategy usually exhibit MLSB phenotype, i.e. they are 
resistant not only to the antibiotic they produce, but to other MLSB drugs as well. 
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The MLSB resistance can be constitutive if the production of active 
methyltransferase mRNA is independent of an inducer (antibiotic).  It can also be 
inducible if activation of the erm mRNA (and therefore Erm production) occurs 
only in the presence of an antibiotic.39  The latter type is more common for 
pathogens, in which the inducible resistance mechanism is turned on when an 
antibiotic of the MLSB family stalls the translation of the mRNA fragment 
preceding the erm sequence.  It is worth noting that the erm mRNA is normally 
present in the inactive conformation.  The stalling of the translation of the 
upstream mRNA region by an antibiotic causes its rearrangement into an active 
conformation.  This allows the translation of the erm gene into N-
methyltransferase Erm.40, 41 
There exists an alternative resistance mechanism by target modification in 
some pathogens, in which A2058 of the 23S rRNA is replaced by cytosine, 
guanosine, or uracil.42  The neighbors of A2058 may also be mutated, e.g. 
G2057A and A2059G, in some cases.  This strategy is often observed in species 
containing only a few copies (one or two) of 23S rRNA genes, such as 
Helicobacter pyroli and Mycobacterium species, whereas methylation of rRNA 
discussed earlier is the predominant strategy in bacteria carrying multiple 23S 
rRNA genes.42  The crystal structures of the complexes of the 50S RNA subunit 
with different macrolides show that perturbations at these residues would impair 
the binding of antibiotics.9, 10  The position corresponding to A2058 is occupied 
by guanosine in the rRNA of higher eukaryotes, and this could contribute to the 
selectivity of macrolides to bacterial ribosomes.9 
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Mutations of ribosomal proteins, most often L4 and L22, conferring 
erythromycin resistance are reported in E. coli,31 and more recently, in clinical 
isolates of S. pneumoniae.43  The proteins L4 and L22 constitute the constriction 
of the polypeptide exit tunnel.  The amino acid residues mutated in the macrolide 
resistant strains are usually located in the highly conserved regions of the 
proteins.  The role of these mutations in the macrolide resistance might be 
attributed to their indirect involvement in the local rearrangements of 23S rRNA 
as the result of amino acid sequence changes.9  However, the interactions between 
mycinose of tylosin with L22 and dimethylforosamine of spiramycin with L4 are 
clearly discernible in crystal structures of the complexes of macrolides with the 
50S ribosomal subunit and might be of some significance for drug binding.10 
 Recently, a new macrolide resistance mechanism was discovered in 
E. coli.44  It was found that treatment with macrolides may induce the expression 
of specific short peptides of 4-6 amino acids.  These peptides may then interact 
with the macrolide molecule bound to the ribosome, causing its displacement 
from the binding site – a “bottle brush” model.45  A similar model is also possible 
in S. aureus,46 but is yet to be confirmed in clinical isolates of pathogens.  The 
details of this resistance mechanism remain elusive. 
1.2.3 Inactivation of Antibiotic 
 A number of resistance mechanisms rely on enzyme-mediated inactivation 
of the drug.  Unlike the two strategies described above, inactivation of the 
antibiotic confers resistance to structurally related compounds only.  Several 
strains of Enterobacteriaceae, e.g. E. coli strains, reportedly produce 
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erythromycin esterase which catalyze lactone ring cleavage47 and macrolide 2´-
phosphotransferase I,48 which target 14- but not 16-membered macrolides.  On the 
other hand, both 14- and 16-membered macrolides can be phosphorylated by 2´-
phosphotransferase II of E. coli.49 
 The presence of a macrolide glycosyltransferase activity in actinomycetes 
not producing macrolides has been reported in a number of cases and constitutes 
these species’ resistance strategy.  For example, Streptomyces vendargensis and 
Streptomyces lividans, which themselves do not produce any macrolides, are 
capable of inactivating erythromycin A by glycosylating the desosamine moiety at 
the 2'-OH position with a glucopyranose residue.50-52 
Until recently, this type of mechanism was found only in non-pathogenic 
species (e.g. Streptomyces), or in bacteria not targeted by macrolides 
(Enterobacteriaceae species are not considered to be a good target for 
macrolides).  However, pathogens employing macrolide inactivation as a defense 
mechanism were discovered recently.  It now appears that the resistance of most 
pathogenic Nocardia species to macrolides is due to the antibiotic inactivation via 
2´-phosphorylation, reduction of a formyl group of macrolactone (e.g. in 
midecamycin, 11), deacylation (the removal of the acyl group from the 4´´ 
position of the sugar moiety by an esterase, e.g. in midecamycin, 11), or 
glycosylation at the 2´-OH of the sugar residue.53, 54 
The gene encoding macrolide 2´-phosphotransferase II was recently found 
in the plasmid of a clinically isolated S. aureus strain.55  This plasmid also 
contains two other resistance genes: msrA, which encodes protein of an active 
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efflux pump, and erm, which encodes a methyltransferase that modifies an 
adenine residue of 23S rRNA.  Therefore, this strain possesses a collection of all 
of the three major resistance tools on a single mobile plasmid.  A presence of 
more than one (usually two) resistance machinery is not uncommon, and has been 
reported in macrolide-resistant enterobacteria56 and staphylococci.57, 58 
 A self-resistance mechanism involving the modification of macrolides has 
also been observed in many macrolide-producing organisms.  In particular, 
glycosylation of macrolides to neutralize their biological activity has been 
detected in 15 out of a total of 32 actinomycete strains producing various 
polyketide antibiotics.59  Interestingly, S. antibioticus, the oleandomycin 
producing strain, possesses not only the glycosyltransferase activity that 
inactivates oleandomycin via glycosylation, but also an extracellular β-
glucosidase activity capable of removing the added glucose from the modified 
inactive drug.60-62  It is thus apparent that S. antibioticus utilizes the glycosylation-
deglycosylation of oleandomycin as a self-resistance mechanism.63 
 Similar to pathogens, more than one of the above mechanisms is often 
utilized by macrolide-producing strains for self-protection.  This is exemplified by 
the tylosin producer, S. fradiae, employing all of the above strategies: methylation 
of 23S rRNA,36, 37 active efflux,23 and inactivation of tylosin, presumably through 
its methylation.64 
1.3 BIOSYNTHESIS OF MACROLIDE ANTIBIOTICS 
Macrolide antibiotics consist of a cyclic aglycone of polyketide nature 
decorated with one or more deoxy sugar moieties.  It is generally believed that the 
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polyketide chain is formed and cyclized first, followed by the attachment of sugar 
residues, and further modifications of both the aglycone core (e.g. hydroxylation) 
and sugars (e.g. methylation).  These three stages of macrolide biosynthesis will 
be discussed in the following sections. 
1.3.1 Biosynthesis of Aglycone by Modular Polyketide Synthase 
The aglycone of a macrolide is an aliphatic polyketide generated by 
consecutive condensations of two- or three-carbon units.  The resulting β-keto 
ester after each condensation can be further modified to a β-hydroxy ester, an 
α,β-unsaturated ester, or a fully reduced unit (Figure 1-3).  The macrolactone is 
biosynthesized by the action of type I polyketide synthases (PKSs), also known as 
PKS I or modular PKS.  PKSs are usually large protein molecules (approximately 
300 kDa and higher) consisting of one or more modules, where each module is a 
functional element responsible for the incorporation and further modification of a 
single unit of the growing polyketide chain.  Each module in turn consists of a 
few catalytic domains, each responsible for a single chemical transformation.  The 
growing polyketide chain is transferred from one module to another, extended by 


















Figure 1-3. General structures of polyketide units: polyketone condensation 
product and its reduced derivatives.  The catalytic domains 
responsible for the modifications of polyketone, β-ketoreductase 
(KR), dehydratase (DH), and enoyl reductase (ER), are discussed in 
text. 
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reminiscent of a conveyor assembly.  The number of modules determines the size 
of the macrolide.  The heptaketide of erythromycin is biosynthesized by three 
PKSs: DEBS1 (containing a loading module and modules 1 and 2), DEBS2 
(containing modules 3 and 4), and DEBS3 (containing modules 5 and 6), a total of 
seven modules altogether. 
This process of polyketide biosynthesis by modular PKS was first revealed 
after the discovery of the modular organization of the genes responsible for 
erythromycin biosynthesis in S. erythraea.65, 66  It is now accepted as a universal 
strategy for the biosynthesis of all macrolides by modular PKSs.  In recent years 
significant progress has been made in the understanding of the mechanistic details 
of individual steps.67-71 
The first step of polyketide synthesis is to prime the loading domain.  Each 





























































Figure 1-4: Activation of ACP domain by PPTase (A) and chain initiation by 
AT0 of the loading domain (B). 
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which needs to be converted to its active holo form.  Specifically, a serine residue 
of the ACP domain is modified with the phosphopantetheine (Ppant) group 
derived from coenzyme A (CoA) by the action of phosphopantetheinyl transferase 
(PPTase) (Figure 1-4 A).  The primary thiol group of Ppant will then be acylated 
with the monomers of the polyketide chain. 
 The next step is executed by the loading module of PKS consisting of only 
two domains: acyl transferase (AT) AT0 and ACP0.  In the case of 6-
deoxyerythronolide B, AT0 catalyzes the acylation of the Ppant thiol group of 
ACP0 with a propionyl group using propionyl-CoA (Figure 1-4 B).  The action of 
AT0 is highly specific to ensure the loading of the appropriate ACP domain with 
the correct acyl moiety. 
 The initiation is followed by a series of elongation steps.  For each step, 







































Figure 1-5: Elongation of polyketide chain.  Propionyl starting unit is shown 
attached to ACP0 (or ACPn-1 in general case); malonyl and (2S)-
methylmalonyl units are shown as acceptors at ACPn and ACPn+1, 
respectively. 
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malonyl moiety derived from methylmalonyl- or malonyl-CoA, respectively.  The 
condensation of the two monomers, one from the donor ACPn-1 and another from 
the acceptor ACPn, is carried out by the ketosynthase (KS) domain.  The acyl 
moiety of ACPn-1 is first transferred to the catalytic cysteine of the KSn domain.  
KSn then decarboxylates methylmalonyl of ACPn, generating a carbanion, which 
in turn attacks the acyl moiety on KSn resulting in the translocation of the 
extended chain to ACPn (Figure 1-5).  ACPn now becomes the source of the donor 
monomer in the next cycle and the process is repeated as many times as needed. 
 Once the linear polyketide reaches the ACP domain of the last module, the 
chain termination takes place.  The polyketide is transferred to a specific serine of 
the thioesterase (TE) domain located downstream of ACP, and the thioester is 
converted into an acylester.  A subsequent nucleophilic attack by the proper 




























Figure 1-6: Chain termination: example of 6-deoxyerythronolide B biosynthesis.
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polyketide chain leads to the cyclization of the linear product, which is then 
released as the macrolactone (Figure 1-6). 
 There are many ways in which the great diversity of macrolide structures 
is achieved by PKS I.  A number of acyl starter units can be used for the chain 
initiation step, including acetyl, propionyl, malonyl, methylmalonyl, and butyryl 
groups.  The units used for the chain elongation are less diverse and are usually 
malonyl- or methylmalonyl-CoA (2S-methylmalonyl-CoA in case of 15).  A final 
tailor-made polyketide is produced due to the strict specificity of each AT domain 
for the acyl moiety and the ACP acceptor.  The KS domains also show high 
selectivity for donor and acceptor ACP domains, accounting for the high fidelity 
of chain transfer between modules.  The inter-modular peptide regions (or linkers) 
within a single PKS and between separate PKS proteins are also known to 
contribute to the precise biosynthesis of the final product.72, 73 
Further diversity is achieved when a minimal PKS (KS, AT, ACP) is 
furnished with one, two or three additional catalytic domains: β-ketoreductase 
(KR), dehydratase (DH), and enoyl reductase (ER) (Figure 1-3).  The KRn domain 
stereospecifically reduces the C-3 ketone group of acyl-Ppant-ACPn to the 
corresponding β-hydroxy ester using NADPH.  It also controls the 
stereochemistry of the methyl group at the C-2 of the acyl moiety (when 
methylmalonyl unit is incorporated) by accepting only one epimer as the 
substrate.  In the absence of other domains, the β-hydroxyl group generated by 
KR will be incorporated into the final polyketide.  Alternatively, the hydroxyl 
group can be eliminated by the action of the DHn domain, and this dehydration is 
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induced by the abstraction of the acidic α-proton of the acyl moiety.  The 
resulting αβ-enoyl-Ppant-ACPn can be further reduced by the ERn domain via a 
hydride addition using reduced flavin coenzyme, FADH–, to form a fully 
saturated unit.  The presence/absence of these sequentially acting domains in any 
of the elongation modules will determine the functionalities of the corresponding 
unit in the final polyketide product. 
Perhaps the best studied PKS-catalyzed synthesis is the biosynthesis of 
erythromycin aglycone, 6-deoxyerythronolide B (15), by three DEBS (6-
deoxyerythronolide B synthase) proteins (Figure 1-7).68, 71, 74, 75 (pp. 186-191)  
Each molecule of 15 is derived from coupling of one propionyl-CoA (starter unit) 
and six (2S)-methylmalonyl-CoA molecules in six elongation cycles.  In addition 
to the minimal PKS domains (KS, AT, ACP), module 4 contains DH, ER, and KR 
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Figure 1-7: The biosynthesis of 6-deoxyerythronolide B by DEBS. 
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methylene unit (C-7 in the final polyketide).  On the other hand, each of the 
modules 1, 2, 5, and 6, contains an additional KR domain, and therefore the keto 
group generated in cycles 1, 2, 5, and 6, is only reduced to a hydroxyl 
functionality (at C-3, 5, 11, and 13), with the specific stereochemistry controlled 
by KR.  Module 3 is a minimal PKS, and consequently the carbonyl group is 
preserved in the final product (C-9).  Six methyl groups at C-2, 4, 6, 8, 10, and 12 
are derived from methyl malonyl extension units.  The stereochemistry at these 
positions is thought to be determined by both the presence/absence of an 
epimerase activity in the corresponding KS domains and the stereoselectivity of 
the downstream KR domain for the specific epimer at C-2.68, 76, 77  Finally, TE at 
the C-terminus of module 6 catalyzes the cyclization of the linear polyketide by 
an attack of the C-13 hydroxyl group at C-1 of the thioester.  The release of 15 
from PKS frees TE for the next cyclization. 
Based on the structural studies of separate DEBS domains, a model for the 
three-dimensional structure of the DEBS complex has been proposed.70, 78  
According to this model, two identical PKS subunits comprised of linear 
sequences of domains are associated head-to-head and tail-to-tail and twisted in a 
helical conformation.  The core of the helix is formed by KS, AT and ACP 
domains, with optional domains (KR, DH, ER) looping out.  In such an 
arrangement, the flexible Ppant linker acts as a “swinging arm”, delivering the 
attached acyl moiety to the corresponding catalytic domains for additional 
reductive modifications.  This model is mainly based on the observation that 
when isolated individually, KS, AT, and TE domains are homodimers, and 
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reductive domains (KR, DH, ER) are monomers.  It has also been suggested that 
the two successive PKS homodimers, e.g. DEBS1 and DEBS2, interact with each 
other through complementary ‘docking domains’ (at the C-terminus of DEBS1 
and N-terminus of DEBS2),79 facilitating the ordered transfer of the growing 
polyketide chain between the ACP and KS domains of the two proteins and 
maintaining the continuity of the DEBS complex.70, 80 
Alternative models for the three-dimensional structure of DEBS have been 
proposed, e.g. involving head-to-tail homodimerization of DEBS.81  There is no 
direct evidence confirming or ruling out any of the models considered, however, 
the head-to-head model appears to be the most plausible one.68  To this moment, 
the only crystal structures available are those of the TE domains of DEBS and 
pikromycin PKS (PIKS, also referred to as PICS), revealing such common 
features as “same protein fold, an open substrate channel and a hydrophobic 
dimer interface”.82, 83 
This example of the biosynthesis of 15 by DEBS illustrates how the size 
of the polyketide product and its functional groups can be predicted from the 
domain composition of the PKS (or from the corresponding DNA sequence) 
responsible for its biosynthesis.  However, the polyketide product itself exhibits 
little or no biological activity and has to be further derivatized, most importantly 
by glycosylation, in several post-PKS steps.  The genes encoding PKS proteins 
are clustered and are flanked by genes for the biosynthesis and attachment of 
deoxy sugar(s), genes for other post-PKS modifications, regulatory genes, and 
resistance determinants.   
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1.3.2 Biosynthesis and Attachment of Sugar Moiety 
The deoxy hexose moieties of macrolide antibiotics are biosynthesized by 
dedicated genes, often grouped together and usually located in the vicinity of 
genes coding for PKS.  The specific function of each gene is usually assigned 
based on the similarity of its translated protein sequence to those of known 
enzymes, and the analysis of the accumulated fermentation products produced by 
gene knock-out mutants.  These methods are useful for establishing the 
biosynthetic pathway to a specific sugar residue.  However, direct enzymatic 
studies are needed to confirm the function of each enzyme in the pathway and to 
investigate the mechanistic details of its catalysis.  Unfortunately, such thorough 
analyses are difficult to accomplish in the case of macrolides due to the 
difficulties in obtaining pure and active enzyme and the often-unstable sugar 
substrates and pathway intermediates.  Recently, a significant amount of 
information has been accumulated on the biosynthesis of deoxy sugars of lipo-
polysaccharides of bacterial cell wall and a few macrolides, e.g. erythromycin, 
pikromycin, and tylosin.  The progress has been summarized in a few 
reviews.68, 84-90 
The general approach to glycosylation of a macrolide with a deoxy sugar 
follows the following path: (i) activation of D-glucose-1-phosphate to TDP-α-D-
glucose by thymidylyltransferase; (ii) modification of TDP-α-D-glucose by a 
series of enzymes to the desired deoxy sugar moiety; (iii) coupling of the deoxy 
sugar to the macrolactone through a nucleophilic displacement of TDP by a 
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specific glycosyltransferase; and (iv) optional modifications of the sugar moiety, 
such as methylation by appropriate tailoring enzymes. 
 Deoxy sugars of macrolides are biosynthesized from D-glucose-1-
phosphate (16), which is first activated to TDP-α-D-glucose (17, sometimes 
referred to as dTDP-α-D-glucose) by the action of D-glucose 1-phosphate 
thymidylyltransferase (also known as Ep) (Figure 1-8).  TDP-D-glucose is then 
converted to TDP-4-keto-6-deoxy-D-glucose (18) by the NAD+ dependent 4,6-
dehydratase (also known as Eod) in a sequence initiated by the oxidation at C-4, 
followed by the dehydration of C-6, and finally the NADH reduction at C-6.  The 
overall transformation is characteristic of an internal H-transfer: the same hydride 
that is abstracted from C-4 is returned to C-6 (Figure 1-8).  Compound 18 is a 
common intermediate for the biosynthesis of all deoxy sugars.  It is the center of 
the crossroads where the pathways branch out to form unusual sugars with 
additional deoxygenations at C-2, 3, or 4, or epimerizations, or amino substitution 











































Figure 1-8: Common steps of deoxy sugar biosynthesis catalyzed by D-glucose 
1-phosphate thymidylyltransferase Ep and TDP-D-glucose 4,6-
dehydratase Eod. 
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in the formation of this diverse array of sugar moieties, and is utilized for the 
activation of α protons (3-H or 5-H) for the subsequent epimerization or 
dehydration reactions.  It can also facilitate tautomerization or transamination, and 
finally, after fulfilling its activating function, can undergo a stereospecific 
reduction (Figure 1-9). 
 The biosynthesis of desosamine, which is a sugar component of a number 
of macrolides (Figure 1-1), including erythromycin (6) and a set of antibiotics 
produced by Streptomyces venezuelae, 1-5, has been well characterized.  The 
pathway to TDP-D-desosamine (through 23 or 20, Figure 1-9) was originally 
proposed based on gene knock-out studies and the sequence homology of the 
deduced gene products.91-97  The only step which lacks solid evidence is the 
conversion of compound 18 to the 3-keto tautomer 23.  This step is speculated to 
be catalyzed by EryCII in S. erythraea (and homologous DesVIII in 
S. venezuelae) mainly based on the fact that the corresponding gene, eryCII, is 
located within the sugar gene cluster and has no close homologues with a 
confirmed function.  The tautomerization of the 4-keto to the 3-keto isomer would 
allow a deoxygenation at C-4 by a mechanism similar to that for the formation of 
ascarylose, a 3,6-dideoxy sugar, from 18 by the E1/E3 enzyme pair in Yersinia 
pseudotuberculosis (comprehensively reviewed by He and Liu).88  E1 is a 
pyridoxamine 5'-phosphate (PMP)-dependent, iron-sulfur-containing enzyme, 
while E3 is a [2Fe-2S]-containing flavoprotein.  In the case of desosamine, this 
transformation would be performed by the action of EryCIV/EryCV or 






































































































































































Figure 1-9: Biosynthetic routes to several macrolide deoxy sugars exemplifying 
the centrality and versatility of common intermediate 18.  The 
assigned catalytic activities of genes found in the biosynthetic 
clusters of methymycin (Des) erythromycin (Ery), tylosin (Tyl), 
oleandomycin (Tü99 and Ole), and spinosin (Spn) are shown.  The 
figure is modified from Ref. 68. 
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However, based on in vitro and in vivo experimental results, including the gene 
knock-out study described in Chapter 2 of this thesis, the route to 20 was revised 
to include the intermediacy of 19 (Figure 1-9, top portion).98  The conversion of 
the intermediate 20 to 3-amino sugar 21 is carried out by a B6-dependent 3-
aminotransferase, EryCI or DesV.  The N,N-dimethylation of 21 by S-adenosyl-
methionine (SAM)-dependent N,N-dimethyltransferase DesVI has been 
demonstrated with the purified enzyme in vitro.99, 100  The final product, TDP-D-
desosamine (22), is then used as a donor substrate for the dedicated glycosyl-
transferase EryCIII or DesVII to make macrolides 1-6. 
Unlike 22, another 3-dimethylamino hexose, TDP-D-mycaminose (25), 
retains the C-4 hydroxyl group, where an additional sugar moiety is attached in 
several macrolides (Figure 1-2).  The tautomer of 18, compound 23, is believed to 
be a pathway intermediate resulting from a tautomerization catalyzed by a 
homologue of EryCII and DesVIII, TylM3.101, 102  Compound 23 is then converted 
to the final product 25 by the action of 3-aminotransferase TylB103 and N,N-
dimethyltransferase TylM1.100, 102  The activity of each enzyme has been 
confirmed by in vitro assays.  In S. fradiae, mycaminose is subsequently attached 
to the tylosin aglycone, tylactone, by the action of glycosyltransferase TylM2. 
 The biosynthetic pathway to the second carbohydrate moiety of tylosin, D-
mycinose (28), has been independently proposed by two research groups and is 
based on the sequence homology of the corresponding genes to genes with known 
functions.104, 105  As shown in Figure 1-9, epimerization at C-3 of 18 by TylJ is 
followed by a stereospecific reduction of the 4-keto group to a hydroxyl, resulting 
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in the formation of TDP-D-6-deoxyallose (27).  After its coupling to mycami-
nosyltylactone by the glycosyltransferase TylN, the D-6-deoxyallose moiety is 
methylated at the 2- and 3-OH by the O-methyltransferases TylE and TylF, 
respectively, completing the full conversion to D-mycinose. 
The path to the third sugar component of tylosin, L-mycarose, involves the 
formation of 2-deoxy intermediate 29 which is the product of a 2,3-dehydratase.  
In vitro studies using purified enzymes have shown that the 2,3-dehydratase 
encoded by tylX3 of the tylosin producer S. fradiae106 or orf10 of the 
oleandomycin producer S. antibioticus Tü99107 catalyzes the formation of 29 in 
the respective pathways.  Compound 29 is then converted in these strains to C-3 
epimers 34 and 30 by TylC1 and Orf11, respectively, both of which are NADPH-
dependent 3-ketoreductases with opposite stereospecificities.  In the case of TDP-
L-mycarose (37) biosynthesis, 34 is further converted to the branched-chain 
intermediate 35 by the action of the SAM-dependent C-methyltransferase 
TylC3.108  The remaining steps are hypothetical and presumably consist of C-5 
epimerization by TylK, followed by TylC2 catalyzed 4-ketoreduction to form 37.  
The attachment of mycarose to the diglycosylated tylosin precursor by the 
glycosyltransferase TylCV completes the biosynthesis of tylosin. 
 A methylated derivative of mycarose, L-cladinose (38), is found in the 
structure of erythromycin.  A set of genes homologous to those dedicated to the 
mycarose biosynthesis in the tylosin cluster can also be found in the erythromycin 
gene cluster.92-94  Although no biochemical studies of the respective enzymes 
have been done, it is likely that the pathway to mycarose is the same as in the 
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tylosin case.  The attachment of L-mycarose to the erythromycin aglycone 15 is 
believed to be catalyzed by glycosyltransferase EryBV.  This is followed by 
attachment of the second sugar, desosamine, and the hydroxylation of the 
aglycone portion at C-12.68  The methylation of the 3-OH of L-mycarose by EryG 
takes place after all of these steps and completes the biosynthesis of the L-
cladinose moiety.109 
 The mycarose precursor 34 is also an intermediate in the pathway to TDP-
L-oleandrose (41), and its precursor, TDP-L-olivose (40).69, 107, 110, 111  It has been 
demonstrated that glycosyltransferase OleG2 from the oleandomycin (9) pathway 
is capable of coupling both 40 and 41 onto the erythromycin aglycone 15.110  
However, the substrate for the O-methyltransferase OleY is L-olivosyl-
erythronolide B rather than the free sugar 40.112  Therefore, it is likely that the 
glycosylation precedes the O-methylation.  Interestingly, in the biosynthesis of the 
macrolide avermectin by Streptomyces avermitilis, 41 is formed from 40 first and 
is then transferred to the aglycone.113, 114 
The C-3 epimer of 34, compound 30, has been proposed to be an 
intermediate in the biosynthesis of TDP-D-dimethylforosamine (33) which is a 
part of the polyketide insecticide spinosyn.  The key step is the conversion of 30 
to the 2,3,4,6-tetradeoxy-4-amino sugar 32 catalyzed by SpnQ/SpnR.115  The 
mechanism of this intriguing transformation remains a mystery.  The D-
dimethylforosamine is also a structural component of spiramycins (e.g. 12, Figure 
1-2).  Meanwhile, C-4 reduction of 30 would yield TDP-D-olivose (31), which is 
found as a part of aromatic polyketides including mithramycin, urdamycin, and 
 28
landomycin, and is also found in macrolides, such as chlorothricin 
(S. antibioticus).   
1.3.3 Other Tailoring Steps 
The most common post-PKS modifications, other than glycosylations, are 
catalyzed by oxidoreductases and methyltransferases.  The former introduce 
hydroxyl, aldehyde, or epoxide functionalities in the aglycone portion, and the 
latter modify side chains of both the aglycone and the sugar components.  These 
modifications often change the solubility of the molecule, alter the pattern of 
hydrogen donor/acceptor sites, impose steric restrictions, and introduce reactive 
functional groups (e.g. aldehyde) or ‘handles’ for further modifications (e.g. 
hydroxyl).116  They can take place before or after glycosylation steps.  The genes 
encoding enzymes for post-PKS tailoring are usually clustered with PKS and 
sugar biosynthetic genes. 
The oxidoreductases involved are usually highly specific heme-containing 
cytochrome P450 monooxygenases.  It is well known that P450 enzymes require 
additional reducing enzymes for ferrous iron regeneration.  However, the genes 
encoding these P450 reductases are usually located outside the macrolide 
biosynthetic gene cluster.  They can be replaced by components from other P450 
systems in in vitro assays.   
In the biosynthesis of erythromycin A the first protein-free PKS product 
15 is hydroxylated at C-6 by hydroxylase EryF to form erythronolide B (42), 
which is glycosylated with the first sugar component, mycarose, by the action of 
EryBV (Figure 1-10).  Subsequent catalysis by glycosyltransferase EryCIII leads 
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to the addition of the desosamine residue at C-5 of the monoglycosylated 43, 
generating erythromycin D (44).  The second hydroxylase, EryK, introduces a 
hydroxyl group at C-12 of 44 to give erythromycin C (45).  The mycarose residue 
of 45 is then converted to cladinose by the action of the SAM-dependent O-
methyltransferase EryG, completing the biosynthesis of 6.  A mutation of eryK in 
S. erythraea led to the accumulation of both erythromycin B (46) and 


























































































Figure 1-10: Post-PKS steps in the biosynthesis of erythromycin A (6). 
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and hydroxylation steps.117  It was later determined that EryG could act upon both 
44 and 45, with a 2-fold preference toward 45 over 44.109  The final conclusion, 
however, was made on the basis of in vitro studies in which EryK was shown to 
have a strong preference for 44 over 46 (greater than 1200-fold).118  Thus, 
methylation by EryG is clearly the last step in the biosynthesis of 6, and 46 is 
merely a shunt product. 
The sequence of the post-PKS steps in the biosynthesis of tylosin (13, see 
Figure 1-11 for the preferred pathway) is more ambiguous.116, 119  It begins with 
the TylM2 catalyzed addition of mycaminose to the tylactone (47) followed by 
oxidation at C-20 and C-23 by dedicated P450 monooxygenases TylI and TylH1, 
respectively.  The hydroxylation at C-23 provides a site in 49 for the second 
glycosylation with 6-deoxyallose by the glycosyltransferase TylN.  This is 
followed by the attachment of the last sugar residue, mycarose, by TylC5.  This 
described order of glycosylation has not been fully established, and the last two 
steps may be reversed.  Mycarose remains intact in the final product, whereas 6-
deoxyallose is further modified by two O-methyltransferases, TylE and TylF, 
completing the construction of the final product 13.104, 120, 121  
The sequence of the post-PKS steps of the oleandomycin (9) biosynthesis 
was recently established by expressing the P450 monooxygenase OleP and two 
glycosyltransferases, OleG1 and OleG2, isolated from the oleandomycin producer 
S. antibioticus in a S. erythraea mutant.122, 123  It was confirmed that OleP is 
indeed responsible for the formation of the epoxide moiety of 9.  It was also found 
that the epoxide formation and the coupling of the first sugar moiety, olivose, by 
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OleG2 can occur in random order.123  The final step involves methylation of the 
olivose moiety attached to the aglycone into oleandrose by the methyltransferase 
OleY, followed by the second glycosyl transfer catalyzed by OleG1 to form 9.112   
The O-methylation of the aglycone portion of polyketides is more 
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Figure 1-11: Post-PKS steps in the biosynthesis of tylosin (13).
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example is the macrolide antibiotic FK-506 produced by Streptomyces sp. 
MA6858, in which the methylation is catalyzed by a SAM-dependent methyl-
transferase.124  An alternative way to incorporate an O-methyl group in the 
macrolides is by using the methoxymalonate unit during the polyketide synthesis 
as exemplified by the biosynthesis of 11, 12, and 14.69 
Another type of post-PKS modification is acylation of hydroxyl groups of 
the aglycone or the sugar moiety by acyltransferases.  For example, MdmB 
catalyzes the acetylation and the propionylation of the 3-OH of mideacamycins 
(e.g. 11) produced by Streptomyces mycarofaciens.125  Likewise, acyltransferase 
CarE catalyzes the conversion of mycarose to isobutyrylmycarose found in 
carbomycins (e.g. 14).126 
1.4 ENGINEERING NOVEL MACROLIDES 
It has become clear in recent decades that the biosynthetic machineries of 
macrolides can be manipulated to create analogs with diverse polyketide as well 
as sugar structures.  These types of studies are fueled by the urgent need for new 
drugs for treatment of bacterial infections caused by pathogens resistant to known 
antibiotics.  This topic has been extensively reviewed in recent literature and will 
only be discussed here in brief.127-130   
The modular nature of PKS and the colinearity between the PKS domains 
and the structural components of polyketide products provide an excellent basis 
for creating structural diversity by gene manipulation.  This approach relies on the 
promiscuity of some PKS domains and is complemented by the exogenous 
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addition of “unnatural” (that is, not normally used by specific enzyme) building 
blocks or intermediates. 
For example, the incorporation of acyl moieties other than propionyl into 
erythromycin analogs during the chain initiation step has been demonstrated when 
the loading module of DEBS1 in S. erythraea is replaced by the more 
promiscuous loading module of the avermectin PKS.  Six new analogs of 
erythromycins A, B, and D (6, 46, and 44), compounds 52–57, were produced by 
this mutant (Figure 1-12A).131  The diversity of such substitutions, however, is 
limited by the availability of the acyl-CoA substrates in the cell.   
As mentioned earlier, the incorporation of the specific extension unit, 











6: R1= Et, R2= OH, R3= Me,
46: R1= Et, R2= H, R3= Me,
44: R1= Et, R2= H, R3= H,
52: R1= i-Pr, R2= OH, R3= Me,
53: R1= i-Pr, R2= H, R3= Me,
54: R1= i-Pr, R2= H, R3= H,
55: R1= s-Bu, R2= OH, R3= Me,
56: R1= s-Bu, R2= H, R3= Me,

















Figure 1-12: Examples of modifications of erythromycin aglycone through A: 
incorporation of alternative starter units, and B: alterations of chain 
extension steps.
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Therefore, the addition or removal of a specific methyl group can be achieved by 
the replacement of the malonate-specific AT with the methylmalonate-specific 
version or vice versa.  For example, the replacement of methylmalonate-specific 
ATs in modules 1 and 2 of DEBS1 with known malonate-specific domains 
resulted in the accumulation of erythromycin analogs lacking methyl substituents 
at C-12 and C-10, respectively.132   
Inactivation of specific KR, DH, and ER domains or their replacement 
with counterparts from other modules of the same PKS (or PKS of different 
pathways) allows manipulation of the stereochemistry (R- or S-hydroxyl, E- or Z- 
double bond) and the oxidation state (ketone, alcohol, double bond, or methylene) 
at a specific β-carbon.  A library of over 50 analogs of the erythromycin aglycone 
15 was generated by substituting AT, KR, DH, and ER domains of DEBS with 
those of the rapamycin PKS.133  Functional groups at up to three carbon centers in 
a single compound could be changed simultaneously.  Figure 1-12B illustrates the 
substitutions that were introduced. 
The size of the macrolide ring can also be altered by the repositioning of 
the TE domain.  When the TE domain of DEBS was moved to the end of DEBS1, 
a shorter polyketide chain was released, and therefore, lactones with a smaller 
ring size were obtained.134  A recently discovered natural phenomenon named 
‘stuttering’ could be of advantage for creating macrolides with a bigger ring size.  
Wilkinson et al. have found that module 4 of DEBS occasionally operates twice 
resulting in a 16- instead of a 14-membered ring final product.135   
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Owing to the importance of the carbohydrate residues for the biological 
activities of macrolides, the manipulation of sugar structures has drawn much 
attention in recent years.86, 116, 136, 137  Modified sugar residues are constructed 
separately by the sugar biosynthetic machinery and then incorporated as a part of 
the macrolide structure.  This approach relies on the relaxed substrate specificity 
of the corresponding glycosyltransferase.  A glycosyltransferase suitable for the 
combinatorial biosynthesis should be able to couple “unnatural” aglycones with 
“unnatural” carbohydrates. 
The simplest way to alter the glycosylation pattern of a macrolide is the 
inactivation of the specific glycosyltransferase gene, thereby preventing the 
attachment of the corresponding sugar moiety.  For example, the inactivation of 
each of the glycosyltransferase genes of the tylosin biosynthesis led to the 
accumulation of tylosin derivatives with different glycosylation patterns (Figure 
1-11).119, 138, 139  This tactic is usually employed for the elucidation of the order of 
glycosylation steps and the function of the particular glycosyltransferase during 
the biosynthesis of the macrolides containing two or more carbohydrate residues.   
Generation of an array of “unnatural” structures requires manipulation of 
the sugar biosynthetic machinery directly.  The best-studied case is the alteration 
of the biosynthetic pathway for desosamine in the methymycin/pikromycin set of 
antibiotics, and it will be discussed in Section 1.5 and Chapter 2.  Alternatively, 
inactivated genes can be replaced with genes from different pathways and/or 
species (Chapter 2).  The development of suitable genetic tools has greatly 
facilitated the construction of hybrid natural products.  For example, shuttle 
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vectors are now available that can be transferred from E. coli to Streptomyces 
species, and are capable of replicating in both species.140  Sugar biosynthetic 
genes have been cloned in such vectors under the control of strong Streptomyces 
promoters and are either integrated into the chromosome of the new host or are 
expressed from the plasmid. 
In the study by Cundliffe and coworkers, two genes of the desosamine 
pathway in the narbomycin producer Streptomyces narbonensis, nbmK and nbmJ 
(homologues of eryCIV and eryCV, respectively, see Figure 1-9), were introduced 
into the tylosin producer S. fradiae.141  This transformation led to the production 
of TDP-D-desosamine in addition to TDP-D-mycaminose.  Consequently, two 
new compounds, 58 and 59, were detected, both containing desosamine (Figure 1-
13A).  The incorporation of desosamine in the final products indicates that the 
glycosyltransferase TylM2 in the tylosin pathway is capable of processing 
desosamine as well as its natural substrate, mycaminose. 
In the study described above, researchers took advantage of the natural 
production of the aglycone by S. fradiae.  Alternatively, McDaniel and Tang used 
S. lividans, which cannot make macrolactones by itself, as their host strain.142  
They integrated all of the genes necessary for the biosynthesis and transfer of 
desosamine into the chromosome of S. lividans.  The resulting strain was then 
transformed with the library of plasmids expressing modified DEBS genes and 
directing the production of different 14-membered macrolides (derivatives of 15 
shown in Figure 1-12B).  Although the yields of glycosylated products were low, 
more then 20 desosaminylated macrolides with detectable activity against 
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Bacillus subtilis were identified by mass spectroscopy (Figure 1-13B).142  This 
case nicely demonstrates the flexibility of the responsible glycosyltransferase, 
DesVII, towards its aglycone substrates. 
Likewise, Salas and coworkers have also employed the ‘sugar flexible’ 
glycosyltransferase of the aromatic polyketide elloramycin biosynthesis, ElmGT, 
for the glycosylation of an aromatic aglycone with diverse deoxysugars.143  A 
plasmid pLN2 containing the genes required for the formation of TDP-L-
























































Figure 1-13: Examples of glycosylated compounds generated by manipulations of 
sugar biosynthetic genes. 
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was further modified by the gene deletion and replacement to create sets of genes 
for the biosynthesis of TDP-L- and -D-olivose, TDP-L-rhamnose, and TDP-L-
rhodinose.  Derivatives of plasmid pLN2 were then used to complement a 
Streptomyces albus mutant expressing the elmGT gene.  The aglycone was either 
supplemented by feeding or produced endogenously from the cosmid containing 
tetracenomycin C biosynthetic genes.  The detection of four glycosylated 
derivatives of tetracenomycin C, 60–63 (Figure 1-13C), confirmed the production 
of the desired sugar residues and illustrated the versatility of the glycosyl-
transferase ElmGT.143  The plasmids created in this study can potentially be used 
in other Streptomyces strains for the attachment of sugar residues to different 
aglycones provided these hosts contain a flexible glycosyltransferase.   
However, the above in vivo engineering of novel glycosylated products 
may be complicated by cell death or cell growth inhibition since the new 
macrolides may be toxic.  A chemoenzymatic approach to the production of 
glycosylated secondary metabolites by carrying out the glycosyl transfer step in 
vitro has been developed by Thorson and coworkers.144  The strategy, termed 
glycorandomization, takes advantage of the versatility of the chemical synthesis 
to make diverse sugar structures and the promiscuity of sugar kinases and 
nucleotidylyltransferases to create activated carbohydrate building blocks.145  
Coupled with a substrate flexible glycosyltransferase, glycorandomization 
potentially allows the construction of a large library of glycosylated molecules in 
vitro (Figure 1-14).  Thorson and coworkers have demonstrated the viability of 
this approach by creating 21 monoglycosylated vancomycin analogs using the 
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vancomycin aglycone, a library of sugar-1-phosphates, and the glycosyl-
transferase of the vancomycin biosynthesis, GtfE.146  The attempt to glycosylate 
the aminocoumarin aglycone using the same library of carbohydrate substituents 
and the glycosyltransferase of the novobiocin biosynthesis, NovM, was less 
successful resulting in only four glycosylated products.147  Perhaps the varied 
result reflects the degree of promiscuity exhibited by the respective glycosylating 
enzymes.  Future protein engineering to make a fully flexible glycosyltransferase 
or a glycosyltransferase with the desired specificity would allow further 
realization of the potential of this combinatorial approach.  Alterations of post-
PKS steps other than the glycosyl transfer reaction are not as common.116 
In summary, advances have been made in engineering new macrolides 
with different aglycone structures and glycosylation patterns.  Gene manipulations 
in vivo have proven to be an effective means to create structural diversity.  The 
coupling of the aglycone and the sugar in vitro allows the incorporation of a great 
variety of sugar structures to achieve glycodiversification.  It also avoids the 
potential toxicity of the new “drug” to the producing host.  It is likely that a 
combination of these methods, e.g. generating a library of aglycones through 
genetic variations and coupling it with a library of synthetic sugar nucleotides in 

































Figure 1-14: Schematic illustration of glycorandomization approach to new 
glycosylated products. 
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1.5 BIOSYNTHESIS OF MACROLIDES BY S. VENEZUELAE 
S. venezuelae ATCC 15439 produces a set of structurally and 
biosynthetically related 12- and 14-membered macrolide antibiotics, each 
containing a single deoxysugar moiety, D-desosamine.  The prevalence of a group 
of macrolides having the same ring size is growth media dependent: the 14-
membered pikromycin (4) and narbomycin (5) are isolated from the cultures 
grown in PGM medium,148 whereas the 12-membered methymycin (1), 
neomethymycin (2), and their non-hydroxylated precursor, YC-17 (3) are 
produced by cultures grown in SCM149 or seed/vegetative150 media (Figure 1-1).  
The reasons why two sets of related macrolides with different ring size are 
produced by S. venezuelae has been puzzling since these compounds were first 
identified. 
Our group, in collaboration with Professor Sherman, has sequenced the 
entire gene cluster for the biosynthesis of methymycin/pikromycin in 
S. venezuelae.95  The initial assignment of the gene functions is based on the 
sequence comparison with genes found in the erythromycin and oleandomycin 
biosynthetic gene clusters.151, 152  The sequence analysis has revealed the presence 
of five open reading frames (ORFs) coding for the modular PKS proteins, pikAI, 
pikAII, pikAIII, pikAIV, and pikAV (Figure 1-15).  These are followed by the 
cluster of genes involved in deoxysugar biosynthesis and attachment, des.  The 
ORF encoding a cytochrome P450 monooxygenase, pikC, is located downstream 
of the des genes, and is followed by a putative regulatory gene, pikD.  Upstream 
of pikAI there exist two MLSB type resistant genes, pikR1 and pikR2, which likely 
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play roles in the self-resistance mechanism via rRNA methylation.  Interestingly, 
within the des cluster there also exists an ORF, desR, encoding a protein 
homologous to β-glycosidase.  This β-glycosidase was speculated to be involved 
in an alternative self-resistance mechanism through the glycosylation-
deglycosylation of the antibiotic.62 
Since the presence of desR in the desosamine biosynthetic cluster is 
intriguing, its function was further investigated by gene disruption experiments.  
Our results showed that the inactivation of desR in S. venezuelae genome resulted 
in the accumulation of two new glycosylated products in addition to 1 and 2.153  
These products were identified as derivatives of 1 and 2 with an additional 
glucose moiety attached at the 2´-OH of the desosamine moiety.  As expected, 















Figure 1-15: Organization of methymycin/pikromycin biosynthetic gene cluster in 
S. venezuelae. 
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evidence supporting the function of DesR as a β-glycosidase, which is likely 
involved in the glycosylation-deglycosylation self-resistance mechanism in 
S. venezuelae.  However, this appears to be a secondary mechanism, since 1 and 2 
remained to be the major products produced by the desR mutant.  Hence, 
methylation of rRNA by PikR1 and PikR2 may still be the primary self-resistance 
strategy.  
The organization and functions of the PikA domains are depicted in Figure 
1-16.  The loading module of PikAI contains a KS-like domain, KSQ, not present 
in DEBS, but typical for other modular PKSs.  It has been shown that KSQ 
possesses a decarboxylase activity154 and is likely involved in the tandem 
formation of the propionyl starter unit from methylmalonyl-CoA.  The AT 
domain of module 2 is malonate-specific, whereas the remaining AT domains, 
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Figure 1-16: Polyketide biosynthesis by PIKS of S. venezuelae. 
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domain of module 3 is inactive, resulting in the retention of the ketone moiety, C-
9 of 64 and C-7 of 65, in the final product. 
An interesting property of pikromycin PKS (PIKS) is that its modules 5 
and 6 are separate proteins, unlike those of DEBS and oleandomycin PKS, where 
they are parts of a single bimodular protein.  This peculiarity has been associated 
with the production of macrolides of two ring sizes, 64 and 65, by a single 
PIKS.95  Furthermore, in addition to a ‘conventional’ TE domain at the C-
terminus of PikAIV, PIKS has a second TE, TEII, encoded by a separate ORF 
pikAV.  Therefore, it has been initially suggested that a longer polyketide results 
from the operation of the entire PIKS, culminating in the chain termination by TE 
and the release of 64.  Alternatively, the 12-membered cyclic product 65 is 
formed when only modules 1 through 5 are used, and the polyketide is 
prematurely released by TEII (Figure 1-16).95  However, a S. venezuelae mutant 
lacking the pikAV gene produced decreased amounts (<5%) of both 12- and 14-
membered macrolides,95 suggesting that TEII is not the key to the alternative 
chain termination and it plays a more general role in macrolide biosynthesis.  This 
general hypothesis is supported by the existence of pikAV homologues in many 
polyketide and nonribosomal peptide biosynthetic gene clusters where a single 
product is produced by the respective biosynthetic machinery.155  It has been 
hypothesized that TEII may have an editing function, which is to remove aberrant 
intermediates from the polyketide assembly line, thereby preventing it from 
stalling.156  However, the exact role of the thioesterase TEII remains to be 
elucidated.  
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Later study by Xue and Sherman confirmed that the release of macro-
lactones of both ring sizes is executed by the TE domain of PikAIV.157  It was 
found that, depending on the culture conditions, two different forms of PikAIV 
can be produced by S. venezuelae.  Under the conditions for the production of 14-
membered 64, the full length PikAIV is produced, and PIKS functions in the 
usual manner.  In contrast, under the conditions for the production of 12-
membered 65, the pikAIV gene is translated from the alternative start codon to 
express the N-terminally truncated PikAIV, lacking roughly half of its KS6 
domain.  Xue and Sherman proposed a structural model where the TE domain of 
the truncated PikAIV occupies the space usually taken by KS6.  This allows a 
direct transfer of the hexaketide from ACP5 to TE, bypassing module 6 and 
resulting in the cyclization of a shorter polyketide chain.157  Further investigation 
by Sherman and coworkers led to the proposal of another mechanism of the chain 
transfer where the hexaketide is first transferred from ACP5 to ACP6 of the 
truncated PikAIV, followed by the relocation to the active serine of TE and the 
release of a 12-membered cyclic product.158  This last model represents our 
current understanding of the dual function of PIKS in the production of two 
related but different macrolides. 
Meanwhile, sequence analysis of the des gene cluster in conjunction with 
the comparison to the desosamine biosynthetic genes found in the erythromycin 
producer S. erythraea,92, 93 allowed a tentative function assignment of the 
desosamine biosynthetic genes in S. venezuelae (Figure 1-17).95  An early study 
showed that the deletion of both desV and desVI genes abolished the production 
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of 1, 2, 4, and 5.  The major products produced by these two mutants are the 
aglycones 64 and 65.  These results indicate that there exists only one set of genes 
for the biosynthesis of desosamine which is used to glycosylate both 12- and 14-
membered macrolides.95 
Further studies showed that the first two steps of desosamine biosynthesis 
are the same as for the biosynthesis of other deoxysugars and are catalyzed by 
DesIII and DesIV (Section 1.3.2).84  DesVII shows a significant sequence 
similarity to several previously identified glycosyltransferases, e.g. TylM2 from 
the tylosin cluster in S. fradiae,101 EryCIII and EryBV from the erythromycin 
cluster.92, 93  These enzymes catalyze the coupling of deoxysugars and polyketide 
aglycones in their respective pathways.  Therefore, DesVII was assigned as a 




































































Figure 1-17: Proposed scheme for the biosynthesis and attachment of TDP-D-
desosamine (22) in S. venezuelae. 
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This DesVII-catalyzed glycosyl transfer should be one of the last steps in the 
pathway. 
The nature and the order of the transformations between these steps are 
less obvious.  The mechanism of the C-4 deoxygenation step is especially 
intriguing, which has been proposed to be catalyzed by a pair of enzymes, DesI 
and DesII.  DesI shows a significant sequence similarity to several known 
enzymes, including the well-characterized E1 enzyme from the CDP-L-ascarylose 
biosynthetic pathway in Yersinia pseudotuberculosis.84  E1 is a PMP-dependent 
enzyme.  When coupled with the reductase E3, E1 catalyzes the C-3 
deoxygenation of 18 during the formation of 3,6-dideoxyhexoses.159-162  However, 
no E3 homologue exists in the des cluster.  Only the desII gene, whose translated 
sequence shows characteristics of a [4Fe-4S] protein, likely encodes a reductase, 
performing the reaction analogous to that catalyzed by E3.  Therefore, the C-4 
deoxygenation in desosamine has been proposed to be catalyzed by DesI and 
DesII following a similar mechanism as C-3 deoxygenation catalyzed by E1 and 
E3.97  If the proposed mechanism of C-O bond cleavage at C-4 is correct, an 
isomerization of the 4-keto-6-deoxyhexose 18 to its 3-keto derivative 23 becomes 
a prerequisite.  Such a tautomerization is speculated to be catalyzed by DesVIII 
which shows modest sequence homology to P450 enzymes but lacks the 
conserved residues for heme binding (Figure 1-17).153 
The next two steps, the introduction of an amino group at the C-3 position 
and the subsequent N,N-dimethylation, are catalyzed by DesV and DesVI, 
respectively.  The functions of the desV and desVI genes have been confirmed by 
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gene disruption experiments96, 97 as well as in vitro biochemical studies.99, 100, 163  
In these studies, two mutants of S. venezuelae, KdesV and KdesVI, were 
constructed that had desV and desVI genes disrupted, respectively.96, 97  When 
they were fermented under the 12-membered ring production conditions, in both 
cases, no metabolites containing desosamine were detected.  Instead, small 
quantities of new glycosylated products were obtained. 
A fermentation of KdesV led to the isolation of two methymycin/ 
neomethymycin analogs, 66 and 67, each carrying a 4,6-dideoxy hexose (Figure 
1-18).  These results strongly supported the assignment of desV as the gene 
encoding the 3-aminotransferase that catalyzes the conversion of the 3-keto-sugar 
20 to the corresponding amino sugar 21.  The deletion of this gene prevents the C-
3 transamination, resulting in the accumulation of 20.  The production of 66 and 
67 (which have a hydroxyl group at C-3 of the sugar moiety instead of the 










































Figure 1-18: Novel macrolides produced by S. venezuelae mutants lacking DesV 
and DesVI activities. 
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in S. venezuelae that can stereospecifically reduce the C-3 keto group of the sugar 
metabolite.  These results contradict an alternative pathway to desosamine 
favored at the time by Salah-Bey et al., in which the introduction of the amino 
group was proposed to occur first at C-3 of the intermediate 23, followed by C-4 
deoxygenation.94  Since the deletion of the desV gene leads to the incorporation of 
a 4-deoxy sugar in the final products, it is evident that deoxygenation at C-4 takes 
place prior to the transamination at C-3.  Protein DesV was later overproduced in 
E. coli and purified to homogeneity.163  The assay of DesV activity in the reverse 
direction, using a chemically synthesized compound 21 as substrate, led to the 
production of 20.  These experiments provide unequivocal evidence establishing 
the role of DesV as the aminotransferase required for the C-3 transamination step 
in the biosynthesis of desosamine. 
The fermentation of the KdesVI mutant resulted in the isolation of another 
pair of methymycin/neomethymycin analogs, 68 and 69, each containing a 3,4,6-
trideoxy-3-acetamido-D-glucose (Figure 1-18).96  Since no N-methylated sugar 
derivatives were obtained in the absence of desVI, its encoded protein DesVI must 
be the desired N,N-dimethyltransferase catalyzing N-methylation in the 
desosamine biosynthesis.  Interestingly, instead of the expected sugar with a free 
amino group, each of the fermentation products carried an acetylated amino 
hexose.  It has been proposed that the observed N-acetylation might be a 
necessary step for the self-protection of S. venezuelae.96  The biochemical 
evidence supporting the DesVI function assignment was obtained by using 
heterologously produced and homogeneously purified DesVI in the activity 
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assay.99, 100  The isolation of product 22 from the incubation of compound 21, 
SAM, and purified DesVI confirms the function of DesVI as a N,N-dimethyl-
transferase. 
These gene disruption experiments demonstrated the feasibility of such an 
approach for the investigation of the deoxysugar biosynthetic pathway.  The 
results also provided strong evidence for the relaxed substrate specificity of the 
glycosyltransferase DesVII based on its ability to accept various unnatural sugar 
substrates.  Moreover, these studies resulted in the production of a series of 
“unnatural” natural products, setting up the stage for future application of the 
gene disruption technique towards the creation of new macrolide antibiotics.137 
The last step of the macrolide biosynthesis in S. venezuelae is the 
hydroxylation at C-10 and C-12 of 3, giving rise to 1 and 2, respectively, and also 

















































Figure 1-19: Final steps of macrolide biosynthesis by S. venezuelae. 
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hydroxylations are catalyzed by a cytochrome P450 monooxygenase (or 
monooxygenases), and are preceded by the glycosylation of 64 and 65.164, 165  The 
sequencing of the pikromycin gene cluster95 and the independent screening of the 
S. venezuelae genome165 have identified a single gene encoding such a P450 
enzyme, pikC (also referred to as picK).  PikC has been heterologously produced 
in E. coli and shown to be capable of catalyzing the hydroxylation of 3 and 5 in 
vitro with a slight preference for 5 (kcat/Km: 0.023±0.01 vs. 0.008±0.004 
µM-1s-1).166  The inactivation of pikC in S. venezuelae abolished the production of 
all hydroxylated macrolides, 12- and 14-membered, and gave only 3 and 5 as the 
products.167  These results confirmed that S. venezuelae possesses a single P450 
enzyme, PikC, responsible for the hydroxylation of both 3 and 5.  It is worth 
mentioning, that macrolide-hydroxylating enzymes, e.g. EryF and EryK involved 
in the erythromycin biosynthesis, usually have a stringent substrate 
specificity.118, 168  In contrast, PikC discriminates between glycosylated and 
unglycosylated macrolides, but is able to accept macrolides of two ring sizes and 
hydroxylate 3 at two different positions.  These unusual properties may prove to 
be useful for a combinatorial approach to biosynthetically produce new 
macrolides. 
In summary, the biosynthesis of macrolides by S. venezuelae has a number 
of unique features.  It is the only example known where a single PKS naturally 
produces macrolides of two different ring sizes.  Its post-PKS enzymes, DesVII 
and PikC, exhibit an unprecedented versatility in the modification of both 12- and 
14-membered macrolactone rings.  All of the macrolides produced by 
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S. venezuelae contain a single carbohydrate substituent, D-desosamine.  This 3-
amino-3,4,6-trideoxy sugar moiety is a common sugar component of clinically 
important macrolides.  Its formation is intriguing because of the yet unknown 
mechanism of the C-4 deoxygenation step.  Finally, genetic manipulations of 
S. venezuelae proved to be useful for the generation of novel metabolites, and its 
potential applications certainly worth further exploration. 
1.6 THESIS STATEMENT 
Combinatorial biosynthesis of secondary metabolites has been an 
emerging strategy for making novel compounds.  Over the last ten years, the 
biosynthetic routes to several clinically important macrolide antibiotics have been 
extensively studied, and significant progress has been made in our understanding 
of the underlying chemistry of the key steps in each pathway.  However, our 
knowledge of the biosynthesis of the deoxy sugar components in macrolides and 
their attachment to the respective aglycone remains scarce.  The above overview 
of the biosynthesis of desosamine in S. venezuelae clearly shows that, more 
efforts are needed to fully elucidate the detailed pathway, especially the roles of 
desI, desII and desVIII.  
Described in Chapter 2 of this dissertation are the experiments intended to 
uncover the details of the formation of desosamine in S. venezuelae, in particular, 
the results of the gene disruption analyses of desI, desII, and desVIII.  Chapter 3 
focuses on the study of the secondary self-protection mechanism in S. venezuelae 
and documents the discovery and the initial analysis of the glycosyltransferase 
DesG involved in the self-resistance to macrolides.  The last chapter is dedicated 
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to an in-depth study of the glycosyltransferase DesVII, which catalyzes the 
coupling of desosamine to the aglycones.  The in vitro reconstitution of the 
DesVII activity proved to be difficult, but the problem was eventually resolved 
because of the identification of its catalytic partner, DesVIII, as an essential 
component for the glycosyltransferase activity.  The study has resulted in the first 
report of a demonstrated macrolide glycosyltransferase activity in vitro. 
As a whole, the work presented here contributes significantly to our 
understanding of the biosynthesis of macrolide antibiotics, specifically the 
formation of a novel deoxy hexose and its coupling to the macrolactone aglycone.  
The mechanisms of an unusual self-resistance were also biochemically 
established.  Moreover, the discovery of the specific requirement of a second 
protein component for the glycosyl transfer activity of DesVII opens new 
possibilities for future in vitro generation of biologically active macrolides using 
unnatural aglycones and various sugar nucleotides. 
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Chapter 2: Probing Biosynthetic Steps and Enzyme Activities of 
D-Desosamine Biosynthesis Using Gene Disruption Experiments 
2.1 INTRODUCTION 
D-desosamine is a common sugar component found in many macrolide 
antibiotics.  The biosynthesis of TDP-D-desosamine (22) has attracted 
considerable attention from several research groups.1-5  Extensive genetic and 
biochemical studies of the pathway to 22 in S. erythraea6-8 and in 
S. venezuelae 9-12 have been performed.  However, parts of the proposed 
biosynthetic scheme for the formation of 22 (Figure 1-17) remain speculative.  In 
particular, the functions of the desI, desII, and desVIII genes (and their 
homologues in the erythromycin pathway) are assigned solely on the basis of 
sequence homology to other known genes. 
The biosynthesis of 22 in the producer of macrolide antibiotics 1, 2, 4, and 
5, S. venezuelae, represents a particularly attractive system suitable for genetic 
studies for several reasons.  Firstly, D-desosamine is the sole carbohydrate residue 
in these natural products thus simplifying the genetic manipulations to be carried 
out as well as the structural analysis of the secondary metabolites produced by 
these mutant strains.  Secondly, growth conditions for the culture of 
S. venezuelae13 in addition to procedures for the genetic alteration of this 
particular species have been established.14, 15  Lastly, the glycosyltransferase 
DesVII involved in the biosynthesis of 1, 2, 4, and 5 has been shown to possess a 
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rather relaxed substrate specificity.9, 10  This last property is desirable for the 
construction of hybrid metabolites using genetic engineering. 
Gene disruption is a useful tool in the study of natural product 
biosynthesis.  A correlation between the generated mutant and its phenotype 
(accumulated intermediates) can be helpful in assigning the function of the gene 
as well as in establishing the biosynthetic pathway.  The biosynthesis of 
macrolides is composed of two pathways that are connected through the action of 
glycosyltransferases: the macrolactone synthesis by the PKS, and the deoxy sugar 
nucleotide synthesis by a set of dedicated sugar biosynthetic genes.  The 
macrolactone derivatives generated by the manipulation of the PKS genes can be 
readily isolated from the fermentation culture of the mutants through organic 
solvent extraction.  However, the detection and/or isolation of the TDP-sugar 
intermediates accumulated in the macrolide producing strains can be difficult due 
to their instability and the high water solubility.  Only those sugar intermediates 
that are recognized and coupled to the aglycone by the existing glycosyl-
transferase can be isolated as a part of the macrolide products.  Thus, the 
interpretation of the disruption studies of deoxy sugar genes should be taken with 
caution, since the results may not provide a direct correlation between gene 
function and the biosynthetic pathway.  Insight can only be obtained if the 
glycosyltransferase can incorporate the accumulated sugar intermediate into the 
final compound in sufficient amounts for isolation and characterization. 
This chapter summarizes the experiments designed to investigate the roles 
of the desI, desII and desVIII genes in the biosynthesis of 22, using gene 
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disruption and gene replacement methods.  Our goals are to establish the 
biosynthetic pathway to 22 and to evaluate the potential of a combinatorial 
biosynthetic approach towards the generation of novel macrolide antibiotics 
containing unusual sugar appendages via genetic manipulation of the biosynthetic 
machinery. 
2.2 EXPERIMENTAL PROCEDURES 
2.2.1 General 
Bacterial Strains.  E. coli DH5α from Invitrogen (Carlsbad, CA) was used 
throughout the study as the regular cloning host.  E. coli S17-116 was the donor 
strain for the conjugal transfer to S. venezuelae.  Strains S. venezuelae 
ATCC 15439, Streptomyces peucetius ATCC 29050, and S. erythraea 
ATCC 11635 were obtained from American Type Culture Collection (ATCC, 
Rockville, MD) as freeze-dried pellets and were revived according to the 
instructions provided by ATCC. 
Plasmids, Vectors and DNA Manipulations.  Cosmid pLZ4 (a derivative of 
the pNJ1 vector)17 containing the desosamine biosynthetic cluster and a part of the 
polyketide synthase cluster14, 15 was used as the template for the polymerase chain 
reaction (PCR) to obtain the appropriate DNA fragments.  Plasmid pL005 was 
used as the source of the appropriate DNA fragments for the desII disruption 
construct.15  Plasmid pKC1139, used for the conjugal transfer of DNA to 
S. venezuelae, was a gift from Dr. Leonard Katz of Abbott Laboratories.18  Vector 
pDHS617, used for the complementation of the S. venezuelae mutant strains with 
the additional genes, was a gift from Professor David Sherman of the University 
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of Michigan.19  Cosmid pFD666 was used as the source of the neo fragment.20, 21  
Cosmid pZHG4 was used as the template for the PCR amplification of the tylM3 
gene of S. fradiae.22  The general methods and protocols for recombinant DNA 
manipulations were followed per the description by Sambrook et al.,23 and those 
dealing with Streptomyces strains per the description by Hopwood et al.24 and 
Kieser et al.25 
Biochemicals.  The enzymes used in the cloning experiments were 
obtained from Invitrogen or Promega (Madison, WI).  The 32P labeled nucleotides 
and the Multiprime DNA Labeling System used for the DNA probe labeling 
during the Southern blot hybridization analysis were purchased from Amersham 
Biosciences (Piscataway, NJ).  Antibiotics and biochemicals used in this study 
were products of Sigma-Aldrich (St. Louis, MO) or Fisher Scientific (Pittsburgh, 
PA).  The growth media components were obtained from BD Diagnostics System 
(Sparks, MD).  The purification of DNA after digestion reactions and from an 
agarose gel was achieved using the Bio101 Geneclean II® kit purchased from 
Fisher Scientific. 
Instrumentation.  The pH values were obtained using a Corning pH meter 
240 purchased from Fisher Scientific.  The mini-sub cell GT from Biorad 
(Richmond, CA), powered by either a FB600 or a FB135 power supply from 
Fisher Scientific, was used for agarose gel electrophoresis.  All centrifugation 
procedures were performed using an Avanti J-25 unit from Beckman (Arlington 
Heights, IL).  Microcentrifugations were done with an Eppendorf 5415C from 
Brinkmann Instruments, Inc (Westbury, NY).  The gel documentation was 
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performed with a Polaroid MP-4 Land Camera (Cambridge, MA) loaded with a 
Polaroid Type 667 coatless black and white instant film, and illuminated with a 
Foto UV 310 transilluminator from Fotodyne Inc (New Berlin, WI).  The 
polymerase chain reactions were conducted with a Perkin Elmer Cetus DNA 
Thermal Cycler (Norwalk, CT).  The HPLC separations were achieved on a 
Beckman 366 instrument (Beckman Instruments, Fullerton, CA) equipped with 
Econosil C18 columns from Alltech (Deerfield, IL).  The NMR spectra were 
acquired on a Varian Unity 300 or 500 spectrometer, and the chemical shifts (δ in 
ppm) are given relative to those for Me4Si (for 1H and 13C) with the coupling 
constants reported in hertz (Hz).  The high-resolution FAB mass spectra were 
obtained using a VG 7070E-HF mass spectrometer.  Flash chromatography was 
performed on Lagand Chemical silica gel (230-400 mesh) by elution with the 
specified solvents.  Analytical thin-layer chromatography (TLC) was carried out 
on Polygram Sil G/UV254 plates (0.25 mm) (Macherey-Nagel Inc., Easton, PA). 
Preparation of Competent Cells.  Cells were made competent according to 
the RbCl method.23  A single fresh colony of the appropriate E. coli strain was 
used to inoculate 2 mL of the Luria-Bertani (LB) liquid medium and the resulting 
culture was grown overnight at 37 °C with shaking at 250 rpm.  A 500 µL aliquot 
of an overnight culture was used to inoculate 50 mL of the LB medium in an 
Erlenmeyer flask.  When the cell growth at 37 °C reached an OD600 of 
approximately 0.4, the culture was transferred into a pre-chilled polypropylene 
tube and incubated on ice for 30 min.  After centrifugation at 3,000 g for 5 min, 
the supernatant was discarded, and the cell pellet was gently resuspended in 
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13 mL of an ice-cold RF1 solution (100 mM RbCl, 15% glycerol, 50 mM MnCl2, 
30 mM potassium acetate, 10 mM CaCl2, pH 5.8, sterilized by filtering through a 
0.22 µm membrane).  After incubation on ice for 15 min, another centrifugation 
step at 3,000 g, 4 °C for 5 min was performed and the resulting cell pellet was 
resuspended in 4 mL of an ice-cold RF2 solution (10 mM RbCl, 10 mM MOPS, 
75 mM CaCl2, 15% glycerol, pH 6.8).  The cells were aliquotted into 100 µL 
portions in pre-chilled microcentrifuge tubes and frozen at –80 °C. 
PCR Amplification of DNA.  The general procedure for the polymerase 
chain reaction amplification of DNA fragments was followed as described below.  
Two oligonucleotide primers complementary to the sequences at each end of the 
target gene were designed and the appropriate restriction enzyme sites were 
incorporated when necessary.  A polymerase-mediated amplification was carried 
out in a 0.5 mL microcentrifuge tube.  The reaction mixture consisted of 59.5 µL 
of de-ionized water, 10 µL of the pfu polymerase buffer (10x), 8 µL of the deoxy-
ribonucleotidyl triphosphate mix (2.5 mM each), 10.0 µL of DMSO, 2.5 µL of 
40% glycerol, 4 µL of each of the primers (20 µM stock concentration), 1.0 µL of 
the template (approximately 0.1 µg), and 1.0 µL of the cloned pfu polymerase 
(2.5 units, Invitrogen).  The reaction mixture was overlaid with a drop of mineral 
oil and subjected to the following thermal cycling: (1) 1 cycle of incubation at 
95 °C for 3 min (2) 30 cycles of incubation at 95 °C for 30 s, 60 °C for 30 s, and 
72 °C for 90 s.  The tubes were held at 4 °C prior to being removed from the 
thermal cycler. 
 76
2.2.2 Construction of the Disruption Plasmids 
Plasmid pDesI-K.  Plasmid pDesI-K (Figure 2-1) was generated for the 
deletional inactivation of the desI gene in S. venezuelae.  For the construction of 
pDesI-K, a 1.1 kb fragment of desII located downstream of desI, “desI”, was 
amplified by PCR using pLZ4 as the template with the following primers: 5′-
GCGCGAATTCGCTCCTCGAAGGCGTTGAGG-3′ and 5′-GCGCTCTAGA-
CATCCACGCCCACGATTGG-3′ (the engineered restriction sites EcoRI and 
XbaI, respectively, are underlined).  A 1.0 kb fragment located upstream of desI, 
”sug-d”, was amplified by PCR using the same template and the following 
primers: 5′-GGCCAAGCTTGGAGTCGATGAGC-3′ and 5′-GGCCCTGCAG-
AAGAATGCGAGGTCG-3′ (the engineered restriction sites HindIII and PstI, 
respectively, are underlined).  The fragment containing the neomycin resistance 
gene (“neo”, 1.4 kb) was amplified by PCR using pFD666 as the template with 
primers 5′-CGCGTCTAGATACCTACAGCGTGAGC-3′ and 5′-CGCG-
CTGCAGCCACGAATTAGCC-3′ containing the restriction sites XbaI and PstI 
(underlined), respectively. 
The three fragments, “desI”, “sug-d”, and “neo”, were digested with the 
appropriate restriction enzymes and simultaneously ligated into the HindIII-EcoRI 
sites of pUC119.  The 3.5 kb insert of the resulting plasmid pDesI-d1 was then 
removed by the digestion with EcoRI-HindIII and cloned into the same restriction 
sites of the pKC1139 vector, resulting in the plasmid pDesI-K (Figure 2-1). 
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Construction of Plasmid pDesII-K.  Plasmid pDesII-K (Figure 2-2) was 
generated for the deletional inactivation of the desII gene in S. venezuelae.  The 
1.2 kb fragment “desII-up” located upstream of desII was amplified by PCR using 
pLZ4 as the template with the following primers: 5′-CGCGCTGCAGTCCAAT-
































Figure 2-1: Construction of the disruption plasmid pDesI-K.  The endonuclease 
restriction sites are abbreviated as follows: E, EcoRI; H, HindIII; P, 
PstI; X, XbaI.  Plasmid pDesI-d1 is derived from pUC119 and 
contains fragments “desI”, “neo”, and “sug-d”.  The origin of DNA 
replication (ORI), lacI operon, and the ampicillin resistance gene 
(AmpR) of pUC119 are shown.  Plasmid pDesI-K is derived from 
pKC1139 and contains the E. coli origin of DNA replication from 
the pUC plasmid (reppUC), the apramycin resistance gene (AprR), a 
temperature sensitive replicon from Streptomyces ghanaensis 
functioning only at temperatures below 34 oC (repts), and the origin 
of transfer for conjugation (oriT). 
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CGTGGGCGTGGATGTC-3′ and 5′-CGCGAAGCTTATCCGACCTCGCATTC-
3′ (the engineered restriction sites PstI and HindIII, respectively, are underlined).  
To obtain the fragment “desII-down” located downstream of desII, the plasmid 
pL005 was digested with the restriction endonuclease SmaI first.  A 2.2 kb portion 
of the digested DNA was purified from the agarose gel and cloned at the PvuII 
site of pUC119 through the blunt-ended ligation.  The resulting plasmid pDesII-
d2 was digested with the HindIII and XbaI enzymes.  It was then ligated with the 
fragments “neo” and “desII-up” producing the plasmid pDesII-d1.  The 4.5 kb 
EcoRI-HindIII fragment of pDesII-d1 was subsequently cloned into the same 
restriction sites of pKC1139 giving pDesII-K (Figure 2-2). 
Construction of the Plasmid pDesVIII-K.  Plasmid pDesVIII-K (Figure 2-
3) was generated for the deletional inactivation of the desVIII gene in 
S. venezuelae.  A strategy similar to the one described for the construction of 
pDesI-K was used to generate pDesVIII-K.  Two fragments, “sug-up” (0.9 kb) 






























Figure 2-2: Construction of the disruption plasmid pDesII-K.  Abbreviations are 
as described in the caption to Figure 2-1.
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downstream, respectively, were amplified by PCR using pLZ4 as the template.  
Primers 5′-CCGGTCTAGACGTGGATCCAGTGGATGC-3′ and 5′-CGCG-
GAATTCCAGCTACTTCTTCC-3′ were used for the amplification of the “sug-
up” fragment (the engineered restriction sites XbaI and EcoRI, respectively, are 
underlined) and 5′-GCGCAAGCTTGGTGTGCATCGGGTAGTTGC-3′ and 5′-
CCGGCTGCAGTCAGCAGCTCCTGAGACAC-3′ were used for the 
amplification of the “desVIII” fragment (the engineered restriction sites HindIII 
and PstI, respectively, are underlined).  These two fragments and the ”neo” 
fragment were ligated into pUC119 to give the plasmid pDesVIII-d1.  The 3.3 kb 
insert of pDesVIII-d1 was then removed by digestion with restriction enzymes 
EcoRI and HindIII and cloned into pKC1139, resulting in the plasmid pDesVIII-
K (Figure 2-3). 
2.2.3 Conjugal Transfer of Disruption Plasmids into S. venezuelae 
These experiments were performed by following a published procedure18 




























Figure 2-3: Construction of the disruption plasmid pDesVIII-K.  Abbreviations 
are as described in the caption to Figure 2-1.
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initially propagated in E. coli DH5α but were subsequently transferred to E. coli 
S17-1 prior to being transferred to S. venezuelae.  All of the culture tubes and 
flasks were equipped with glass beads or springs. 
A 1 mL aliquot of S. venezuelae (recipient) mycelia was inoculated into 
9 mL of the tryptic soy broth (TSB) and grown at 29 oC for 18 h.  Meanwhile, 
E. coli S17-1, which contains the disruption plasmid (donor), was streaked out on 
LB plates containing apramycin (100 µg/mL), kanamycin (50 µg/mL), and 
streptomycin (10 µg/mL) and incubated at 37 oC overnight.  Subsequently, an 
aliquot (2 mL) of the recipient culture was re-inoculated into 18 mL of TSB and 
allowed to grow for another 18 h.  A brief sonication was carried out to 
homogenize the culture when cells were forming clumps.  Single colonies of 
donor cells were inoculated into 2 mL of TSB containing apramycin (100 µg/mL), 
kanamycin (50 µg/mL), and streptomycin (10 µg/mL), and allowed to grow at 
37 oC overnight in an orbital shaker.  Afterwards, 1 mL of the recipient culture 
was transferred into 9 mL of TSB for a 3 h growth.  In parallel, an overnight 
donor culture (20 µL) was transferred into 2 mL of TSB containing the 
appropriate antibiotics, and allowed to grow at 37 oC for 3 h. 
Both recipient and donor cells were recovered by centrifugation and 
washed twice with TSB.  A 2 mL aliquot of TSB was then used to resuspend the 
recipient and donor cells separately.  Three mixtures of the recipient and donor 
cells were prepared with ratios of 1:1, 9:1, and 1:9, respectively.  Aliquots of 
100 µL of the mixed cultures were spread on freshly prepared AS1 agar plates 
(per 1 L: 1 g of yeast extract, 0.2 g of L-alanine, 0.5 g of L-arginine, 5 g of soluble 
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starch, 2.5 g of NaCl, 10 g of Na2SO4, 20 g of agar, pH 7.5; after autoclaving, 
MgCl2 was added to the final concentration of 10 mM).26  Three to five replicates 
were normally made for each mixture.  In addition, two plates were inoculated 
with Streptomyces cells and one plate was inoculated with E. coli cells as 
controls.  The plates were incubated at 29 oC overnight prior to overlaying with 
the appropriate antibiotics.  For conjugation plates, 1 mL of aqueous solution of 
nalidixic acid (500 µg/mL), apramycin (500 µg/mL) and kanamycin (500 µg/mL) 
was applied on the surface.  For negative controls, one Streptomyces plate was 
overlaid with all three antibiotics, and one E. coli plate was overlaid with 
nalidixic acid (500 µg/mL).  For a positive control, one Streptomyces plate was 
overlaid with nalidixic acid (500 µg/mL).  The plates were incubated at 29 oC for 
7 to 10 days. 
2.2.4 Screening for Double-Crossover Mutants 
Plasmids pDesI-K, pDesII-K, and pDesVIII-K were introduced into the 
wild type S. venezuelae via conjugal transfer.  The conjugants usually became 
visible on the plates after 4–5 days of incubation.  Individual colonies were picked 
and streaked on SPA plates (per 1 L: 1 g of yeast extract, 1 g of beef extract, 2 g 
of tryptone, 10 g of glucose, several crystals of FeSO4, 15 g of agar) 
supplemented with apramycin (100 µg/mL) and kanamycin (50 µg/mL).  Three 
spore-to-spore passages were carried out on SPA plates without antibiotics to 
facilitate the homologous recombination between the disruption plasmid and the 
S. venezuelae chromosome, and the natural loss of the plasmid by S. venezuelae.  
The resulting spores were inoculated into 5 mL of SGGP medium (per 1 L: 4 g of 
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peptone, 4 g of yeast extract, 4 g of casamino acids, 2 g of glycine, 0.25 g of 
MgSO4•7 H2O; after autoclaving, glucose was added to 1% w/v and KH2PO4 to 
the final concentration of 10 mM) without antibiotics for the growth at 29 oC.  
Overnight cultures were diluted 10-5–10-7 fold with SGGP and plated on SPA 
supplemented with 50 µg/mL of kanamycin.  Single colonies were then replicated 
on SPA plates containing 100 µg/mL of apramycin.  The colonies, which showed 
kanamycin resistant (KanR) and apramycin sensitive (AprS) characteristics, were 
identified as double-crossover mutants.  These mutant strains are referred to as 
KdesI, KdesII, and KdesVIII. 
2.2.5 Preparation of Spore Suspensions and Frozen Mycelia for 
S. venezuelae Strains 
The wild type S. venezuelae and its mutant strains were stored as spore 
suspensions in 20% glycerol at –80 oC.  Colonies of S. venezuelae strains were 
first streaked out on SPA plates containing the appropriate antibiotics and allowed 
to grow for up to one week at 27–29 °C.  To prepare spore suspensions, 2 mL of 
sterile 20% glycerol in water was added to each plate, and the spores were 
scraped off with small sterile Q-tips.  The resulting suspensions were transferred 
to a pipette tip plugged with cotton wool.  The spore suspensions were pipetted 
through cotton into sterile Eppendorf tubes and stored at –80 °C. 
To prepare frozen mycelia of S. venezuelae strains, a 10 µL aliquot of 
spore suspension was inoculated into 25 mL of SGGP or TSB medium in a 
250 mL baffled flask and allowed to grow for 28 h at 29 °C in an orbital shaker.  
Cell cultures were transferred to a 50 mL conical tube and centrifuged for 10 min 
at 1,700 g.  The supernatant was discarded and cell pellet was resuspended in 
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15 mL of 10.3% sucrose.  Cells were centrifuged again and the supernatant was 
discarded.  Resuspension of cells in 15 mL of 20% glycerol yielded a stock 
mycelia solution that was stored at –20 °C. 
2.2.6 Confirmation of Deletional Disruption in KdesII-101 Mutant by 
Southern Blot Hybridization 
The replacement of the desII gene with the kanamycin resistance marker, 
neo, in the chromosome of one of the S. venezuelae KdesI mutants, KdesI-101, 
was confirmed by the Southern blot hybridization analysis.  The samples of 
genomic DNA from the wild type S. venezuelae and KdesI-101 strains were 
prepared using a previously described procedure.24  The genomic DNA was 
digested with the BamHI enzyme, separated by agarose gel electrophoresis, and 
transferred to a nylon membrane using a standard procedure.23  A 0.95 kb “desII-
probe” fragment from the desIII region of the S. venezuelae chromosome and the 
neo fragment were used as probes.  The fragment “desII-probe” was synthesized 
by PCR using the following primers: 5'-CGCGTCTTCCTTTCGGTCGC-
GCTGTA-3' and 5'-GCGCTCGGTCATTTCGAAGCAGAT-3'.  The probes were 
labeled with 32P-containing nucleotides using the Multiprime DNA Labeling 
System (Amersham Biosciences) according to the manufacturer’s instructions.  
Standard Southern hybridization protocols were used per description by Hopwood 
and coworkers.24  
2.2.7 Purification and Characterization of Metabolites Produced by 
S. venezuelae KdesI, KdesII, and KdesVIII Mutants 
General Procedure.  One of each kind of S. venezuelae double-crossover 
mutant was selected for further experiments: KdesI-80, KdesII-101, and 
 84
KdesVIII-92.  The analysis was carried out by growing the KdesI-80, KdesII-101, 
and KdesVIII-92 mutants under the conditions described by Cane et al., favoring 
the formation of 12-membered ring macrolides (1 and 2).13  Specifically, 5 mL of 
the seed medium (per 1 L: 20 g of glucose, 15 g of soybean flour, 5 g of CaCO3, 
1 g of NaCl, 0.002 g of CoCl2•6H2O, pH 7.2) was inoculated with 10 µL of spore 
suspension of either KdesI-80, KdesII-101, or KdesVIII-92 mutant and grown at 
29 oC for 48 h.  The culture was then transferred to 50 mL of the vegetative 
medium (per 1 L: 20 g of glucose, 30 g of soybean flour, 2.5 g of CaCO3, 1 g of 
NaCl, 0.002 g of CoCl2•6H2O, pH 7.2) and allowed to grow for another 48 h.  The 
mycelia and cellular debris were removed by centrifugation at 10,000 g for 
20 min.  The supernatant was collected, adjusted to pH 9.5 with 10 N KOH, and 
extracted four times with an equal volume of chloroform.  The evaporation of the 
organic solvent resulted in a dark-yellow residue, which was analyzed by TLC 
employing a solvent mixture of chloroform/methanol/25% NH4OH (90:9.9:0.1).  
Visualization of the compounds present in the crude extract was accomplished by 
exposure to vanillin stain (0.75% vanilla, 1.5% H2SO4, in methanol) followed by 
heating with the heat gun.  Methymycin (1) and its derivatives showed a green 
color, whereas neomethymycin (2) and its derivatives showed an orange color.  
To isolate the glycosylated methymycin/neomethymycin analogs, a large-
scale fermentation was carried out in which 200 mL of the seed medium was 
inoculated with 20 µL of the spore suspension of the corresponding S. venezueale 
mutant strain.  This mixture, after incubating at 29 oC for 48 h, was used to 
inoculate the vegetative medium (20 mL per liter).  The crude products were first 
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purified by flash chromatography on silica gel using a gradient of 0–40% 
methanol in chloroform.  Further purification was performed by HPLC on a C18 
column (Econosil, 10×250 mm, 10 µm) eluted isocratically with 40% acetonitrile 
in water.  The detector was set at 235 nm.  Details related to each of the mutants 
are as follows. 
Characterization of Metabolites Produced by S. venezuelae KdesI-80.  
The macrolides produced by the desI-deleted mutant of S. venezuelae were 
isolated from 8 L of the fermentation broth of KdesI-80.  A total of 600 mg of 10-
deoxymethynolide (65), 40 mg of methynolide (74), 2 mg of neomethynolide 
(75), and 3.2 mg of 76 were obtained. 
1H NMR (500 MHz, CDCl3) of 65: δ (ppm) 6.75 (1H, dd, J = 15.5, 5.5 Hz, 
9-H), 6.42 (1H, dd, J = 15.5, 1.0 Hz, 8-H), 5.00 (1H, ddd, J = 8.2, 5.5, 2.2 Hz, 11-
H), 3.56 (1H, dd, J = 10.2, 5.2 Hz, 3-H), 2.64 (1H, m, 10-H), 2.60 (1H, dq, J = 
10.5, 7.0 Hz, 2-H), 2.53 (1H, m, 6-H), 1.70 (1H, m, 12a-H), 1.66 (1H, m, 5a-H), 
1.57 (1H, m, 12b-H), 1.56 (1H, m, 5b-H), 1.31 (3H, d, J = 6.5 Hz, 2-Me), 1.28 
(1H, m, 4-H), 1.22 (3H, d, J = 7.0 Hz, 6-Me), 1.12 (3H, d, J = 7.0 Hz, 10-Me), 
1.01 (3H, d, J = 6.5 Hz, 4-Me), 0.92 (3H, t, J = 7.5 Hz, 12-Me). 
1H NMR (500 MHz, CDCl3) of 74: δ (ppm) 6.59 (1H, d, J = 15.8 Hz, 9-
H), 6.34 (1H, d, J = 15.8 Hz, 8-H), 4.78 (1H, dd, J = 11.0, 2.0 Hz, 11-H), 3.58 
(1H, d, J = 10.5 Hz, 3-H), 2.61 (1H, dq, J = 10.5, 7.0 Hz, 2-H), 2.54 (1H, m, 6-H), 
1.94 (1H, ddq, J = 14.5, 7.5, 2.0 Hz, 12a-H), 1.63 (2H, t, J = 7.5 Hz, 5H), 1.52 
(1H, ddq, J = 14.5, 11.0, 7.5 Hz, 12b-H), 1.37 (3H, s, 10-Me), 1.33 (3H, d, J = 
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7.5 Hz, 2-Me), 1.30 (1H, m, 4-H), 1.21 (3H, d, J = 7.0 Hz, 6-Me), 1.09 (3H, d, J = 
6.0 Hz, 4-Me), 0.91 (3H, t, J = 7.2 Hz, 12-Me). 
1H NMR (500 MHz, CDCl3) of 75: δ (ppm) 6.63 (1H, dd, J = 16.0, 5.5 Hz, 
9-H), 6.44 (1H, dd, J = 16.0, 1.5 Hz, 8-H), 4.84 (1H, dd, J = 9.0, 2.2 Hz, 11-H), 
3.90 (1H, dq, J = 5.5, 3.0 Hz, 12-H), 3.57 (1H, d, J = 10.5 Hz, 3-H), 2.61 (1H, dq, 
J = 10.5, 7.0 Hz, 2-H), 2.44 (1H, m, 6-H), 1.62 (1H, t, J = 12.5 Hz, 5a-H), 1.45 
(1H, dd, J = 12.5, 5.5 Hz, 5b-H), 1.31 (3H, d, J = 7.0 Hz, 2-Me), 1.31 (1H, m, 4-
H), 1.22 (3H, d, J = 7.0 Hz, 6-Me), 1.22 (3H, d, J = 6.5 Hz, 12-Me), 1.18 (3H, d, 
J = 7.0 Hz, 10-Me), 1.02 (3H, d, J = 6.5 Hz, 4-Me).   
1H NMR (500 MHz, CDCl3) of 76: δ (ppm) 6.76 (1H, dd, J = 16.0, 5.5 Hz, 
9-H), 6.43 (1H, d, J = 16.0 Hz, 8-H), 4.97 (1H, ddd, J = 8.4, 5.9, 2.5 Hz, 11-H), 
4.29 (1H, d, J = 8.0 Hz, 1'-H), 3.62 (1H, d, J = 10.5 Hz, 3-H), 3.49 (1H, t, J = 
9.0 Hz, 3'-H), 3.36 (1H, dd, J = 9.0, 8.0 Hz, 2'-H), 3.32 (1H, dq, J = 8.5, 5.5 Hz, 
5'-H), 3.23 (1H, dd, J = 9.0, 8.5 Hz, 4'-H), 2.82 (1H, dq, J = 10.5, 7.0 Hz, 2-H), 
2.64 (1H, m, 10-H), 2.55 (1H, m, 6-H), 1.70 (1H, m, 12a-H), 1.66 (1H, bt, J = 
12.5 Hz, 5b-H), 1.56 (1H, m, 12b-H), 1.40 (1H, dd, J = 12.5, 4.5 Hz, 5a-H), 1.35 
(3H, d, J = 7.0 Hz, 2-Me), 1.31 (3H, d, J = 5.5 Hz, 5'-Me), 1.24 (1H, bdd, J = 
10.0, 4.5 Hz, 4-H), 1.21 (3H, d, J = 7.0 Hz, 6-Me), 1.11 (3H, d, J = 6.5 Hz, 10-
Me), 1.00 (3H, d, J = 7.0 Hz, 4-Me), 0.92 (3H, t, J = 7.5 Hz, 12-Me).  13C NMR 
(125 MHz, CDCl3): δ (ppm) 205.0 (C-7), 174.7 (C-1), 146.9 (C-9), 125.9 (C-8), 
102.9 (C-1'), 85.4 (C-3), 76.5 (C-3'), 75.5 (C-4'), 74.7 (C-2'), 73.9 (C-11), 71.6 
(C-5'), 45.0 (C-6), 43.9 (C-2), 37.9 (C-10), 34.1 (C-5), 33.4 (C-4), 25.2 (C-12), 
17.7 (6-Me), 17.5 (5'-Me), 17.4 (4-Me), 16.2 (2-Me), 10.3 (12-Me), 9.6 (10-Me).  
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High-resolution (HR) FAB-MS: calculated for C23H38O8 (M + H)+ 443.2644, 
found 443.2661. 
Characterization of Metabolites Produced by S. venezuelae KdesII-101.  
The macrolides produced by the desII-deleted mutant of S. venezuelae were 
isolated from 3 L of the fermentation broth of KdesII-101.  Medium pressure 
liquid chromatography (MPLC) on silica gel with a gradient of 0–20% methanol 
in chloroform was used to separate the products.  It was followed by further 
HPLC purification of fractions of interest as described above.  A total of 
approximately 560 mg of 10-deoxymethynolide (65), approximately 80 mg of 
methynolide (74), approximately 20 mg of neomethynolide (75), 2.4 mg of 77 and 
1 mg of 78 were obtained. 
1H NMR (500 MHz, CDCl3) of 77: δ (ppm) 6.75 (1H, dd, J = 16.0, 5.5 Hz, 
9-H), 6.44 (1H, dd, J = 16.0, 1.2 Hz, 8-H), 5.34 (1H, d, J = 8.0 Hz, N-H), 4.96 
(1H, m, 11-H), 4.27 (1H, d, J = 7.5 Hz, 1'-H), 3.66 (1H, dd, J = 9.5, 8.0 Hz, 4'-H), 
3.60 (1H, d, J = 10.5 Hz, 3-H), 3.50 (1H, t, J = 9.5 Hz, 3'-H), 3.4 (1H, m, 5'-H), 
3.4 (1H, m, 2'-H), 2.84 (1H, dq, J = 10.5, 7.0 Hz, 2-H), 2.64 (1H, m, 10-H), 2.53 
(1H, m, 6-H), 2.06 (3H, s, Me-C=O), 1.7 (1H, m, 12a-H), 1.66 (1H, m, 5a-H), 
1.56 (1H, m, 12b-H), 1.4 (1H, m, 5b-H), 1.36 (3H, d, J = 7.5 Hz, 2-Me), 1.25 (3H, 
d, J = 6.5 Hz, 6'-H), 1.24 (1H, m, 4-H), 1.21 (3H, d, J = 7.5 Hz, 6-Me), 1.10 (3H, 
d, J = 6.5 Hz, 10-Me), 0.99 (3H, d, J = 6.0 Hz, 4-Me), 0.91 (3H, t, J = 7.2 Hz, 12-
Me).  13C NMR (125 MHz, CDCl3): δ (ppm) 205.3 (C-7), 175.1 (C-1), 171.9 (Me-
C=O), 147.1 (C-9), 126.1 (C-8), 103.0 (C-1'), 85.8 (C-3), 75.8 (C-5'), 75.8 (C-3'), 
74.1 (C-11), 70.8 (C-2'), 57.6 (C-4'), 45.3 (C-6), 44.0 (C-2), 38.1 (C-10), 34.2 (C-
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5), 33.6 (C-4), 25.4 (C-12), 23.7 (Me-C=O), 18.1 (C-6'), 17.9 (6-Me), 17.6 (4-
Me), 16.4 (2-Me), 10.5 (12-Me), 9.8 (10-Me).  HR FAB-MS: calculated for 
C25H42O8N (M + H)+ 484.2910, found 484.2904. 
1H NMR (500 MHz, CDCl3) of 78: δ (ppm) 6.69 (1H, dd, J = 16.0, 6.0 Hz, 
11-H), 6.09 (1H, dd, J = 16.0, 1.5 Hz, 10-H), 5.35 (1H, d, J = 8.5 Hz, N-H), 4.96 
(1H, m, 13-H), 4.36 (1H, d, J = 7.5 Hz, 1'-H), 4.19 (1H, m, 5-H), 3.83 (1H, q, J = 
7.0 Hz, 2-H), 3.68 (1H, dt, J = 10.0, 8.5 Hz, 4'-H), 3.52 (1H, t, J = 8.5 Hz, 3'-H), 
3.50 (1H, m, 5'-H), 3.42 (1H, t, J = 8.5 Hz, 2'-H), 2.92 (1H, dq, J = 7.5, 5.0 Hz, 4-
H), 2.81 (1H, m, 8-H), 2.73 (1H, m, 12-H), 2.06 (3H, s, Me-C=O), 1.8 (1H, m, 6-
H), 1.6 (1H, m, 14a-H overlapping with H2O peak), 1.55 (1H, m, 7a-H), 1.37 (3H, 
d, J = 6.5 Hz, 2-Me), 1.32 (3H, d, J = 7.0 Hz, 4-Me), 1.3 (1H, m, 14b-H), 1.27 
(3H, d, J = 6.5 Hz, 6'-H), 1.25 (1H, m, 7b-H), 1.12 (3H, d, J = 6.0 Hz, 8-Me), 1.11 
(3H, d, J = 6.5 Hz, 12-Me), 1.07 (3H, d, J = 6.0 Hz, 6-Me), 0.91 (3H, t, J = 
7.2 Hz, 14-Me).  HR FAB-MS: calculated for C28H46O9N (M + H)+ 540.3172, 
found 540.3203. 
2.2.8 Construction of the Expression Plasmids 
Plasmids pDesVII, pDesVIII, pTylM3, pEryCII, and pDnrQ were 
constructed for the expression of the desVII, desVIII, tylM3, eryCII, and dnrQ 
genes, respectively, in the S. venezuelae KdesVIII mutant.  The fragments 
containing these genes were amplified by PCR using the primers listed in Table 2-
1.  These primers were designed to contain restriction sites for EcoRI (underlined 
in the forward primer) and XbaI (underlined in the reverse primer) for the 
subsequent cloning.  One base in the sequence of the forward primer for the 
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“eryCII” fragment was modified (T→A silent mutation of the residue shown in 
brackets) to eliminate the innate EcoRI restriction site.  Cosmid pLZ4 was used as 
the template for the amplification of the “desVII” and “desVIII” fragments and 
the cosmid pZHG4 was used as the template for PCR amplification of the 
“tylM3” fragment.  Genomic DNA of S. erythraea and S. peucetius digested with 
BamHI was used as the template for the amplification of the fragments “eryCII” 
and “dnrQ”, respectively.  The PCR products were cloned into the EcoRI-XbaI 
sites of the vector pDHS617, containing the apramycin resistance marker, to give 
plasmids pDesVII (Figure 2-4), pDesVIII, pTylM3, pEryCII, and pDnrQ.  Each of 
these plasmids was used to transform E. coli S17-1 and then introduced into the 
KdesVIII-92 mutant. 
Table 2-1:  Primers Used for the Amplification of the Heterologous Genesa 




























a The respective restriction sites are underlined in the sequence of the primers. 
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2.2.9 Construction of S. venezuelae KdesVIII Strains Expressing desVII, 
desVIII, tylM3, eryCII, and dnrQ Genes 
Each of the plasmids pDesVII, pDesVIII, pTylM3, pEryCII, and pDnrQ 
was introduced into the S. venezuelae KdesVIII-92 strain via conjugal transfer as 
described above.  Selected colonies of S. venezuelae desVII/KdesVIII, 
desVIII/KdesVIII, tylM3/KdesVIII, eryCII/KdesVIII, and dnrQ/KdesVIII mutants 
were propagated on SPA plates containing apramycin (50 µg/mL) and kanamycin 
(50 µg/mL), and spore suspensions were prepared for storage. 
2.2.10 Purification and Characterization of Metabolites Produced by 
S. venezuelae dnrQ/KdesVIII 
The isolation and purification of the metabolites produced by the 
recombinant S. venezuelae dnrQ/KdesVIII strain were carried out as described 












Figure 2-4: An example of the expression plasmid, pDesVII.  Plasmids 
pDesVIII, pTylM3, pEryCII, and pDnrQ differ from pDesVII only 
by the sequence of the insert between the EcoRI and XbaI restriction 
sites.  The promoter derived from the S. venezuelae (PpikAI), the 
streptomycete origin of DNA replication (repSCP2*), the apramycin 
resistance gene (AprR), the origin of transfer for conjugation (oriT), 
and the E. coli origin of DNA replication from the pUC plasmid 
(reppUC) are labeled.
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(yellow oil, approximately 120 mg) were first purified by flash chromatography 
on silica gel using a gradient of 0–24% methanol in chloroform.  Further 
purification was performed by HPLC on a C18 column (Econosil, 10×250 mm, 
10 µm) eluted isocratically with 40% acetonitrile in 57 mM ammonium acetate 
buffer (pH 6.7).  A total of 40 mg of 10-deoxymethynolide (65), approximately 
3 mg of each methymycin (1) and neomethymycin (2), approximately 4 mg of 
crude pikromycin (4), approximately 2–5 mg of crude methynolide (74) and 
neomethynolide (75), and approximately 7 mg of pure neomethymycin (83) were 
obtained. 
1H NMR (500 MHz, CDCl3) of 83: δ (ppm) 6.65 (1H, d, J = 16.0 Hz, 9-
H), 6.31 (1H, d, J = 16.0 Hz, 8-H), 4.67 (1H, d, J = 9.0 Hz, 11-H), 4.29 (1H, d, J = 
7.0 Hz, 1′-H), 4.13 (1H, dq, J = 9.0, 6.5 Hz, 12-H), 3.61 (1H, d, J = 10.5 Hz, 3-H), 
3.52 (1H, dqd, J = 11.0, 6.5, 1.5 Hz, 5′-H), 3.32 (1H, dd, J = 10.5, 7.0 Hz, 2′-H), 
2.88–2.80 (2H, m, 3′-H and 2-H), 2.57 (1H, m, 6-H), 2.44 (6H, s, -NMe2), 1.76 
(1H, ddd, J = 12.0, 3.5, 1.5 Hz, 4′eq-H), 1.67 (1H, bt, J = 13.5 Hz, 5a-H), 1.52 
(3H, s, 10-Me), 1.44 (1H, m, 5b-H), 1.41 (3H, d, J = 6.5 Hz, 2-Me), 1.32 (1H, bq, 
J = 12.0 Hz, 4′ax-H), 1.25 (3H, d, J = 6.5 Hz, 5′-Me), 1.20 (1H, m, J = 6.5 Hz, 4-
H), 1.184 (3H, d, J = 6.5 Hz, 12-Me), 1.178 (3H, d, J = 7.0 Hz, 6-Me), 1.01 (3H, 
d, J = 6.5 Hz, 4-Me).  13C NMR (125 MHz, CDCl3): δ (ppm) 204.1 (C-7), 174.1 
(C-1), 148.3 (C-9), 125.4 (C-8), 104.7 (C-1′), 85.5 (C-3), 75.5 (C-10), 74.2 (C-
11), 70.0 (C-2′), 68.9 (C-5′), 67.8 (C-12), 65.9 (C-3′), 45.2 (C-6), 44.0 (C-2), 39.8 
(NMe2), 33.8 (C-4), 33.7 (C-5), 29.1 (C-4′), 21.07 and 21.04 (5′-Me and 12-Me), 
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20.2 (10-Me), 17.6 (6-Me), 17.4 (4-Me), 15.9 (2-Me).  HR FAB-MS: calculated 
for C25H43NO8 (M + H)+ 486.3067, found 486.3076. 
2.3 RESULTS AND DISCUSSION 
2.3.1 Inactivation of desI via Partial Gene Deletion 
The protein encoded by desI shows sequence homology to coenzyme B6-
dependent enzymes and has been assigned as the dehydrase involved in the C-4 
deoxygenation step.  Hence, if desI is disrupted in the pathway, desosamine 
biosynthesis will be “terminated” prior to C-4 deoxygenation, leading to an 
accumulation of the 3-keto-6-deoxyhexose 23, which may also be in equilibrium 
with the 4-keto intermediate 18 (Figure 2-5).  As mentioned earlier, the 
production of 66 and 67 by the KdesV mutant is indicative of the existence of a 
pathway-independent reductase in S. venezuelae that could stereospecifically 


















































Figure 2-5: Predicted macrolides produced by KdesI mutants. 
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reductase can also stereospecifically reduce compound 23 to TDP-D-quinovose 
(70), also known as TDP-6-deoxy-D-glucose.  The glycosyltransferase, DesVII, 
with its relaxed specificity toward sugar substrates, may catalyze the coupling of 
70 to the aglycone 65.  The resulting product is expected to be further modified by 
a PikC-catalyzed hydroxylation to give new macrolides 71 and 72 containing D-
quinovose.  Thus, if a glycosylated product is successfully isolated, the structural 
analysis of its sugar moiety should provide significant insight into the 
biosynthetic pathway for the formation of D-desosamine. 
Accordingly, the pDesI-d1 plasmid was constructed for the deletional 
disruption of desI (Figure 2-1).  Two DNA fragments flanking desI, named “desI” 
and “sug-d”, were amplified by PCR.  These fragments, together with another 
DNA fragment, “neo”, containing the neomycin resistance gene (also conferring 
resistance to kanamycin), were ligated into the HindIII-EcoRI sites of the vector 
pUC119.  The 3.5 kb EcoRI-HindIII section of the resulting pDesI-d1 plasmid 
was subsequently cloned into the pKC1139 vector.  The pKC1139 vector contains 
an apramycin resistance marker as well as a conjugal transfer gene, oriT, and is 
used for the transfer of DNA from E. coli to Streptomyces strains.18  The resulting 
plasmid, pDesI-K, (Figure 2-1) was used to transform E. coli S17-1, which serves 
as the donor strain to introduce the pDesI-K construct via conjugal transfer into 
the wild-type S. venezuelae.  As shown in Figure 2-6, the homologous 
recombination between pDesI-K and the S. venezuelae chromosome led to an 
alteration of the S. venezuelae chromosome.  The mutants in which neo was 
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inserted in the chromosomal desI gene were selected according to their 
kanamycin-resistant (KanR) and apramycin-sensitive (AprS) characteristics.  
One colony, KdesI-80, was chosen for further study.  This mutant was 
grown in the methymycin production medium (8 L),13 and its metabolites were 
extracted with chloroform and analyzed by TLC.  A preliminary TLC analysis 
revealed that no methymycin (1) or neomethymycin (2) were produced.  
However, a comparison of the extracts of the wild-type strain with extracts from 
KdesI-80 resulted in the appearance of several new spots that may correlate to 
novel macrolides (Figure 2-7, lane 1). 
The crude extract (yellow oil) was subjected to flash chromatography on 
silica gel, and the isolated products were further purified by HPLC.  Indeed, no 
methymycin or neomethymycin were detected.  Instead, 10-deoxymethynolide 
(65) was found as the major product (approximately 600 mg).  Significant 














Figure 2-6: Replacement of the target gene with antibiotic resistance marker 
(neo) via homologous recombination. 
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(approximately 2 mg) were also isolated.  These compounds were identified by 
comparison of their NMR data with published spectra for 65,27 74,28, 29 and 75.30  
Most importantly, a new macrolide 76 containing D-quinovose (3.2 mg) was 
produced by this mutant.  The structure of 76 was established by spectral analyses 
(1H NMR, 13C NMR, COSY, HMQC, and high resolution FAB-MS).  
Compounds 65 and 74–76 are shown in Figure 2-8. 
The fact that the macrolide 76 containing D-quinovose is indeed produced 
by the desI mutant is significant.  Firstly, the formation of quinovose as predicted 
further corroborates the presence of a pathway-independent reductase in 
S. venezuelae that reduces 3-keto sugars.  Interestingly, this reductase is able to 
act on the 4,6-dideoxy sugar 20 (Section 1.5), as well as the 6-deoxy sugar 23, 





1 2 3 4  
Figure 2-7: TLC analysis of macrolide production by S.venezuelae strains: 
KdesI-80 (lane 1), KdesII-101 (lane 2), KdesVIII-92 (lane 3), and 
wild type (lane 4).  The major products are labeled: 10-
deoxymethynolide (65), methynolide (74), neomethynolide (75), 
methymycin (1), and neomethymycin (2). 
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also possible that multiple pathway-independent reductases exist in S. venezuelae.  
However, it is not clear whether the reduction occurs before or after the 
monosaccharide is appended to the aglycone (Figure 2-5). 
Secondly, the retention of the 4-OH in quinovose as the result of the desI 
deletion provides strong evidence supporting the assigned role of desI as encoding 
a C-4 dehydrase.  This finding also lends further credence to the proposed 
biosynthetic pathway in which C-4 deoxygenation precedes C-3 
transamination.9, 10  An alternative pathway,6, 8 where the order of these two steps 
is reversed, is incompatible with the current observation. 
Furthermore, the data again shows that the glycosyltransferase (DesVII) of 
this pathway can recognize alternative sugar substrates whose structures are 
considerably different from the original amino sugar substrate, desosamine.  
While the incorporation of quinovose is important, another noteworthy, albeit 
unexpected, result is the fact that the aglycone of the isolated macrolide (76) is 
10-deoxymethynolide (65) instead of methynolide (74) or neomethynolide (75).  
It appears that PikC, which catalyzes the hydroxylation of 10-deoxymethynolide 















methynolide, 74: R1=OH, R2=H
neomethynolide, 75: R1=H, R2=OH  
Figure 2-8: Isolated macrolide products produced by KdesI-80 mutant. 
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variations in the appended sugar.  It could be argued that the presence of the 4-OH 
group in the sugar moiety is somehow responsible for decreasing or fully 
preventing the hydroxylation of the macrolide. 
2.3.2 Inactivation of desII via Partial Gene Deletion 
On the basis of the assumption that DesII, a putative reductase, may assist 
DesI to effect a C-4 deoxygenation in a manner similar to the C-3 deoxygenation 
catalyzed by E1/E3, the disruption of the desII gene should result in the 
accumulation of a Schiff base adduct (Figure 1-17).  However, since this adduct is 
expected to exist in an equilibrium with 23, the pathway-independent C-3 keto 
reductase should stereospecifically reduce 23 to generate D-quinovose as is the 
case with the desI disruption.  Therefore, it is likely that the macrolide 76, 
produced by the KdesI-80 mutant, may also be produced by the desII-deleted 
mutant. 
We used the same methodology as for the desI-deleted mutant in order to 
create a desII-deleted mutant.  First, the pDesII-d1 plasmid was constructed, 
containing two fragments flanking desII, “desII-up” and “desII-down”, as well as 
“neo”, ligated into the EcoRI-HindIII sites of the vector pUC119.  In this case, 
PCR was not successful for the “desII-down” fragment.  Therefore, this fragment 
was obtained by digestion of the pL005 plasmid containing a part of the des gene 
cluster, specifically desI, desII, and desIII genes.15  The 4.5 kb EcoRI-HindIII 
fragment of the plasmid pDesII-d1 was subsequently cloned into the pKC1139 
vector giving pDesII-K.  This latter plasmid was introduced into the wild-type 
S. venezuelae via conjugal transfer. 
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Using the same methodology as for the desI-deleted mutant, the KdesII-
101 mutant was subsequently created, in which the desII gene was replaced by 
neo.  The macrolide products (Figure 2-7, lane 2) were isolated from KdesII-101 
(3 L of culture), and their structures were established by spectral analyses.  These 
metabolites included previously identified aglycones 65 (the major product), 74, 
and 75 (minor products) (Figure 2-8).  However, no 76 was found in the 
fermentation broth.  Instead, a YC-17 derivative 77 (2.4 mg) and a pikromycin 
derivative 78 (approximately 1 mg) were isolated.  Both compounds carry an 
acetylated 4-aminosugar (Figure 2-9). 
The production of macrolides 77 and 78 by the KdesII-101 mutant was 
completely unexpected.  On the basis of the proposed biosynthetic pathway for 
TDP-D-desosamine, no route exists for the generation of such a C-4 amino sugar 
intermediate.  The presence of a pathway-independent C-4 aminotransferase is not 
likely since the KdesI-80 mutant did not produce compounds 77 and 78.  
In light of the surprising outcome of the experiment, we decided to verify 
that the mutation introduced was correct.  A Southern blot hybridization analysis 
was done using the “neo” or the 0.95 kb “desII-probe” fragment.  The latter was 

















Figure 2-9: Isolated macrolide products produced by KdesII-101 mutant. 
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2-10, when the BamHI-digested chromosomal DNA prepared from the mutant 
KdesII-101 was probed with the 32P-labeled “neo”, a 2.0 kb BamHI band was 
detected, while no such band was detected in the S. venezuelae wild-type strain.  
With the “desII-probe”, a 3.0 kb BamHI band was detected for the mutant strain, 
while a 5.0 kb BamHI band was revealed in the wild-type DNA.  This experiment 
confirmed that the desII gene was indeed replaced by neo on the chromosome of 
the KdesII mutant. 
As confirmed by Southern blot hybridization, the production of the 
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Figure 2-10: Disruption of the desII gene of S. venezuelae.  (A) Generation of the 
desII-disrupted KdesII-101 mutant via a homologous recombination.  
The BamHI restriction site is abbreviated as B.  (B)  Southern blot 
analysis of BamHI digested genomic DNA of S. venezuelae wild-
type and the KdesII-101 mutant. Lanes 1 (KdesII-101) and 2 (wild-
type) were probed by the 1.4 kb “neo” DNA fragment; lanes 3 
(KdesII-101) and 4 (wild-type) were probed by the 0.95 kb “desII-
probe” fragment. 
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disruption of the desII gene in the KdesII-101 mutant.  A plausible explanation is 
that DesI may possess aminotransferase activity.  However, whether this activity 
is an intrinsic property of DesI, or an activity exhibited by DesI in the absence of 
DesII, can only be established by further biochemical studies.  Nonetheless, the 
observation of a C-4 amino sugar as a part of the macrolide metabolites produced 
by the desII mutant represents the first evidence that is inconsistent with the 
proposed biosynthetic pathway for TDP-D-desosamine (22) shown in Figure 1-17. 
2.3.3 Inactivation of desVIII via Partial Gene Deletion 
The assignment of DesVIII as the tautomerase catalyzing the conversion 
of TDP-4-keto-4,6-dideoxyhexose 18 to its 3-keto analog 23 (Figure 1-17) was a 
speculation based solely on chemical intuition.  An inactivation of the desVIII 
gene, however, should shed light on this assignment, provided that the predicted 
sugar intermediate (4-keto-6-deoxy sugar, or D-quinovose) can be incorporated 
into the macrolides produced by the desVIII-deleted mutant. 
The KdesVIII-92 mutant was subsequently created, in which the desVIII 
gene was replaced by neo, using the method described for the desI deletion.  After 
fermentation, aglycones 65, 74, and 75 were isolated (Figure 2-7, lane 3).  
However, no glycosylated macrolides were found despite repeated attempts.  A 
Southern blot hybridization analysis was used to confirm that desVIII is indeed 
replaced by neo in KdesVIII-92.  The genomic DNA of the wild type 
S. venezuelae and the KdesVIII-92 mutant were isolated, digested with restriction 
endonucleases BamHI and PstI, and analyzed using Southern blot hybridization.  
As expected, no hybridization of the neomycin resistance gene with the wild type 
 101
DNA was observed.  Meanwhile, a prominent band of 1.4 kb corresponding to the 
approximate size of the neo gene was detected on the autoradiogram of the mutant 
DNA.  In a separate experiment, the 1.0 kb NcoI-XhoI fragment of the desosamine 
gene cluster outside the desVIII gene was used as a probe.  The bands 
corresponding to 4.7 kb and 5.5 kb hybridized fragments were expected for the 
BamHI-PstI fragment derived from the mutant and the wild type DNA, 
respectively.  Indeed, these bands were detected on the autoradiogram.  Therefore, 
the replacement of desVIII with neo was successful. 
One of the possible explanations for the absence of glycosylated 
compounds is that the disruption of desVIII has a polar effect on the downstream 
desVII.  If this is the case, the desVII gene will not be transcribed.  Consequently, 
no glycosyltransferase will be synthesized resulting in an inability to glycosylate 
any macrolides. 
In order to test this hypothesis, an extra copy of the desVII gene was added 
into the KdesVIII-92 mutant.  The 1.3 kb desVII gene was amplified by PCR 
using synthetic oligonucleotide primers and the pLZ4 cosmid as the template.  
The amplified gene was cloned into the EcoRI-XbaI restriction sites of the 
expression vector pDHS617, which contains an apramycin resistance marker 
(AprR).  The plasmid pDHS617 is derived from pOJ446.18  It contains the 
promoter sequence from the methymycin/neomethymycin cluster14 to drive the 
expression of genes in S. venezuelae.  The resulting plasmid, pDesVII (Figure 2-
4), was introduced by conjugal transfer using E. coli S17-118 into a previously 
constructed S. venezuelae mutant KdesVIII-92.  The colonies of S. venezuelae 
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KdesVIII containing pDesVII were identified on the basis of their resistance to 
both apramycin and kanamycin.  One of the engineered strains, S. venezuelae 
desVII/KdesVIII, was chosen for further study and its fermentation products were 
isolated as described above.  Again, only aglycones were isolated, and no 
macrolides containing a sugar moiety were observed.  Judging by TLC analysis, 
the phenotype of the desVII/KdesVIII mutant was identical to that of KdesVIII-
92.  Thus, no polar effect exists on the genes located downstream of desVIII.  In a 
separate experiment, a copy of the desVIII gene was introduced into KdesVIII-92 
using the same experimental procedure.  The phenotype (based on TLC analysis) 
of the resulting strain desVIII/KdesVIII closely resembles that of the wild type 
S. venezuelae, suggesting again that the expression of the downstream genes is not 
affected by the deletion of desVIII.  Therefore, the absence of glycosylated 
products is not caused by the polar effect. 
The fact that only aglycones were produced by the S. venezuelae KdesVIII 
and desVII/KdesVIII mutants strongly suggests that desVIII is involved in deoxy 
sugar biosynthesis and/or the attachment of deoxy sugars to the aglycones.  
Whether it catalyzes a specific reaction in the pathway is yet unclear. 
2.3.4 Implications on the Revised Biosynthetic Pathway for D-Desosamine 
The isolation and characterization of macrolide 76 produced by the desI-
deleted mutant have provided direct evidence confirming the involvement of desI 
in the C-4 deoxygenation step and the initial reaction sequence of the desosamine 
pathway.  The disruption of desII, resulting in the isolation of the macrolides 77 
and 78 containing an acetylated 4-aminosugar suggested that DesI may possess 
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C-4 aminotransferase activity.  Indeed, recent biochemical studies conducted in 
our group confirmed this hypothesis.15, 31  As shown in Figure 2-11, when 
compound 18 was incubated with the recombinant DesI in the presence of an 
amino donor (L-glutamate) and PLP, the 4-aminosugar 19 was isolated.  This 
result firmly established, for the first time, the function of DesI as the PLP-
dependent aminotransferase catalyzing the conversion of 18 to 19 in the 
biosynthesis of TDP-D-desosamine.  Compounds 77 and 78 are likely derived 
from the coupling of 19 and the corresponding aglycone, followed by N-
acetylation.  It is also conceivable that N-acetylation of 19 occurs prior to its 
coupling to the aglycones.  Regardless of the sequence of events, the production 
of 77 and 78 indicates that 19 must be accumulated in the desII-deleted mutant of 
S. venezuelae.  It can also be concluded that DesII is most likely the enzyme 
whose action occurs immediately after that of DesI in the desosamine biosynthetic 
pathway. 
The fact that DesI catalyzes the conversion of 18 to 19 has important 

















Figure 2-11: C-4 transamination reaction catalyzed by DesI in the presence of L-
glutamate and PLP. 
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tautomerization of 18 to 23 is no longer a necessary step in the pathway (Figure 1-
17).  This conclusion is also supported by the desVIII disruption study.  Since 23 
is not a part of the pathway, the originally proposed mechanism of the C-4 
deoxygenation is no longer possible.  Therefore, a new mechanism, which 
involves a 4-amino sugar intermediate (19), must be considered for the C–O bond 
cleavage at C-4. 
The genetic studies described herein, combined with the biochemical 
studies on DesI, have allowed us to propose a revised biosynthetic pathway for 
TDP-D-desosamine (Figure 2-12).  In this pathway, TDP-4-keto-6-deoxyglucose 
(18), generated from glucose-1-phosphate in two consecutive steps catalyzed by 
DesIII and DesIV, is converted to TDP-3-keto-4,6-dideoxyglucose (20) via a 4-
amino sugar intermediate (19) catalyzed by DesI and DesII.  The subsequent 
amination of 20 by DesV leads to TDP-3-amino-3,4,6-trideoxyglucose (21).  
Finally, the DesVI-catalyzed N,N-dimethylation of 21 completes the biosynthesis 













































Figure 2-12: The biosynthetic pathway for TDP-D-desosamine (22) by 
S. venezueale. 
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the desosamine formation, in particular the transformation from 19 to 20, must 
await further biochemical investigations. 
2.3.5 Implications on the Genetic Engineering of 
Methymycin/Neomethymycin Analogs 
Manipulations of the desosamine biosynthetic genes of S. venezuelae have 
led to the construction of several macrolides that carry two different deoxy sugars, 
D-quinovose and 4,6-dideoxy-4-acetamido-D-glucose.  The work presented here 
demonstrates the feasibility of combining pathway-dependent genetic 
manipulations and pathway-independent enzymatic reactions as a means to 
engineer sugars of designed structures.  The fact that pathway-independent 
enzymes could be used in concert with the natural biosynthetic machinery to 
generate further structural diversity is especially encouraging.  Most importantly, 
the methymycin/neomethymycin glycosyltransferase, DesVII, has been shown to 
be promiscuous, tolerating significant structural variations of its sugar substrates. 
The deletion of desI in S. venezuelae led to the accumulation of the 4-keto 
intermediate 18, a common precursor for bacterial deoxy sugars.  Thus, the 
S. venezuelae KdesI mutant may serve as a useful host for the construction of 
“tailored” deoxy sugar biosynthetic machineries which use 18 as the initial 
precursor.  Several proof of principle experiments have been carried out in our 
group and others.  For example, Zhao et al. have expressed the calH gene, 
involved in the calicheamicin biosynthesis by Micromonospora echinospora spp. 
Calichensis, in the S. venezuelae KdesI mutant.19  The resulting hybrid strain 
produced the same glycosylated products, 77 and 78 (Figure 2-9), as those 
produced by the S. venezueale KdesII mutant.  This result confirms that the 
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function of calH is the same as that of desI, namely a C-4 aminotransferase.19  
Another example is reported by Yamase et al., in which two genes of the L-
dihydrostreptose biosynthetic pathway in the streptomycin producer Streptomyces 
griseus, strM and strL, were introduced into the S. venezuelae KdesI mutant.32  
The strM and strL genes have been proposed to encode the TDP-4-keto-6-
deoxyglucose-3,5-epimerase and the dihydrostreptose synthase, respectively.  The 
resulting strain produced four new macrolides, 79–82, all of which contain an L-
rhamnose residue (Figure 2-13).  This study demonstrated the capability of 
DesVII to recognize and process sugar substrates possessing an L-hexose 
configuration. 
It is hoped that the knowledge and experience gained from the ongoing 
research of unusual sugar biosynthesis will facilitate the development of novel 
drugs against bacterial infections based on a combinatorial biosynthetic approach. 
2.3.6 Replacement of desVIII with Its Homologues from Other Pathways 
The deduced product of desVIII displays a significant sequence similarity 





















81: R1=H, R2=OH  
Figure 2-13: Macrolides produced by S. venezuelae KdesI carrying both strM and 
strL genes. 
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S. erythraea,7, 8 tylM3 (34% identity) in the tylosin gene cluster of S. fradiae,33, 
and dnrQ (35% identity, also known as dnmQ) in the aromatic polyketide 
daunorubicin (84, Figure 2-14 B) gene cluster of S. peucetius,34, 35 among several 
others.  These enzymes have been proposed to be involved in the biosynthesis of 
the deoxyamino sugars attached to their respective aglycones: EryCII in the 
desosamine pathway, TylM3 in the mycaminose pathway, and DnrQ in the 
daunosamine pathway.  While their functions remain uncertain, EryCII has been 
suggested to serve as a tautomerase catalyzing the conversion of the 4-keto sugar 
18 to the corresponding 3-ketosugar 23.7  However, it should be noted that the 
biosynthetic pathway to daunosamine does not necessarily require a 
tautomerization step.35  In fact, it has been shown that the formation and the 
attachment of daunosamine was significantly diminished, but not abolished, when 
dnrQ gene was inactivated.36  Since all four gene display significant sequence 
similarity, the fact that a tautomerization step may not be required in the 
biosynthesis of TDP-L-daunosamine raises questions as to the actual roles of the 
gene products of eryCII, tylM3, dnrQ, and desVIII.   
The gene disruption results described above led to the proposal of a new 
pathway to TDP-D-desosamine (22) (Figure 2-12) in which the DesI/DesII couple 
catalyzes the transformation of 18 to 20.  This revised biosynthetic pathway does 
not provide a role for DesVIII.  However, the fact that desVIII is located within 
the desosamine gene cluster (Figure 1-15) implicates a role of DesVIII in either 
the biosynthesis of desosamine or its attachment to the macrolide aglycone.  The 
inability of the S. venezuelae KdesVIII mutant to produce glycosylated products 
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further confirmed the importance of desVIII for the complete biosynthesis of the 
macrolides. 
Encouraged by the successful expression of heterologous genes in the 
S. venezuelae KdesI mutant, we decided to probe whether desVIII and its 
homologues, eryCII, tylM3, and dnrQ, have similar functions.  Our approach is to 
explore the complementarity of these genes to desVIII in the S. venezuelae 
KdesVIII mutant. 
Plasmids pEryCII, pTylM3, and pDnrQ were created, in which the genes 
eryCII, tylM3 and dnrQ, respectively, were cloned into the Streptomyces 
expression vector pDHS617.  The plasmids were introduced into the 
S. venezuelae KdesVIII-92 mutant via conjugal transfer.  The secondary 
metabolites produced by the resulting mutant strains, eryCII/KdesVIII, 
tylM3/KdesVIII, and dnrQ/KdesVIII, were then subjected to TLC analysis. 
Two of the mutant strains, eryCII/KdesVIII and tylM3/KdesVIII, 
produced only aglycone products 65, 74, and 75, indicating that their phenotypes 
were identical to that of the KdesVIII-92 strain.  No methymycin, 
neomethymycin, or other glycosylated analogs were detected in these strains.  The 
inability of the eryCII/KdesVIII mutant to produce glycosylated compounds is a 
surprise, since eryCII and desVIII are found in the biosynthetic gene clusters of 
the same sugar product, TDP-D-desosamine (22) in S. erythraea and 
S. venezuelae, respectively.  Given the substantial degree of sequence similarity 
between these two genes, they are expected to have the same catalytic function(s) 
and to work on the same substrate if both are directly involved in the formation of 
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desosamine.  However, the above negative complementation results suggested 
that they may catalyze the same reaction, but have different substrate preferences.  
A possible scenario is that DesVIII and EryCII are involved in the attachment of 
desosamine to the respective aglycone, not the construction of desosamine itself.  
The differences in the structures of 10-deoxymethynolide (65) and mycarosylated 
erythronolide B (43) may contribute to the lack of complementarity between 
EryCII and DesVIII.  A similar argument can also be applied to TylM3. 
Unlike the cases of eryCII/KdesVIII and tylM3/KdesVIII, a TLC 
comparison of the crude extract of the dnrQ/KdesVIII strain with that of the wild 
type S. venezuelae showed that dnrQ/KdesVIII is able to produce methymycin 
and neomethymycin, albeit in lower quantities than the wild type strain.  The 
crude extract of dnrQ/KdesVIII culture (3 L) was subjected to separation on a 
silica gel column followed by HPLC purification.  As before, the major product 
was 10-deoxymethynolide (65, approximately 40 mg), but hydroxylated 
aglycones 74 and 75 were also present (approximately 2–5 mg each).  In addition, 
we isolated approximately 3 mg each of pure methymycin (1) and 
neomethymycin (2), as well as approximately 4 mg of crude pikromycin (4).  
Interestingly, we also isolated approximately 7 mg of a new product, compound 
83 (Figure 2-14 A).  Compound 83 contains the same sugar moiety as 1 and 2, D-
desosamine, but has two positions of the aglycone, C-10 and C-12, hydroxylated 
instead of one. 
While the production of 1 and 2 by the dnrQ/KdesVIII mutant is only 1/10 
as efficient as the wild type, the fact that the wild type products 1, 2, and 4 were 
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produced indicates that dnrQ can at least partially replace desVIII. The lower 
yield of 1 and 2 may be attributed to the less efficient expression of the plasmid 
gene as compared to the expression of the genes located on the chromosomal 
DNA.  It may also be due to the intrinsic differences in the biochemical properties 
of these two proteins.  Significantly, compound 83 was obtained in quantities 
comparable to or even larger than those of 1 and 2. 
Shortly after we completed the characterization of the metabolites 
produced by the S. venezuelae dnrQ/KdesVIII strain, a report was published 
describing the isolation and characterization of 83 as a minor component 
produced by the wild type S. venezuelae.37  It was shown that 1 was converted to 
83 by PikC in vitro, providing insight into how 83 is formed in the wild type 
S. venezuelae.37  Thus, our discovery of 83 as one of the major glycosylated 
products produced by S. venezuelae dnrQ/KdesVIII strain, along with 1 and 2, 























Figure 2-14: (A)  New macrolide compound produced by the S. venezuelae 
dnrQ/KdesVIII strain, novamethymycin (83).  (B)  The structure of 
daunorubicin (84) produced by S. peucetius.  The homologue of 
desVIII in S. peucetius, dnrQ, is involved in the biosynthesis of 84. 
 111
Although desVIII and dnrQ were originally proposed to be involved in 
deoxy sugar biosynthesis or attachment, the results of this experiment clearly 
demonstrated that the replacement of desVIII with dnrQ can influence the extent 
of hydroxylation of the aglycone.  It is unlikely that these proteins directly 
participate in the hydroxylation.  Instead, desVIII and its homologues may have a 
regulatory function and their expression affects the hydroxylation as well as the 
glycosylation catalyzed by the corresponding P450 hydroxylase and glycosyl-
transferase in the respective pathways.  Clearly, the heterologous expression and 
the analysis of the catalytic function of DesVIII in vitro would be helpful.  The 
detailed biochemical characterization of DesVIII will be discussed in Chapter 4. 
2.4 CONCLUSIONS 
The results of the desI and desII gene disruptions, combined with the 
biochemical studies of DesI, led to the establishment of the function of DesI as a 
PLP-dependent aminotransferase.  It catalyzes the conversion of the 4-keto sugar 
substrate 18 to an amino sugar intermediate 19 during the biosynthesis of TDP-D-
desosamine (22).  A revised pathway, which involves a 4-aminosugar 
intermediate 19, was proposed on the basis of these studies (Figure 2-12).  This 
pathway may be a general route for the biosyntheses of other 4,6-dideoxyhexoses.  
The disruption of desVIII and its replacement with homologues from different 
pathways showed that although this gene is involved in the deoxysugar 
biosynthesis or/and attachment, DesVIII unlikely catalyzes a specific chemical 
transformation in the pathway.  Rather, DesVIII may serve a regulatory function.   
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Moreover, methymycin analogs carrying altered deoxy sugar moieties 
were generated via genetic engineering.  These results demonstrated the 
feasibility of combining pathway-dependent transformations and pathway-
independent enzymatic reactions as a means to tailor-make sugars of the designed 
structures.  In addition, the relaxed specificity of the glycosyltransferase DesVII 
was also demonstrated. 
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Chapter 3: Secondary Self-Protection Mechanism in S. venezuelae 
3.1 INTRODUCTION 
Three genes involved in self-resistance have been identified in the 
methymycin/pikromycin biosynthetic gene cluster of S. venezuelae (Chapter 1).1  
Two of them, pikR1 and pikR2, are MLSB type resistance genes.  They encode 
methyltransferases responsible for the methylation of a specific adenosine residue 
near the macrolide binding site in the rRNA.  The third one, desR, encodes a β-
glycosidase whose function was not apparent when this gene was first identified.2  
Because of the presence of this gene in the cluster, it was speculated that the 
macrolide antibiotics produced by S. venezuelae may be modified by a specific 
macrolide glycosyltransferase (MGT) to incorporate a glucose moiety in the final 
products.  Such a modification of glycosylation may render the antibiotic in the 
cell inactive.  The glucosylated macrolides may then be excreted together with the 


































Figure 3-1: The mechanism of self-resistance in S. venezuelae through 
glucosylation of 1 and 2 by macrolide glycosyltransferase (MGT).  
DesR reactivates glucosylated products 85 and 86 outside the cell. 
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second glycosidic linkage, reverting the inactivated antibiotic to its active form 
(Figure 3-1). 
 The function of DesR as a β-glycosidase was initially verified by gene 
disruption experiments2 and was later confirmed by in vitro assay of the purified 
DesR.3  The isolation of 85 and 86 (Figure 3-1) is a strong indication for the 
presence of an MGT to catalyze the glucosylation of 1 and 2.  However, no 
glycosyltransferase genes other than desVII were found in the vicinity of the 
methymycin/pikromycin gene cluster of S. venezuelae.  The desR-deleted 
S. venezuelae mutant still produces 1 and 2 as the major metabolites, indicating 
that the efficiency of the responsible MGT may be low.  From this observation we 
were also able to suggest that perhaps the methylation of the rRNA by PikR1 and 
PikR2, is the primary resistance mechanism in S. venezuelae.2  Whether the 
methylation of rRNA is indeed the primary resistance mechanism, or whether it 
only comes into play when the glucosylation-deglucosylation routine is hampered, 
remains to be elucidated. 
 The genetic and biochemical study of the resistance determinants in 
S. venezuelae is described in this chapter.  The inviability of the S. venezuelae 
triple mutant lacking pikR1, pikR2, and desR suggested that the methylation of 
rRNA is the primary self-resistance mechanism.  We also carried out an initial 
biochemical study of the MGT OleD from the oleandomycin producer 
S. antibioticus.  Most significantly, we screened the genome of S. venezuelae for 
oleD homologue, and identified an MGT gene.  The MGT of S. venezuelae, 
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DesG, was expressed in E. coli and its expected catalytic function was confirmed 
in a preliminary in vitro assay. 
3.2 EXPERIMENTAL PROCEDURES 
3.2.1 General 
Bacterial Strains.  E. coli DH5α from Invitrogen (Carlsbad, CA) was used 
throughout the study as the regular cloning host.  E. coli S17-14 was the donor 
strain for the conjugal transfer to S. venezuelae.  E. coli BL21(DE3) from 
Novagen Inc. (Madison, WI) was used as the host for the overexpression of oleD 
and desR gene.  E. coli LE392 was used as the host for the construction of a 
cosmid library of the S. venezuelae genomic DNA.  The strains S. venezuelae 
ATCC 15439 and S. antibioticus ATCC 11891 were obtained from American 
Type Culture Collection (ATCC, Rockville, MD) as freeze-dried pellets and were 
revived according to the instructions provided by ATCC.  The strain S. venezuelae 
KdesR, in which the wild type desR gene is replaced with the thiostrepton 
resistance gene (through the homologous recombination between the wild type 
S. venezuelae and the disruption construct pBL1005) was previously prepared by 
a former group member Dr. Lishan Zhao.2, 5 
Plasmids, Vectors and DNA Manipulations.  The pME43 cosmid (the 
derivative of the pNJ1 vector)6 containing pikR1 and pikR2 genes, as well as 
fragments of the polyketide synthase cluster5 was used as the template for 
polymerase chain reaction (PCR) and as the source of the appropriate DNA 
fragments for the pikR1/pikR2 disruption experiments.  The pKC1139 plasmid, 
used for the conjugal transfer of DNA to S. venezuelae, and the cosmid vector 
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pNJ1 were gifts from Dr. Leonard Katz of Abbott Laboratories.7  The pDHS617 
vector, used for the complementation of the S. venezuelae KdesR strain with the 
oleD gene, was a gift from Professor David Sherman of the University of 
Michigan.8  The pFD666 cosmid was used as the source of the neo fragment.9, 10  
The expression vectors pET24b(+) and pET28b(+) were obtained from Novagen.  
The general methods and protocols for recombinant DNA manipulations followed 
the description by Sambrook et al.,11 and those dealing with Streptomyces strains 
followed the description by Hopwood et al.12 and Kieser et al.13 
Biochemicals.  The enzymes used in the cloning experiments were 
obtained from Invitrogen or Promega (Madison, WI).  The 32P labeled nucleotides 
and the Multiprime DNA Labeling System used for the DNA probe labeling 
during the Southern blot hybridization analysis were purchased from Amersham 
Biosciences (Piscataway, NJ).  The antibiotics and biochemicals used in this study 
were the products of Sigma-Aldrich (St. Louis, MO) or Fisher Scientific 
(Pittsburgh, PA).  The growth media components were obtained from BD 
Diagnostics System (Sparks, MD).  The purification of DNA after digestion 
reactions and from an agarose gel was achieved using the Bio101 Geneclean II® 
kit purchased from Fisher Scientific. 
The Ni-NTA resin for the affinity purification of His-tagged proteins was 
obtained from Qiagen (Valencia, CA).  Glycosyltransferase Affinity Gel-UDP 
was purchased from EMD Biosciences Inc. (San Diego, CA).  The DEAE 
Sepharose CL-6B resin for ion exchange and Sephacryl S200 HR resin for size 
exclusion protein chromatography were obtained from Amersham Biosciences 
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(Piscataway, NJ).  All protein purification steps were carried out at 4 oC except 
for FPLC chromatography (Amersham Biosciences) that was performed at room 
temperature.  FPLC was equipped with the ion exchange MonoQ HR 10/10 or the 
size exclusion Superdex 200 HR 10/30 column. 
Instrumentation.  The pH values were obtained using the Corning pH 
meter 240 purchased from Fisher Scientific.  The mini-sub cell GT from BioRad 
(Hercules, CA), powered by either a FB600 or a FB135 power supply from Fisher 
Scientific, was used for the agarose gel electrophoresis.  All centrifugation 
procedures were performed using an Avanti J-25 unit from Beckman (Arlington 
Heights, IL).  Microcentrifugations were done with an Eppendorf 5415C from 
Brinkmann Instruments, Inc (Westbury, NY).  The gel documentation was 
performed with a Polaroid MP-4 Land Camera (Cambridge, MA) loaded with a 
Polaroid Type 667 coatless black and white instant film and illuminated with a 
Foto UV 310 transilluminator from Fotodyne Inc (New Berlin, WI).  The 
polymerase chain reactions were conducted using a Perkin Elmer Cetus DNA 
Thermal Cycler (Norwalk, CT).  The ultraviolet–visible spectra were recorded 
with a Beckman DU-650 spectrophotometer.  The HPLC separations were 
achieved on a Beckman 366 instrument (Beckman Instruments, Fullerton, CA) 
equipped with Econosil C18 columns from Alltech (Deerfield, IL).  The NMR 
spectra were acquired on a Varian Unity 300 or 500 spectrometer, and the 
chemical shifts (δ in ppm) are given relative to those for Me4Si (for 1H and 13C) 
with the coupling constants reported in hertz (Hz).  The flash chromatography 
was performed on the Lagand Chemical silica gel (230–400 mesh) by the elution 
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with the specified solvents.  The analytical thin-layer chromatography (TLC) was 
carried out on the Polygram Sil G/UV254 plates (0.25 mm) (Macherey-Nagel Inc., 
Easton, PA). 
Preparation of Competent Cells and the PCR Amplification of DNA.  Cells 
were made competent by the RbCl method,11 following the procedure described in 
Chapter 2.  The general procedure for the PCR amplification of DNA fragments 
was the same as these described in Chapter 2. 
SDS-PAGE.  The protein purity and an estimated molecular mass were 
obtained by the sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) at 25 mA per gel, using a discontinuous buffer system.14  The separating 
gel and the stacking gel were 12% and 4% polyacrylamide, respectively.  Prior to 
electrophoresis, the protein samples were heated for 5 min at 100 oC (or 10 min at 
37 oC for the samples containing high imidazole concentrations) in 62.5 mM Tris-
HCl buffer (pH 6.8) containing 10% glycerol, 2% SDS, 5% β-mercaptoethanol, 
and 0.0025% bromophenol blue.  Electrophoresis of the denatured samples was 
run in 25 mM Tris-HCl, 192 mM glycine, and 0.1% SDS (pH 8.3) using the Mini-
PROTEAN II vertical system from BioRad.  Gels were stained with Coomassie 
blue (2.5 g/L of Coomassie Brilliant Blue G-250 in acetic acid : water : methanol, 
1:4:5 by volume) and de-stained in ethanol : acetic acid : water (4:5:41 by 
volume).15  The protein concentrations were determined according to Bradford,16 
using bovine serum albumin (BSA) as the standard and the dye reagent from 
BioRad. 
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3.2.2 Construction of S. venezuelae KdesR Strain Complemented with oleD 
Construction of Plasmid pOleD-1.  The pOleD-1 plasmid was constructed 
for the expression of the oleD gene in the S. venezuelae KdesR mutant.  The 
1.3 kb DNA fragment containing oleD was amplified by PCR using primers 5'-
GCCGGAATTCGCAACGTCTCGTCTACC-3' (forward) and 5'-CGCG-
TCTAGATCACAAAGCGGATCTC-3' (reverse) with the genomic DNA of 
S. antibioticus digested with EcoRI as the template.  The PCR product was 
digested with EcoRI and XbaI (the restriction sites are underlined in the sequence 
of the primers) and cloned into the EcoRI/XbaI sites of the vector pDHS617,8 
containing the apramycin resistance marker, to give the pOleD-1 plasmid.  This 
plasmid was used to transform E. coli S17-1 and then introduced into the KdesR-
11 mutant. 
Complementation of S. venezuelae KdesR Strain with oleD.  The pOleD-1 
plasmid was introduced into the S. venezuelae KdesR-11 strain via conjugal 
transfer as described in Chapter 2.  Selected colonies of the S. venezuelae 
oleD/KdesR mutant were propagated on SPA plates containing apramycin 
(100 µg/mL) and thiostrepton (50 µg/mL), and spore suspensions were prepared 
for storage. 
Analysis of Metabolites Produced by S. venezuelae oleD/KdesR.  For the 
analysis of the metabolite production of the recombinant S. venezuelae 
oleD/KdesR, this strain was grown under the 12-membered ring production 
conditions.  The metabolites were isolated from a small-scale culture and 
analyzed by TLC as described in Chapter 2.  The standards of 85 and 86 for TLC 
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comparison were obtained by Dr. Lishan Zhao from the fermentation broth of 
S. venezuelae KdesR-11.2 
3.2.3 Construction of the Triple KdesR/KpikR1,R2 Mutant of S. venezuelae 
Construction of the Disruption Plasmid pPikR-K.  The pPikR-K plasmid 
was constructed and used to replace the pikR1 and pikR2 genes with the neomycin 
resistance gene (which also confers the resistance to kanamycin) in the genome of 
S. venezuelae KdesR strain to eliminate the PikR1 and PikR2 activities.  The 
genes pikR1 and pikR2 are clustered and located upstream of the PKS cluster.1  
The two sequence fragments flanking pikR1 and pikR2 genes were amplified by 
PCR using primers: 5'-CGGACACGAATTCCTCGGAC-3' and 5'-GCGC-
TCTAGAATACGGTGACCCTCTCC-3' for the ”pikR1 end” (1.1 kb long) and 5'-
CGCGAAGCTTTGCAGCATGTTCCTGTCC-3' and 5'-GGTACTGCAG-
GAAGTCGTGG-3' for the “pikR2 end” (1.3 kb long).  These primers contain the 
recognition sites (underlined) for the restriction enzymes EcoRI, XbaI, HindIII, 
and PstI, respectively.  The pME43 cosmid,5 which contains the pikR1 and pikR2 
genes as well as a part of the polyketide synthase gene cluster, was used as the 
template for the PCR amplification.  To amplify the fragment “neo” containing 
the neomycin resistance gene (1.4 kb long) from the pFD666 plasmid,10 the 
following primers were used: 5'-CGCGTCTAGATACCTACAGCGTGAGC-3' 
and 5'-CGCGCTGCAGCCACGAATTAGCC-3' (the restriction sites for XbaI and 
PstI, respectively, are underlined). 
The PCR products were digested with the corresponding restriction 
enzymes and ligated into the EcoRI and HindIII sites of pUC119 to give the 
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pPikR-d plasmid.  The product of the four-way ligation, pPikR-d, was then 
digested with the EcoRI and HindIII enzymes and the resulting 3.74 kb fragment 
was cloned into pKC1139 affording the disruption plasmid pPikR-K, which 
conferred the resistance to both apramycin and kanamycin.  Following the same 
procedure as for the construction of the KdesI, KdesII, and KdesVIII mutants 
(Chapter 2), this plasmid was used in the homologous recombination with the 
chromosomal DNA of the S. venezuelae KdesR-11 mutant to create the triple 
disruption mutant of S. venezuelae, KdesR/KpikR1, R2. 
Screening of the Triple KdesR/KpikR1,R2 Mutant of S. venezuelae.  The 
conjugal transfer of pPikR-K into the S. venezuelae KdesR-11 and screening for 
double-crossover mutants were carried out as described in Chapter 2 with the 
following exceptions.  First, the S. venezuelae KdesR-11 recipient strain was used 
in place of the wild-type strain.  Second, thiostrepton (20 µg/mL) was used for the 
propagation of the recipient and the resulting mutant cultures.  The conjugation 
plates were flooded with 1 mL of an aqueous solution of nalidixic acid 
(500 µg/mL), apramycin (500 µg/mL), kanamycin (500 µg/mL), and thiostrepton 
(500 µg/mL) per plate.  Throughout the screening, individual colonies exhibiting 
thiostrepton resistant (ThioR), kanamycin resistant (KanR), and apramycin 
sensitive (AprS) characteristics were identified as double-crossover mutants 
KdesR/KpikR1, R2. 
3.2.4 Expression of oleD and Purification of the Recombinant Protein 
Construction of the Expression Plasmid pOleD-2.  The oleD gene was 
expressed as a recombinant protein with a C-terminal His6 tag.  The oleD gene 
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was amplified by PCR using the following primers: forward primer 5'-GCCG-
CATATGACCACCCAGACCACAC-3', containing an NdeI restriction site 
(underlined), and reverse primer 5'-GCGCAAGCTTCAAAGCGGATCTCTGC-
3', containing a HindIII restriction site (underlined).  The genomic DNA of 
S. antibioticus digested with EcoRI was used as the template.  The PCR-amplified 
DNA fragment was cloned into the NdeI-HindIII sites of the vector pET24b(+) to 
give pOleD-2.  This plasmid was used to transform E. coli BL21(DE3). 
Cell Growth.  An overnight culture of E. coli BL21(DE3)/pOleD-2 was 
used to inoculate five 1 L cultures (0.2% v/v) of the LB medium containing 
kanamycin (35 µg/mL).  The cultures were incubated at 37 oC until the OD600 
reached 0.5.  The temperature of the incubation was lowered to 25 oC and the 
cultures were induced with 0.1 mM IPTG, and incubation at 25 oC continued for 
16 h.  The cells were harvested by centrifugation (5,000 g, 15 min). 
Crude Extract Preparation.  Cell pellet was re-suspended in 85 mL of 
lysis buffer (50 mM sodium phosphate, 300 mM NaCl, 15% glycerol, pH 8.0) 
containing 2 mg/mL of lysozyme and incubated on ice for 30 min.  The cells were 
disrupted by sonication in five 1-min bursts with a 1-min cooling period between 
each blast.  Cell debris was removed by centrifugation (35,000 g, 30 min), and the 
supernatant was used in the next step. 
Affinity Purification Using Ni-NTA Resin.  The supernatant was mixed by 
a slow agitation with 3 mL of the packed Ni-NTA agarose resin (Qiagen, 
Valencia, CA) for 1 h at 4 oC.  The slurry was poured into a capped column and 
washed with 120 mL of a lysis buffer.  It was followed by washing with 60 mL of 
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the lysis buffer that contained 15 mM imidazole and 30 mL of the lysis buffer that 
contained 20 mM imidazole.  The desired protein eluted in the flow-through 
fractions.  It was later determined that due to the mutation in the pET24b(+) 
vector sequence, a stop codon was introduced upstream of the sequence coding 
for the His6 tag.  Consequently, the recombinant OleD protein did not have a His6 
tag.  Therefore, it was purified using DEAE anion exchange chromatography. 
Anion Exchange Chromatography Using DEAE Resin.  The sample 
selected after the Ni-NTA purification was loaded onto a DEAE Sepharose CL-
6B column (70 mL bed volume) and washed with 100 mL of a 50 mM potassium 
phosphate (pH 7.5) containing 15% glycerol.  The bound proteins were then 
eluted using a linear gradient between equal volumes (1 L) of the loading buffer 
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Figure 3-2: SDS-PAGE of proteins described in this chapter.  Lane 1 is DesG-N-
His (major band of approximately 46 kDa).  Lane 2 is DesG-C-His 
(major band of approximately 45.5 KDa).  Lane 3 is purified OleD 
(major band of approximately 48 kDa).  Lane M is the prestained 
molecular weight marker and bands are as follows: E. coli MBP-
paramyosin, 83 kDa; bovine glutamic dehydrogenase, 62 kDa; rabbit 
aldolase, 47.5 kDa; rabbit triosephosphate isomerase, 32.5 kDa; 
bovine β-lactoglobulin A, 25 kDa. 
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judged by the UV A280 readings) were further analyzed by SDS-PAGE.  The 
desired fractions containing the major protein of 48 kDa were pooled and dialyzed 
against two 1 L changes of the 50 mM potassium phosphate buffer (pH 7.5) 
containing 15% glycerol.  The purified OleD enzyme (Figure 3-2, lane 3) was 
aliquotted and stored at –80 oC. 
3.2.5 OleD Activity Assay 
In order to assay the glycosyltransferase activity of OleD, a TLC assay 
was used.  The assay mixture consisted of 50 mM Tris-HCl (pH 8), 5 mM MgCl2, 
0.5 mM methymycin (1), 2 mM UDP-glucose (87), 2 µM OleD in a total volume 
of 100 µL.  The mixture was incubated in an orbital shaker at 30 oC for 1 h.  The 
products and the remaining 1 were extracted with 100 µL of chloroform.  The 
organic extract was applied on TLC plates (20 µL/spot).  The plates were 
developed with a solvent mixture of chloroform/methanol/25% NH4OH 
(89:9.9:0.1), and stained with 0.75% vanilla and 1.5% H2SO4 in methanol.   
Alternatively, to assess the substrate specificity of OleD, 87 was replaced 
with UDP-D-galactose (88), UDP-D-mannose (89), UDP-D-xylose (90), UDP-D-
glucuronic acid (91), UDP-D-N-acetylglucosamine (92), TDP-D-glucose, CDP-D-
glucose, or GDP-D-glucose, and 1 was replaced with erythromycin A (6, as a 
hydrate), oleandomycin (9, as a phosphate salt), or tylosin (13, as a tartrate).  All 
of the above were purchased from Sigma-Aldrich. 
3.2.6 Coupled Ep/OleD Assay 
 The sample of Salmonella enterica LT2 α-D-glucopyranosyl phosphate 
thymidylyltransferase (Ep) was provided by Professor Jon Thorson currently of 
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the University of Wisconsin.17  The stock of the Ep enzyme has the activity of 
7.04 U/µL, where a unit of activity (U) is defined as the amount of the protein 
needed to produce 1 µmol of TDP-D-glucose per min.  D-Glucose-1-phosphate 
(93) and 2-deoxy-2-amino-D-glucose-1-phosphate (98) were purchased from 
Sigma-Aldrich.  The synthetic samples of 6-deoxy-D-glucose-1-phosphate (94), 4-
deoxy-D-glucose-1-phosphate (95), 3-deoxy-D-glucose-1-phosphate (96), 2-
deoxy-D-glucose-1-phosphate (97), and 4,6-dideoxy-4-amino-D-glucose-1-
phosphate (99) were provided by Professor Jon Thorson.  The Ep reaction was 
conducted first.  The reaction mixture consisted of 50 mM sodium phosphate 
(pH 7.5), 5.5 mM MgCl2, 10 mM sugar-1-phosphate, 5 mM UTP, and 0.5 µL 
(3.52 U) of Ep in a total volume of 50 µL.  The mixture was incubated in an 
orbital shaker at 37 oC for 30 min.  It was then chilled on ice and the components 
of the OleD reaction were added to bring the concentrations to 50 mM sodium 
phosphate (pH 7.5), 5.5 mM MgCl2, 1 mM tylosin (13), and 2.1 µM (0.2 nmol) 
OleD (5 µL of 2 mg/mL stock) in a final volume of 100 µL.  The reaction mixture 
was incubated at 30 oC for 1 h and the products were analyzed by TLC as 
described in Section 3.2.5. 
3.2.7 Screening S. venezuelae Genomic DNA Library for the MGT Gene 
The oleD gene amplified for the construction of the pOleD-1 plasmid 
(1.3 kb) was used in the colony hybridization and the Southern hybridization 
experiments.  The preparation of the 32P-labeled oleD probe was performed using 
the Multiprime DNA Labeling System (Amersham Biosciences) according to the 
manufacturer’s instructions.  The construction of the cosmid library of the 
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S. venezuelae genomic DNA was carried out according to Tuan et al.6 using the 
Packagene Kit from Promega.  Dr. Lishan Zhao of our group fractionated the 
S. venezuelae chromosomal DNA partially digested with Sau3AI.  The fragments 
of approximately 35 kb in length were ligated into the cosmid vector pNJ1 at the 
BglII sites.  The ligation mixture was packaged into a λ phage and used to 
transfect E. coli LE392.  The colonies were lifted onto the Biotrace NT 
nitrocellulose discs (Pall Life Sciences, East Hills, NY; formerly Gelman 
Sciences).  The colony hybridization was carried out according to the protocol 
recommended by Pall Life Sciences.  The preparation of the S. venezuelae 
genomic DNA and standard Southern hybridization protocols followed the 
procedures described by Hopwood et al.12 
The DNA sequencing was performed by the Advanced Genetic Analysis 
Center of the University of Minnesota at St. Paul and the DNA Core Facility at 
the Institute of Cellular and Molecular Biology of the University of Texas at 
Austin.  DNA primers for sequencing were custom-prepared by Invitrogen.  The 
sequence data was assembled and analyzed using software packages GeneWorks 
(Oxford Molecular Group, San Diego, CA) and Vector NTI (Informax, Bethesda, 
MD).  DNA and protein database searches were routinely performed using 
BLAST method of the National Center of Biological Information 
(www.ncbi.nlm.nih.gov). 
3.2.8 Amplification of the 3' End of desG Using RACE Kit 
To determine the missing sequence of the 3' end of the oleD homologue in 
S. venezuelae, desG, the RACE method was used.  The 3' RACE kit was 
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purchased from Roche Molecular Biochemicals (Indianapolis, IN).  All the 
procedures were carried out according to the protocol recommended by Roche 
Molecular Biochemicals.  Total RNA of S. venezuelae was isolated according to 
the procedure described by Kieser et al.13  All media, buffers, and glassware used 
while dealing with RNA were autoclaved twice to remove traces of any RNases.  
New bottles of organic solvents and plastic ware certified as RNase-free were 
used.  The quality of the RNA preparations was assessed using spectrophotometry 
and agarose gel electrophoresis.13   
The first strand of cDNA was synthesized by the AMV reverse 
transcriptase from an mRNA template using the universal oligo dT-anchor primer.  
The total RNA of S. venezuelae was used as the source of the mRNA template.  
The cDNA was in turn used as the template for the PCR synthesis of desG by the 
pfu DNA polymerase (Stratagene, La Jolla, CA), using the sequence specific 
primer SP1 (forward, 5'-CTAGGGTGTCCGCCATGAC-3') and the PCR anchor 
primer (reverse).  The attempts to clone the PCR product (1.8 kb) in the pGEM 
vector (Promega) using the A-tailing procedure recommended by the pGEM 
vector’s manufacturer failed. 
To create the restriction sites for cloning of the PCR product, we amplified 
the fragment of the cDNA using primers desGseq-6 (5′-GCGCAAGCTT-
AGGGTGTCCGCCATGAC-3′, corresponding to the beginning of desG with the 
potential GTG start codon shown in bold) and desGseq-8 (5′-GGCCGAATTC-
CACGCGTATCGATGTCGAC-3′, which is the same as the PCR anchor primer 
with the restriction site added) with engineered HindIII and EcoRI sites 
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(underlined), respectively.  The PCR product of approximately 1.8 kb was cloned 
at the HindIII-EcoRI sites of the pUC119 vector, and the insert of the resulting 
plasmid was sequenced using primers from Promega, M13/pUC-forward and 
M13/pUC-reverse, corresponding to the portions of the pUC119 vector.  No oleD 
homologues were found. 
3.2.9 PCR Amplification of desG Using Degenerated Primers 
The degenerated reverse primer was designed based on the alignment of 
the protein sequences of the homologous macrolide glycosyltransferases.  The 
protein sequence DLIEAEL, located at the C-terminal portion of macrolide 
glycosyltransferases, was used for designing the primer.  Variable bases were 
introduced in the DNA sequence of the primer to match the codon preferences for 
Streptomyces.13  The resulting primer, desGseq-14, had the sequence 5′-GGCC-
GAATTCSAGYTCSGCYTCGATSAGGTC-3′, where the restriction site for 
EcoRI is underlined, S = C + G, and Y = C + T. 
The fragment containing desG was amplified by PCR using primers 
desGseq-6 and desGseq-14, and the pSB-Sv-0301 cosmid containing the entire 
desG gene as the template.  The PCR product (1.2 kb) was cloned in the HindIII-
EcoRI sites of the pUC119 vector to give the plasmid pDesG0614.  The insert of 
pDesG0614 was sequenced using primers M13/pUC-forward and M13/pUC-
reverse.  The obtained nucleotide sequence was determined to be a part of desG.  
It was used to design primers for sequencing the region of desG further 
downstream: desGseq-15 (5′-GGATCCAGGCGGACATGGCG-3′) and desGseq-
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16 (5′-CTGCCGATGGAGAACGTCACC-3′).  The resulting sequencing 
information allowed the completion of the desG sequence (Figure 3-9). 
3.2.10 DesG: Expression, Purification, and Activity Assay 
Construction of the Expression Plasmids pDesG-C-His and pDesG-N-His.  
The desG gene was expressed as two recombinant proteins, DesG-C-His and 
DesG-N-His, containing a C-terminal and an N-terminal His6 tag, respectively.  
For the expression as DesG-C-His, the desG gene was amplified by PCR using 
the following primers: forward primer 5'-GCCGCATATGACCCCCGCTCC-3', 
containing an NdeI restriction site (underlined) and reverse primer 5'-GCGC-
AAGCTTGCCGCGCCGCGGGCCTCGGTCGAGCTCG-3' containing a HindIII 
restriction site (underlined).  For the expression as DesG-N-His, the desG gene 
was amplified by PCR using the same forward primer and the reverse primer 5'-
GCGCAAGCTTCAGCCGCGCCGCGGGCCTCGGTCGAGCTCG-3' containing 
a HindIII restriction site (underlined).  The cosmid pSB-Sv-0301 was used as the 
template.  The DNA fragments were amplified by PCR and cloned into the NdeI-
HindIII sites of the vector pET24b(+) to give pDesG-C-His, or the same sites of 
the vector pET28b(+) to give pDesG-N-His.  These plasmids were used to 
transform E. coli BL21(DE3). 
Cell Growth.  An overnight culture of E. coli BL21(DE3)/pDesG-C-His or 
E. coli BL21(DE3)/pDesG-N-His was used to inoculate 1 L cultures (1% v/v) of 
the LB medium containing kanamycin (35 µg/mL).  The cultures were incubated 
at 37 oC until the OD600 reached 0.5.  The temperature of incubation was lowered 
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to 18 oC and the cultures were induced with 0.3 mM IPTG.  After additional 16 h 
incubation at 18 oC, the cells were harvested by centrifugation (5,000 g, 15 min). 
Crude Extract Preparation.  Cell pellet from 3 L of culture was re-
suspended in 55 mL of the lysis buffer (50 mM potassium phosphate, 0.2% (v/v) 
Triton X-100, pH 7.5) containing 0.1 mg/mL of lysozyme and incubated on ice 
for 30 min.  The cells were disrupted by sonication in thirty 10-sec bursts with a 
20-sec cooling period between each blast.  Cell debris was removed by 
centrifugation (12,000 g, 20 min), and the supernatant was used in the next step. 
Affinity Purification Using Ni-NTA Resin.  The supernatant was mixed by 
a slow agitation with 6 mL of the packed Ni-NTA agarose resin (pre-washed in 
the lysis buffer) for 2.5 h at 4 oC.  The slurry was poured into a capped column 
and washed with 10 mL of a lysis buffer.  It was followed by washing with 20 mL 
of the lysis buffer that contained 10 mM imidazole and 30 mL of the lysis buffer 
that contained 30 mM imidazole.  The target protein was eluted with the lysis 
buffer containing 250 mM imidazole.  The desired fractions, as detected by SDS-
PAGE, were pooled and dialyzed against two 2 L changes of the 50 mM 
potassium phosphate buffer (pH 7.5) containing 10% glycerol.  The protein 
samples were stored at –80 oC.  The SDS-PAGE of DesG-N-His and DesG-C-His 
purified using the Ni-NTA resin is shown in Figure 3-2, lanes 1 and 2, 
respectively. 
Affinity Chromatography Using UDP-agarose Resin.  Attempts were also 
made to further purify DesG-N-His using the UDP-agarose resin.  Two published 
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procedures were tried,18, 19 but DesG-N-His did not bind to the resin under these 
conditions.  This technique was therefore abandoned. 
DesG Activity Assay.  The glycosyltransferase activity of DesG was 
determined by the TLC assay.  The assay mixture consisted of 50 mM Tris-HCl 
(pH 8), 5 mM MgCl2, 0.5 mM methymycin (1) or tylosin (13), 2 mM UDP-
glucose (87), 20 µL of DesG-C-His or DesG-N-His (approximately 2.5 mg/mL, 
0.5 µM), in a total volume of 100 µL.  The mixture was incubated in an orbital 
shaker at 30 oC for 1 h.  The products and the remaining aglycone were extracted 
with 100 µL of chloroform and analyzed by TLC as described in Section 3.2.5. 
3.3 RESULTS AND DISCUSSION 
If the proposed glycosylation-deglycosylation model is the primary self-
resistance mechanism for S. venezuelae, one would expect 85 and 86 be the major 
products produced by the KdesR mutant.  However, contrary to this prediction, 
both compounds were found only as minor products in the fermentation broth of 
the desR mutant.2  Further experiments showed that there is no second copy of 
desR or other desR homologue capable of hydrolyzing the diglycosides produced 
in the desR disrupted mutants.5  Thus, a possible reason for the low yields of 85 
and 86 may be due to the low expression level of the macrolide glycosyl-
transferase. 
3.3.1 Increasing Production of Glucosylated Macrolides by Expression of 
oleD in KdesR Mutant 
The yield of the glucosylated macrolides may be increased if the 
responsible glucosyltransferase is overproduced, or an exogenous MGT, which 
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has an identical function, is introduced into the desR disrupted mutants.  Because 
the glucosyltransferase catalyzing the post-synthesis modification in S. venezuelae 
has not been found, we decided to use OleD instead.  This enzyme, along with 
OleI, are the two macrolide glycosyltransferases involved in the self-resistance 
mechanism in the oleandomycin producer S. antibioticus.20  Both catalyze the β-
glucosylation at the C-2´ hydroxyl of the desosamine moiety.  The oleI gene is 
located within the oleandomycin biosynthetic cluster, and the encoded OleI is 
specific for oleandomycin.  In contrast, oleD is not a part of the oleandomycin 
cluster, and its translated product, OleD, is capable of glycosylating a number of 
macrolide antibiotics including oleandomycin (9), erythromycin (6), carbomycin 
(14) and tylosin (13).20 
In order to express the oleD gene in S. venezuelae, it was amplified by 
PCR from the genomic DNA of S. antibioticus and cloned into pDHS617 at the 
EcoRI-XbaI sites to give the plasmid pOleD-1.  The vector pDHS617 is derived 
from pOJ446,7 and it contains a promoter sequence from the 
methymycin/pikromycin cluster1 that enables the expression of foreign genes in 
S. venezuelae.8  The plasmid pOleD-1 was introduced into KdesR-11 by conjugal 
transfer using E. coli S17-1, and the pOleD-1-containing strains were selected on 
the basis of their thiostrepton resistant (ThioR) and apramycin resistant (AprR) 
phenotypes.  The examination of the macrolide production using TLC showed 
that the amounts of glucosylated methymycin (85) and glucosylated 
neomethymycin (86) made by oleD/KdesR strain were approximately eight times 
 136
more than those made by the KdesR mutants (Figure 3-3).  Up to 40% of 
methymycin and neomethymycin produced are now C-2' glucosylated. 
3.3.2 Deletion of the pikR1 and pikR2 Genes in S. venezuelae KdesR  
Since 1 and 2 are still the major products in the fermentation broth of the 
oleD/KdesR mutant, glucosylation of the macrolide products to give 85 and 86 is 
unlikely the primary self-resistance mechanism in S. venezuelae.  Instead, the two 
MLSB type resistant genes, pikR1 and pikR2, found upstream of the PKS (Figure 
1-15) may provide the major cellular self-protection for S. venezuelae.  The 
reason that two of these genes exist may be related to the fact that two distinct 
polyketide ring systems (1/2 and 4/5) are produced by this strain.  A disruption of 
both genes might force the bacterium to rely on the secondary self-protection 





1  2 3   4
 
Figure 3-3: TLC analysis of the macrolides produced by S. venezuelae KdesR 
(lanes 1 and 2) and S. venezuelae oleD/KdesR (lanes 3 and 4).  
Methymycin (1), neomethymycin (2), glucosylated methymycin (85) 
and glucosylated neomethymycin (86) are labeled. 
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desR genes are disrupted or deleted may lead to the accumulation of 85 and 86 as 
major products.  On the basis of this premise, a disruption plasmid, pPikR-K, was 
constructed, in which most of pikR1 and pikR2 sequences were deleted and 
replaced by the kanamycin resistance gene.  The plasmid pPikR-K was introduced 
into the KdesR-11 mutant, followed by the screening of the double-crossover 
mutants.  However, all attempts to obtain mutants with a phenotype of apramycin 
sensitive (AprS), thiostrepton resistant (ThioR), and kanamycin resistant (KanR) 
failed.  This observation suggests that the methylation of an adenine residue in the 
23S RNA mediated by PikR1/PikR2 likely confers the primary cellular self-
protection to S. venezuelae, and S. venezuelae cannot survive without pikR1 and 
pikR2. 
3.3.3 Purification and Substrate Specificity of the Macrolide 
Glycosyltransferase OleD 
Macrolide glycosyltransferases can potentially be used as a tool for the 
post-synthesis modification of macrolides.  The existing sugar substituent may be 
further derivatized by an MGT to form a disaccharide chain.  If this MGT is 
flexible enough, a variety of disaccharides can be generated, some of which may 
confer enhanced or diverged biological activities to the parent macrolide.  
Alternatively, an MGT may be useful for in vivo glucosylation of genetically 
engineered “unnatural” macrolides.  Such a modification may prevent the 
inhibition of the growth or death of the bacteria producer incurred by the new 
compounds if they are antibiotics and glycosylation catalyzed by MGT leads to 
inactivation of their activities.  The active macrolide can then be regenerated by 
the action of the β-glycosidase in vitro.  In view of these potentials, we decided to 
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first probe the substrate specificity of the MGT in vitro.  Since the MGT of 
S. venezuelae was not available, we expressed and purified the MGT of 
S. antibioticus, OleD.  We then carried out the preliminary testing of its substrate 
specificity using commercially available macrolides and sugar nucleotides.  The 
coupled Ep/OleD assay was also developed, allowing the glycosylation of 
macrolides with sugar-1-phosphates directly. 
Overexpression of oleD and Purification of the Recombinant Protein.  In 
order to purify the OleD protein, the oleD gene was cloned into the expression 
vector pET24b(+) to produce C-terminal His6-tagged fusion protein in E. coli.  
The resulting plasmid, pOleD-2, was used to transform E. coli BL21(DE3) 
competent cells.  The induction of E. coli BL21(DE3)/pOleD-2 with IPTG 
resulted in the expression of OleD.  The desired protein was purified by affinity 
chromatography on the Ni-NTA column, followed by the anion exchange 
chromatography on a DEAE column (Figure 3-2, lane 3).  The purified protein 
was used in the activity assays. 
Testing Substrate Specificity of OleD Using Sugar Nucleotides.  The 
capability of the recombinant OleD to glycosylate various macrolides using 
different sugar nucleotides was investigated using commercially available 
substrates.  The structures of the sugar nucleotides tested in this experiment are 
shown in Figure 3.4.  The extent of the glycosylation was monitored by TLC.  
The products having an Rf value much lower than those of the unmodified 
macrolides are likely being further glycosylated.  Table 3-1 summarizes the 
results of this experiment.  The approximate value for the yield of a glycosylated 
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product (% of the total macrolides present as a glycosylated product) was 
estimated based on the intensity of the TLC spots. 
 It has been reported that OleD can efficiently glycosylate oleandomycin 
(9), erythromycin (6), tylosin (13), and carbomycin (14) using UDP-α-D-glucose 
(87) as the sugar donor.20  Our experimental results are in an agreement with this 
report, since OleD demonstrated the full conversion of 6, 9, and 13 to their 
glycosylated derivatives in the assay with 87 (entries 10, 12, and 14, respectively).  
Furthermore, we found that methymycin (1) was glycosylated by OleD with a 
lower but significant efficiency (entry 1).  This data demonstrates the flexibility of 
OleD toward the acceptor substrate, consistent with its involvement in a general 
resistance mechanism, not a self-resistance one.20   
As expected, OleD showed a strong preference for UDP-D-glucose (87) 
over other nucleotides tested (entry 1 vs. entries 7, 8, and 9).  TDP-D-glucose was 






























































































Figure 3-4: The structures of sugar nucleotides used in the OleD assay. 
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glycosylated methymycin (entry 7), whereas CDP-D-glucose only gave trace 
amounts of the product (entry 8).  GDP-D-glucose was not a substrate at all 
(entry 9).   
We also tested several UDP-sugars as donor substrates for the 
methymycin glycosylation by OleD (entries 1-6).  Only the addition of 87 or 
UDP-D-xylose (90) to the assay resulted in the production of the glycosylated 
methymycin.  Interestingly, neither C-4 nor C-2 epimer of 87, UDP-D-galactose 
(88) or UDP-D-mannose (89), respectively, was a substrate for OleD.  Evidently, 
OleD is much less tolerant to the variation of the sugar donor structures than to 
those of the macrolide acceptors. 
Table 3-1:  Summary of the Glycosylation Reactions Catalyzed by OleD 





1 UDP-D-glucose (87) 1 70 
2 UDP-D-galactose (88) 1 NPa 
3 UDP-D-mannose (89) 1 NP 
4 UDP-D-xylose (90) 1 40 
5 UDP-D-glucuronic acid (91) 1 NP 
6 UDP-D-N-acetylglucosamine (92) 1 NP 
7 TDP-D-glucose 1 20 
8 CDP-D-glucose 1 5 
9 GDP-D-glucose 1 NP 
10 87 6 100 
11 90 6 100 
12 87 9 100 
13 90 9 NP 
14 87 13 100 
15 90 13 60 
a No product detected 
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Ep/OleD Coupled Assay Using Sugar-1-phosphates.  To broaden the 
selection of the donor substrates we designed an Ep/OleD coupled assay to make 
UDP-sugar directly from sugar-1-phosphate in situ.  The Salmonella enterica LT2 
α-D-glucopyranosyl phosphate thymidylyltransferase (Ep) can catalyze the 
conversion of D-glucose-1-phosphate (93) to UDP-D-glucose (87) and has been 
shown to possess a broad substrate specificity.17  Several synthetic sugar-1-
phosphates, as well as the stock of Ep enzyme, were kindly provided by Professor 
Jon Thorson of the University of Wisconsin.  Dr. Thorson and his coworkers have 
developed the general conditions for the Ep assay. 
The schematic illustration of the coupled Ep/OleD assay is shown in 
Figure 3-5.  In this assay, sugar-1-phosphate was first converted to its UDP 
derivative by Ep in 50 µL of buffer.  Then, tylosin (13) was added to this reaction, 
and the reaction volume was brought to 100 µL.  The amounts of reagents were 
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Figure 3-5: Scheme of Ep/OleD assay.
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to a 2.5 fold excess of the UDP-sugar over tylosin.  OleD was then added and, 
after incubation, the macrolides were extracted with chloroform and analyzed by 
TLC.  The sugar-1-phosphates tested are shown in Figure 3-6.  The results of this 
experiment are summarized in Table 3-2.  Tylosin (13) was used as an acceptor in 
all experiments, since it is a good substrate for OleD, as was demonstrated in the 
previous assay. 
The results obtained in this experiment showed that OleD is quite sensitive 
to the variations in the structure of the sugar donor.  Among the compounds 
tested, only UDP-6-deoxy-D-glucose (derived from 94) (entry 2) was accepted by 
OleD as efficiently as its natural substrate, UDP-D-glucose (derived from 93) 
(entry 1).  The inclusion of UDP-2-deoxy-D-glucose-1-phosphate (derived from 
97) in the assay only resulted in a very low yield of glycosylated tylosin (entry 5).  
Table 3-2:  Summary of the Glycosylation Reactions Catalyzed by Ep/OleD 






1 D-glucose-1-phosphate (93) ≥95 99.5 
2 6-deoxy-D-glucose-1-phosphate (94) ≥95 99.1 
3 4-deoxy-D-glucose-1-phosphate (95) NPb 99.3 
4 3-deoxy-D-glucose-1-phosphate (96) NP 6.5 
5 2-deoxy-D-glucose-1-phosphate (97) ~5 22.3 
6 2-deoxy-2-amino-D-glucose-1-phosphate (98) NP ~100 
7 4,6-dideoxy-4-amino-D-glucose-1-phosphate (99) NP ~50 
a The values are as reported in the Ref. 16 (entries 1-5) or provided by Prof. 
Thorson through personal communications (entries 6 and 7);  b No product 
detected 
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Meanwhile, incubation with UDP derivatives of sugar-1-phosphates 95, 96, 98, 
and 99 did not give glycosylation of tylosin at all (entries 3, 4, 6, and 7, 
respectively).  The low conversion of 96 by Ep to its UDP derivative may have 
limited the supply of the sugar donor.  However, the failure to glycosylate tylosin 
by OleD in the presence of the UDP derivatives of 95, 96, 98, and 99 is most 
likely because they are not substrates for OleD. 
3.3.4 Identification and Sequencing of the Macrolide Glycosyltransferase 
Gene of S. venezuelae 
The above results clearly showed that the UDP-sugar substrate specificity 
of the MGT OleD is quite stringent.  It would be interesting to determine whether 
other MGTs also share a similar stringency of substrate specificity.  Our next 
target is the MGT, designated as DesG from here on, operating in S. venezuelae.  
Its existence is implicated by the detection of diglycosylated macrolides 85 and 86 
produced by the S. venezuelae KdesR strain.  Because the corresponding gene is 
not a part of the methymycin/pikromycin biosynthetic cluster, it is possible that, 
like OleD, DesG is involved in the general resistance mechanism rather than the 
self-resistance mechanism.  If this is the case, it may have broad substrate 
specificity, a property desirable for post-synthesis modification. 
Screening S. venezuelae Genomic DNA Library for the MGT Gene.  The 
cosmid library of the S. venezuelae genome was constructed using the cosmid 
pNJ1.  It was packaged into the λ phage, and the phage mix was used to transfect 
E. coli LE392.  A library of 1039 clones was generated.  This library was 
screened by colony hybridization for the MGT gene using the 32P labeled oleD 
probe.  Three positive clones were identified.  The cosmid DNA of these clones 
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was digested with BamHI.  Southern hybridization with the oleD probe revealed 
that one of them, pSB-Sv-0301, carries a gene homologous to oleD.  The same 
band of 4 kb was detected by Southern blot for pSB-Sv-0301 and BamHI-digested 
S. venezuelae genomic DNA. 
The 4 kb BamHI fragment of pSB-Sv-0301 was subcloned into pUC119 to 
generate the plasmid pSB-Sv-B4.0.  This plasmid was digested by HincII.  The 
resulting five fragments were ligated into pUC119 and sequenced using the 
primers complementary to the pUC119 sequence.  The comparison of the 
sequencing data to the nucleotide sequences in the GenBank led to the 
identification of an approximately 1 kb of the gene with high sequence similarity 
to MGT genes, desG.  Two putative start codons, six base pairs apart, were found, 
confirming that 5' terminus of desG has been found.  However, the plasmid pSB-
Sv-B4.0 is missing an estimated 200 bp of the 3'-terminal gene sequence. 
Since the sequence of the ends of the pSB-Sv-0301 insert showed little 
homology to MGT genes, this plasmid must harbor the entire desG in the middle.  
Initially, “primer walking” was used in an attempt to sequence the 3'-terminal 
region of desG.  The primers complementary to the upstream region of desG that 
had been sequenced were designed.  However, the attempts to sequence the 
missing part of desG using these primers were unsuccessful.  Over 40 subclones 
of pSB-Sv-0301 were then generated and probed with labeled oleD.  The ends of 
the inserts in selected clones were sequenced.  Only one of these plasmids, pSB-
Sv-P20.0, was found to contain the entire desG.  However, we had little success in 
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sequencing pSB-Sv-P20.0 using “primer walking”.  This effort only added the 
sequence of 50 bp to the 3'-terminus.   
Using 3' RACE to Determine 3' Sequence of desG.  The method called 3′ 
RACE was used to identify and isolate the desG gene.  This method takes 
advantage of the natural poly(A)-tail of mRNA as a priming site for the PCR 
amplification.  As illustrated in Figure 3-7, The first-strand cDNA synthesis is 
initiated at the poly(A)-tail of mRNA using the universal oligo dT-anchor primer.  
After converting mRNA into cDNA, the latter is used without further purification 
as the template for the PCR amplification using the PCR anchor primer and a 
designed specific primer. 
Total RNA of S. venezuelae was isolated and its quality was assessed 
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Figure 3-7: Overview of 3′ RACE.  The figure is taken from the “5′/3′ RACE 
Kit” instruction manual by Roche Molecular Biochemicals. 
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for the selected RNA sample was 2.02, indicating that it is not contaminated with 
protein (it is above 1.9), and RNA is not degraded (values greater than 2.10 
indicate severe degradation).  The bands for 23S, 16S, and 5S rRNA were clearly 
visible on the agarose gel, indicating that RNA is not degraded.  The mRNA is 
usually not visible on the gel due to its low abundance.  The sheared 
chromosomal DNA was removed by the treatment with DNase.  The sample of 
total RNA was subjected to 3′ RACE. 
The 3′ RACE procedure led to the amplification of an approximately 
1.8 kb fragment of DNA.  This fragment was cloned into the pUC119 vector, and 
the insert was sequenced.  To our disappointment, the sequence of the insert 
showed no homology to oleD.  It appears that a nonspecific DNA product was 
isolated.  Increasing the annealing temperature from 60 to 65 oC during the PCR 
amplification of the cDNA led to the production of the same 1.8 kb DNA 
fragment.  Therefore, this method was abandoned. 
PCR Amplification of desG Using Degenerated Primers.  After failing to 
determine the 3′-terminal sequence of desG using 3′ RACE, we attempted to 
amplify desG using degenerated primer designed based on the sequence of the 
MGT genes homologous to desG.  Using BlastX, the following macrolide 
resistance glycosyltransferases which have high sequence similarity to the 
translated known portion of desG were selected: OleD of S. antibioticus (74% 
sequence identity),21 MgtA of Streptomyces ambofaciens (70%),22 Mgt of 
Streptomyces cœlicolor A3(2) (70%),23 and StrLI of Streptomyces lividans 
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(69%).24  These sequences were aligned using VectorNTI software (Figure 3-8 
shows the C-terminal portion of the alignment).   
The alignment of the translated desG homologues revealed the segment of 
DLIEAEL (shown in bold in Figure 3-8) conserved among all four MTGs.  This 
short protein sequence was used to design the reverse primer for the desG 
amplification.  Variable bases were introduced in the primer sequence to 
accommodate the codon preferences for Streptomyces.13  The resulting primer, 
together with the forward primer complementary to the 5′ terminus of desG, were 
used in the PCR amplification.  The pSB-Sv-0301 cosmid was used as the 
template.  The PCR product of approximately 1.2 kb was cloned into the pUC119 
vector and sequenced.  To our delight, not only that sequence was indeed a part of 
desG¸ but it also contained an additional 150 bp of the DNA sequence at its 3′ 
terminus that have not been seen before.  Two sequencing primers matching this 
new sequence were designed and used for the sequencing of the remaining portion 
of desG in the pSB-Sv-0301 cosmid.  This led to the completion of the desG 
sequence. 
                361                                                            426
      Mgt (361) TLPTEEATAKALRTAALALVDDPEVAARLKEIQARMAQEGGTRRAADLIEAELAAARG 
     MgtA (360) HLPTEEATAEALRAAGLALVEDPEVARRLKEIQAGMAREGGTRRAADLIEAELAAART 
     OleD (346) KLATEEATADLLRETALALVDDPEVARRLRRIQAEMAQEGGTRRAADLIEAELPARHERQEPVGDR
    StrLI (361) TLPTEEATAKALRTAALALVDDPEVAARLKEIQARMAQEAGTRGPADLIEAELAAARG 
Consensus (361) TLPTEEATAKALRTAALALVDDPEVARRLKEIQARMAQEGGTRRAADLIEAELAAARG      
Figure 3-8: Protein sequence alignment of C-terminal portions of DesG 
homologues: Mgt of Streptomyces cœlicolor A3(2), MgtA of 
Streptomyces ambofaciens, OleD of S. antibioticus, and StrLI of 
Streptomyces lividans.  The last 25 residues of OleD are not shown. 
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              V   S  A  M  T   P  A  P   P  A  H   L  A  M   F  S  I  A 
   1  ATCTAGGGTG TCCGCCATGA CCCCCGCTCC CCCCGCCCAC CTGGCCATGT TCTCGATCGC 
        rbs1↑ ↑         ↑ 
              Start2?   Start1? 
       A  H  G   H  V  N   P  S  L  D   V  V  R   E  L  V   A  R  G  H 
  61 CGCCCACGGA CACGTGAACC CGAGCCTGGA CGTCGTCCGC GAGCTCGTCG CGCGCGGCCA 
       R  V  S   Y  A  I   P  A  P  F   A  E  K   V  A  E   T  G  A  T 
 121 CCGCGTCAGT TACGCGATCC CCGCCCCCTT CGCCGAGAAG GTCGCGGAGA CCGGGGCCAC 
       P  V  V   Y  A  S   M  L  P  T   D  D  D   P  D  A   W  G  T  E 
 181 GCCCGTCGTC TACGCCTCGA TGCTGCCGAC CGACGACGAC CCGGACGCCT GGGGCACGGA 
       L  I  D   H  V  E   P  F  L  N   D  A  V   Q  A  L   P  Q  L  A 
 241 GCTCATCGAC CACGTCGAGC CCTTCCTGAA CGACGCCGTG CAGGCCTTGC CGCAGCTCGC 
       K  A  F   E  E  D   V  P  D  L   V  L  H   D  I  T   A  Y  P  A 
 301 CAAGGCCTTC GAGGAGGACG TGCCGGACCT GGTGCTCCAC GACATCACGG CCTACCCGGC 
       P  V  L   A  H  T   W  G  V  P   S  L  S   L  W  P   N  L  V  P 
 361 CCCCGTCCTC GCCCACACCT GGGGCGTGCC CTCGCTCTCG CTGTGGCCGA ACCTCGTGCC 
       W  E  G   Y  E  E   E  V  A  E   P  M  F   A  E  L   K  A  S  P 
 421 GTGGGAGGGG TACGAGGAGG AGGTCGCCGA GCCGATGTTC GCCGAGCTCA AGGCGTCGCC 
       R  G  K   A  Y  Y   A  R  F  E   A  W  L   A  E  H   G  V  D  T 
 481 GCGTGGCAAG GCGTACTACG CGCGGTTCGA GGCGTGGCTG GCCGAGCACG GGGTCGACAC 
       P  P  D   R  L  I   A  R  P  R   R  A  L   V  L  I   P  R  A  L 
 541 CCCTCCGGAC CGGCTGATCG CGCGGCCGAG GCGCGCGCTC GTGCTCATCC CCCGGGCGCT 
       Q  P  H   A  D  R   V  D  E  S   V  Y  T   F  V  G   A  C  Q  G 
 601 CCAGCCGCAC GCCGACCGGG TCGACGAGTC CGTCTACACC TTCGTCGGCG CCTGCCAGGG 
       A  R  A   G  Q  G   E  W  R  R   P  A  G   A  E  R   V  V  L  V 
 661 CGCGCGCGCC GGCCAGGGCG AGTGGCGGCG GCCGGCGGGC GCGGAGAGGG TCGTCCTGGT 
       S  L  G   S  S  F   T  K  R  P   E  F  Y   R  A  C   A  E  A  F 
 721 GTCGCTGGGT TCCTCCTTCA CCAAGCGGCC GGAGTTCTAC CGGGCCTGCG CGGAGGCGTT 
       R  T  L   P  D  W   H  V  V  L   Q  I  G   R  F  V   D  A  A  E 
 781 CCGCACGCTG CCCGACTGGC ACGTCGTCCT GCAGATCGGG CGGTTCGTCG ATGCCGCCGA 
       L  G  D   L  P  G   N  V  E  V   H  S  W   V  P  Q   L  A  I  L 
 841 GCTCGGGGAC CTGCCGGGCA ATGTCGAAGT GCACTCCTGG GTGCCCCAGT TGGCGATCCT 
       R  Q  A   D  V  F   V  T  H  A   G  A  G   G  S  Q   E  G  L  A 
 901 GCGGCAGGCC GACGTGTTCG TCACCCACGC GGGTGCGGGC GGGAGCCAGG AGGGCCTGGC 
       T  A  T   P  M  V   A  V  P  Q   A  V  D   Q  F  G   N  A  E  V 
 961 CACCGCGACG CCGATGGTCG CCGTCCCGCA GGCCGTCGAC CAGTTCGGGA ACGCCGAGGT 
       L  Q # A   L  G  V   A  R  H  L   P  M  E   N  V  T   P  E  R  L 
1021 GCTCCAG#GCC CTGGGGGTCG CCCGGCACCT GCCGATGGAG AACGTCACCC CCGAGCGGCT 
       R  E  A   V  L  A   L  V  D  D   P  E  V   A  R  R   A  A  R  I 
1081 GCGCGAGGCC GTGCTCGCGC TCGTCGACGA CCCCGAGGTG GCCCGCCGGG CCGCCCGGAT 
                                                                  BamHI 
       Q  A  D   M  A  R   E  G  G  T   R  R  A   A  D  L   I  E  A  E 
1141 CCAGGCGGAC ATGGCGCGGG AGGGCGGCAC GCGCCGCGCC GCCGACCTGA TCGAGGCCGA 
                                                    ←degenerated primer
       L  D  R   G  P  R   R  G  * 
1201 GCTCGACCGA GGCCCGCGGC GCGGCTGA 
Figure 3-9: The complete nucleotide sequence of the desG gene and its 
translated protein sequence.  Two possible start codons, the ribosome 
binding site (rbs1), and the region complementary to the degenerated 
primer are labeled.  The beginning of the problem region of the DNA 
sequence is denoted by #. 
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The complete sequence of desG and its translated amino acid sequence are 
shown in Figure 3-9.  Two possible start codons were identified: ATG (start1) and 
GTG (start2).  Depending on which start codon is used, desG is either 1212 
(start1) or 1221 (start2) bp long, and encodes a 403- or 406-amino acid protein.  
The sequence of AGGG, 8 bp upstream of start1, may serve as the potential 
ribosome binding site (RBS) for the translation of DesG from start1.  There was 
no such RBS corresponding to start2.  The entire translated desG maintains the 
level of sequence identity to OleD, MgtA, Mgt of Streptomyces cœlicolor A3(2), 
and StrLI. 
3.3.5 Preliminary Characterization of S. venezuelae Macrolide 
Glycosyltransferase DesG 
Having successfully completed the sequencing, the desG gene was 
overexpressed to determine whether the DesG protein can act as an MGT.  The 
desG gene (the 1212 bp version) was cloned into pET28b(+) and pET24b(+) 
vectors for the expression as an N- and a C-terminal His6-tagged protein, 
respectively.  Both proteins, DesG-N-His and DesG-C-His, were overproduced in 
E. coli BL21 and purified using affinity chromatography on the Ni-NTA resin.  
DesG-N-His and DesG-C-His showed similar properties during the purification.  
Even though some of the protein existed as inclusion bodies after cell disruption, 
there was a large amount of soluble protein.  The yields of DesG-N-His and 
DesG-C-His after the Ni-NTA column purification (Figure 3-2, lanes 1 and 2, 
respectively) were approximately 50–55 mg of protein per 3 L of the culture.  The 
protein samples contained minor impurities.  However, they were used without 
further purification for the preliminary activity assays. 
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The ability of the fusion proteins to glucosylate methymycin (1) and 
tylosin (13) using UDP-α-D-glucose (87) was tested.  Analysis by TLC 
demonstrated that the addition of either enzyme, DesG-N-His or DesG-C-His, to 
the reaction mixture led to the conversion of the macrolide starting material to a 
more polar product (Figure 3-10).  This product is most likely a glucosylated 
methymycin or tylosin in the respective assays.  It will be necessary to perform a 
large-scale reaction and fully characterize these glucosylated products.  It will 
also be interesting to test various sugar nucleotides and macrolides in the DesG 
assay in order to compare its substrate preferences to those of OleD. 
Methymycin →
Glucosylated
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Figure 3-10: Preliminary TLC analysis of the DesG-N-His activity as a macrolide 
glycosyltransferase (similar results were obtained with DesG-C-His). 
Lanes 1 and 2 are extracts of the assays run with methymycin (1), 
and lanes 3 and 4 are those with tylosin (13).  Lanes 1 and 4 are 
control reactions without enzyme.  The DesG-N-His protein was 
added to the assay run on lanes 2 and 3. 
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3.4 CONCLUSIONS 
The strategy of glycosylation-deglycosylation discussed in this chapter 
may not be the primary self-resistance mechanism operating in S. venezuelae, 
since the glucosylated methymycin and neomethymycin are produced in 
significantly less quantities than their unmodified parent compounds in KdesR 
mutants.2, 3  The introduction of a copy of the MGT gene from S. antibioticus, 
oleD, into the desR mutant of S. venezuelae led to the increase in the production 
of glucosylated macrolides.  However, more than half of the macrolides remained 
unglycosylated.  The mutant of S. venezuelae with pikR1, pikR2, and desR genes 
deleted could not be isolated.  This is most likely because the deletion of pikR1 
and pikR2 is lethal to the strain.  Taken together, these results suggest that 
methylation of rRNA by PikR1 and PikR2 is the primary self-resistance 
mechanism for S. venezuelae. 
The β-glucosidase, DesR, responsible for the deglycosylation step has 
been identified, since the encoding gene is in the desosamine gene cluster.  The 
catalytic activity of DesR has been demonstrated by in vitro assays.3  However, to 
study the corresponding MGT in S. venezuelae responsible for the glycosylation 
step has been much more challenging.  In order to study the general properties of 
MGT, we have expressed and purified the OleD protein and chracterized its 
substrate specificity in vitro.  To compensate for the small selection of the 
commercially available sugar nucleotides, the coupled Ep/OleD assay was 
developed, allowing the use of synthetic sugar-1-phosphates as sugar donors for 
OleD.  It was found that although OleD can recognize a variety of structurally 
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diverse acceptors, it is considerably more stringent towards the sugar nucleotide 
donor. 
Finally, we screened the genome of S. venezuelae and identified the MGT 
gene, desG, involved in the glucosylation of methymycin and neomethymycin.  
This gene was expressed in E. coli, and the catalytic activity of the purified 
polypeptide DesG as a macrolide glycosyltransferase was confirmed.  Additional 
experiments are necessary to fully assess the substrate specificity of DesG.  The 
DesG enzyme may prove to be useful as a tool for the incorporation of  
“unnatural” sugar moieties into monoglycosylated macrolides.  This may 
potentially improve the biological activity of new compounds.  Alternatively, 
DesG, together with DesR, may be used for the selective inactivation-reactivation 
of macrolide antibiotics. 
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Chapter 4:  Study of the Glycosyl Transfer by  
DesVII and DesVIII 
4.1 INTRODUCTION 
Carbohydrates play an essential role in a vast array of biological 
processes.  It is, therefore, not surprising that glycosylating enzymes, glycosyl-
transferases, are abundant in all living organisms.  They catalyze the transfer of 
carbohydrate moieties from activated donor substrates, usually nucleotide-sugars, 
onto a wide variety of acceptors, such as other sugars, proteins, nucleic acids, 
lipids, polyketides, and nonribosomally synthesized peptides, through the 
formation of O-, N-, or C- linkages.  Of particular interest to our laboratory are the 
glycosyltransferases in prokaryotes that modulate the activity of macrolide 
antibiotics. 
The biological activity and potency of many secondary metabolites are 
dependent on the composition of carbohydrate constituents of these compounds.  
Several comprehensive reviews summarize the role that carbohydrates play in 
biologically active bacterial metabolites.1-3  It is now clear that altering the 
composition of sugar appendages in glycoconjugates is a promising strategy for 
creating new products with novel or enhanced biological activities.  Hence, efforts 
to develop effective glycosylation strategies have been vigorously pursued by 
scientists for decades.  Significant progress has been made recently using genetic 
and biochemical methods to perform glycosylation in vivo.  As highlighted by the 
results of the studies described in Chapter 2, as well as numerous studies 
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published by our and other groups, many glycosyltransferases have been shown to 
possess relaxed substrate specificity and be able to couple diverse sugar and 
aglycone structures in vivo (for relevant recent reviews, see references 3-7).  
However, the yields are generally low, and product isolation from the 
fermentation broth is tedious.  Moreover, such an in vivo approach has limited 
general applicability since the production of antimicrobial agents would cause 
inhibition of cell growth or cell death.  One potential solution to overcome these 
hurdles is to carry out the glycosylation step in vitro using isolated glycosyl-
transferases.  The in vitro approach would also be facilitated by using genetically 
engineered glycosyltransferases with the desired substrate specificity. 
Although many putative glycosyltransferase genes have been identified in 
gene clusters encoding the biosynthetic pathways to glycosylated secondary 
metabolites, few of the corresponding gene products have been purified and their 
catalytic roles verified.  In particular, examples of characterized glycosyl-
transferases involved in the biosynthesis of antibiotics are scarce with GtfA, GtfB, 
GtfC, GtfD, GtfE, and NovM, which are found in the vancomycin (100), 
chloroeremomycin (101),8-10 and novobiocin (102) pathways,11 as the only known 
examples.  Both 100 and 101 are nonribosomal peptide based antibiotics, while 
102 is an aromatic polyketide derived antibiotic (Figure 4-1).  It should be noted 
that a few glycosyltransferases responsible for resistance and self-resistance to 
macrolide antibiotics have also been characterized in vitro, among which OleD 
and OleI from the oleandomycin (9) producer Streptomyces antibioticus are the 
most comprehensively studied.12, 13  However, in these cases the enzymes are not 
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a part of a biosynthetic pathway.  Instead, they catalyze the attachment of a 
glucose to the sugar appendages of macrolides, not the aglycone directly (Figure 
























































































































Figure 4-1: Examples of characterized glycosyltransferases involved in the 
biosynthesis of and resistance to secondary metabolites. 
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characterization of a glycosyltransferase participating in the biosynthesis of a 
macrolide.  Clearly, it is important to learn the specifics of the macrolactone 
glycosylation.  There is also an obvious need for catalysts capable of 
glycosylating new macrolide aglycones generated via manipulation of polyketide 
biosynthetic pathways. 
This chapter describes our efforts to purify and biochemically characterize 
glycosyltransferase DesVII of Streptomyces venezuelae involved in the 
biosynthesis of macrolide antibiotics methymycin (1), neomethymycin (2), 
pikromycin (4), and narbomycin (5) (Figure 4-2).  Initial attempts were made by a 
former group member, Dr. Lishan Zhao, to detect the desosaminyltransferase 
activity in the crude extracts of Escherichia coli expressing desVII as C-terminal 
His6-tagged fusion protein.  Dr. Zhao tested a range of glycosyltransferase assay 
























































Figure 4-2: The function of macrolide glycosyltransferase DesVII described in 
this study. 
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desosaminylated 10-deoxymethynolide (3, YC-17, or 10-deoxymethymycin).  In 
this study we have achieved the purification of DesVII.  We have also developed 
effective assay conditions for its activity.  The most important discovery for this 
glycosyltransferase is that it is active only at high pH (approximately 9) and in the 
presence of another protein component, DesVIII.  The study resulted in the first 
report of a demonstrated macrolide glycosyltransferase activity in vitro.14  To 
learn more about the catalytic properties of the DesVII/DesVIII pair, we have also 
tested the specificity of this enzyme pair towards various donor and acceptor 
substrates, mainly the intermediates of the biosynthesis of tylosin (13) and 
erythromycin (6). 
4.2 EXPERIMENTAL PROCEDURES 
4.2.1 General 
Bacterial Strains.  Escherichia coli DH5α from Invitrogen (Carlsbad, 
CA)  was used throughout the study as the regular cloning host.  E. coli S17-115 
was the donor strain for conjugal transfer to S. venezuelae.  The strains used as 
hosts for gene overexpression include E. coli BL21(DE3) and E. coli 
NovaBlue(DE3) from Novagen Inc. (Madison, WI), and E. coli BL21(DE3)pLysS 
and E. coli BL21-CodonPlus (DE3) from Stratagene (La Jolla, CA).  Strains 
S. venezuelae ATCC 15439, S. antibioticus ATCC 11891, S. lividans/pIJ702 
ATCC 35287, and S. lividans TK64 ATCC 69441 were obtained from American 
Type Culture Collection (Rockville, MD) as freeze-dried pellet and were revived 
according to the instructions provided by ATCC. 
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Plasmids, Vectors, and Biomaterials.  Cosmid pLZ4 (derivative of pNJ1 
vector)16 containing desosamine biosynthetic cluster and part of polyketide 
synthase cluster17, 18 was used as a template for polymerase chain reaction (PCR) 
to obtain appropriate DNA fragments.  Plasmid pKC1139, used for conjugal 
transfer of DNA to S. venezuelae, was a gift from Dr. Leonard Katz of Abbott 
Laboratories.19  Plasmid pDHS5000, which contains the tsr gene, was a gift from 
Professor David Sherman of the University of Michigan.  Expression vectors 
pET24b(+) and pET28b(+) were from Novagen.  Pfu DNA polymerase used for 
most of the PCR reactions was purchased from Stratagene.  The Advantage 
cDNA polymerase was from Clontech (Palo Alto, CA).   
Enzymes used in the cloning experiments, such as restriction 
endonucleases and T4 DNA ligase, the corresponding buffers, and DNA 
molecular weight marker were products of Invitrogen.  QIAprep and QIAquick 
DNA purification kits from Qiagen (Valencia, CA) were used for plasmid DNA 
minipreps and purification of PCR products, respectively.  Rapid Translation 
System (RTS 500) product of Roche Molecular Biochemicals (Indianapolis, IN).  
The procedures for in vitro transcription/ translation recommended by the 
manufacturer’s manual were closely followed. 
The DNA sequencing was performed by the DNA Core Facility at the 
Institute of Cellular and Molecular Biology of the University of Texas at Austin.  
DNA primers for PCR amplification and sequencing were custom-prepared by the 
DNA Core Facility or by Integrated DNA Technologies (IDT, Coralville, IA). 
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The general methods and protocols for recombinant DNA manipulations 
described by Sambrook et al.,20 and those dealing with Streptomyces strains 
described by Hopwood et al.21 and Kieser et al.22 were followed in this study. 
Antibiotics and most chemicals used in this study are products of Sigma-
Aldrich (St. Louis, MO), VWR International (West Chester, PA), and Fisher 
Scientific (Pittsburgh, PA).  Cytochrome P450 enzymes were obtained from 
Sigma-Aldrich.  Radiolabeled [acetyl-3H] coenzyme A was purchased from ICN 
Biomedicals, Inc. (Irvine, CA).  Culture and media components were from BD 
Diagnostics System (Sparks, MD). 
Ni-NTA resin for affinity purification of His-tagged proteins was obtained 
from Qiagen.  DEAE Sepharose CL-6B resin for ion exchange and Sephacryl 
S200 HR resin for size exclusion protein chromatography were from Amersham 
Biosciences (Piscataway, NJ).  Amylose affinity matrix used for purification of 
maltose binding protein and its fusion proteins were from New England Biolabs 
(Beverly, MA).  Protein purification and native molecular mass determination was 
performed using FPLC (Amersham Biosciences) equipped with ion exchange 
MonoQ HR 10/10 or size exclusion Superdex 200 HR 10/30 column.  Protein 
purification steps were carried out at 4 oC except for FPLC chromatography that 
was performed at room temperature. 
Pre-stained protein marker was obtained from New England Biolabs.  
Mini-PROTEAN II vertical system used for sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE), Mini trans-blot assembly 
apparatus used for Western blot, GelAir drying system used to dry gels, and the 
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necessary accessories and reagents were all products of BioRad.  The 
nitrocellulose Hybond-C Extra membrane used for Western blot was from 
Amersham Biosciences.  The antibodies monoclonal anti-polyhistidine clone His-
1 and anti-mouse IgG alkaline phosphatase conjugate were purchased from 
Sigma.  For Western blot detection, nitroblue tetrazolium (NBT) and 5-bromo-4-
chloro-3-indolyl-phosphate (BCIP) were both obtained from Promega. 
Instrumentation.  HPLC applications on enzyme assays and purification of 
incubation products were performed on a Beckman Coulter (Fullerton, CA) 
HPLC instrument equipped with Alltech Econosil C18 columns (Deerfield, IL).  
The NMR spectra were acquired on Varian Unity 300 or 500 spectrometers.  
Flash chromatography was performed on Lagand Chemicals silica gel (230-400 
mesh) by elution with the specified solvents.  Analytical thin-layer 
chromatography (TLC) was carried out on Polygram Sil G/UV254 plates (0.25 
mm) (Macherey-Nagel Inc., Easton, PA). 
The ultraviolet–visible spectra were recorded with a Beckman DU-650 
spectrophotometer.  The pH measurements were made with a Corning pH Meter 
240. Cell disruption was achieved with a Fisher 550 Sonic Dismembrator.  
Centrifugation was performed using either an Avanti J-25 or a J-E instrument of 
Beckman Coulter.  Microcentrifugations were conducted with an Eppendorf 
5415C microcentrifuge.  Scintillation counting was carried out with a Beckman 
LS6500 counter. 
SDS-PAGE.  Protein purity and estimated molecular mass were obtained 
by SDS-PAGE at 25 mA per gel using a discontinuous buffer system.23  The 
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separating gel and stacking gel were 12% and 4% polyacrylamide, respectively.  
Prior to electrophoresis, protein samples were heated for 5 min at 100 oC (or 
10 min at 37 oC for samples containing high imidazole concentrations) in 
62.5 mM Tris-HCl buffer (pH 6.8) containing 10% glycerol, 2% SDS, 5% β-
mercaptoethanol, and 0.0025% bromophenol blue.  Electrophoresis of the 
denatured samples was run in 25 mM Tris-HCl, 192 mM glycine, and 0.1% SDS 
(pH 8.3).  Gels were stained with Coomassie blue (2.5 g/L of Coomassie Brilliant 
Blue G-250 in acetic acid : water : methanol, 1:4:5 by volume) and de-stained in 
ethanol : acetic acid : water (4:5:41 by volume).24  Protein concentrations were 
determined according to Bradford25 using bovine serum albumin (BSA) as the 
standard and dye reagent from BioRad (Hercules, CA). 
Western Blot Analysis.  Western blot was used to detect poly-histidine tag 
on recombinant proteins.26  SDS-PAGE of the proteins of interest, containing one 
lane of pre-stained protein marker, was carried out as described above up to the 
staining step.  The proteins on the gel were transblotted to the nitrocellulose 
membrane at 100 V for 1 h as described in the BioRad Guide using Mini Trans-
Blot cell, with the running buffer containing 25 mM Tris base, 192 mM glycine, 
20% v/v methanol, pH 8.3.  The detection of the polyhistidine-tagged proteins 
was done as follows unless noted otherwise.  Membrane was immersed in the 
blocking solution of 1% non-fat dry milk in TBST (20 mM Tris-HCl, 150 mM 
NaCl, 0.05% v/v Tween® 20, pH 7.5) and agitated at room temperature for 1 h.  
Membrane was then agitated at room temperature with the primary antibody 
solution (1:3,000 dilution of monoclonal anti-polyhistidine clone His-1, Sigma 
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H1029, in TBST) for 1 h, rinsed with TBST for 5 min three times, then incubated 
with the secondary antibody solution (1:30,000 dilution of anti-mouse IgG [Fc 
specific] alkaline phosphatase conjugate, Sigma A2429, in TBST), and rinsed 
again with TBST for 5 min three times.  Detection was achieved by incubation of 
membrane in a solution of 0.33 mg/mL NBT and 0.165 mg/mL BCIP in 10 mL of 
an alkaline phosphatase buffer (100 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl2, 
pH 9.5) in the dark for 10 to 30 min. 
4.2.2 Preparation of the DesVII Substrates and Product 
 TDP-D-desosamine (22).  The donor substrate for DesVII studies, TDP-D-
desosamine (22), was prepared by a former group member, Dr. Cheng-wei Chang, 
and a visiting researcher, Dr. Haruko Takahashi, via hydrolysis of erythromycin 
to release desosamine followed by chemical conversions to its TDP form 
according to a published procedure.27, 28 
 Alternative Donor Substrates.  TDP-D-mycaminose (25) and TDP-α-L-
rhamnose (108) were obtained through chemical syntheses by former group 
members Dr. Huawei Chen and Dr. Alexander Wong, respectively.  TDP-β-L-
rhamnose (109) was obtained through an enzymatic synthesis by a current group 
member Dr. Hua Zhang. 
 10-Deoxymethynolide (65).  Gram quantities of the acceptor, 10-
deoxymethynolide (65), were obtained from the fermentation broth of 
S. venezuelae KdesI-80 mutant by extracting the products from the supernatant 
followed by silica gel purification as described in Chapter 2.29  Typically, 6 L of 
KdesI-80 culture yielded approximately 1.5 g of crude oil, from which 
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approximately 0.7 g of pure 10-deoxymethynolide was obtained.  The identity of 
the compound was confirmed by 300 MHz 1H NMR (CDCl3). 
 Alternative Acceptor Substrates.  Narbonolide (64) was provided by Dr. 
Takahashi and was obtained from culturing various S. venezuelae mutants with 
defective sugar genes under the 14-membered ring production conditions.30  
Tylactone (47) and 15-methyl-6-deoxyerythronolide B (107) were kindly donated 
by Eli Lilly and Company and Kosan Biosciences, respectively. 
 Preparation of DesVII Product, YC-17 (3). 
Fermentation of S. venezuelae AX906.  S. venezuelae AX906 was 
provided by Professor David Sherman as a frozen spore suspension.  Strain 
propagation and fermentation were carried out as previously reported.31  No 
methymycin- or pikromycin-related macrolide products were detected in the 
fermentation broth despite multiple attempts, including isolation and fermentation 
of individual colonies. 
Inhibition of monooxygenases in S. venezuelae.  To accumulate non-
hydroxylated methymycin or neomethymycin, YC-17 (3), wild type S. venezuelae 
was fermented in the presence of a known P450 inhibitor, xanthotoxin (or 8-
methoxypsoralen), as follows.  Strain was inoculated as a spore suspension 
(10 µL) in 5 mL of a seed medium (Chapter 2) and grown at 29 oC for 48 h.  
Vegetative medium was then inoculated with 100 µL of the seed culture and 
0.5 M stock of xanthotoxin in DMSO was added to the growth medium to a final 
concentration of 2 mM.  The control culture did not contain xanthotoxin.  The 
cultures were then fermented at 29 oC for another 48 h, after which the cells and 
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media particles were removed by centrifugation, pH of the supernatant was 
adjusted to 9.5, and the products were extracted with an equal volume of 
chloroform.  After evaporation of the solvent, the remaining residue was re-
dissolved in 200 µL of chloroform, and 10 µL of each of the resulting samples 
were analyzed by TLC using a chloroform : methanol : 25% NH4OH (90:9.9:0.1) 
solvent system.  TLC plates were developed with a vanillin stain (0.75% vanilla, 
1.5% v/v H2SO4, methanol). 
Construction of KpikC S. venezuelae mutant.  The construction of pikC 
mutant of S. venezuelae analogous to AX906 was undertaken.  First, two 
fragments flanking pikC gene in the genome of S. venezuelae (pikC-A and pikC-
B) and kanamycin resistance gene (neo) were cloned into the vector pUC119.  
Fragments pikC-A (924 bp) and pikC-B (881 bp) were amplified by PCR using 
HindIII-digested S. venezuelae genomic DNA as the template with the following 
primers: pikC-K12 (5´-GGCCGAATTCGTCGAAGTACAG-3´, EcoRI 
restriction site is underlined) and pikC-K2 (5´-GCGCTCTAGAGAAGCG-
GTCGTTC-3´, XbaI) for pikC-A; pikC-K3 (5´-GGCCCTGCAGTGTGGTA-
TCCGAAC-3´, PstI) and pikC-K4 (5´-GCGCAAGCTTCGGGGCCGTAGT-
AGTG-3´, HindIII) for pikC-B.  The resulting PCR fragments were digested with 
the corresponding pairs of restriction endonucleases and purified from agarose gel 
using the QIAquick kit.  Fragment neo/XbaI, PstI was previously obtained as 
described in Chapter 2.  Fragments pikC-A/EcoRI, XbaI , pikC-B/PstI, HindIII, 
and neo/XbaI, PstI were ligated into EcoRI and HindIII sites of pUC119, the 
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resulting construct, pPikC-d (Figure 4-3), was confirmed by a series of restriction 
digestions and the sequencing of the incorporated inserts. 
The EcoRI-HindIII fragment (3143 bp) of pPikC-d was excised and 
ligated into the same restriction sites of the pKC1139 vector.  The resulting 
construct, pPikC-K, was used to transform E. coli S17-1 competent cells.  The 
homologous recombination and the screening of the double-crossover mutants 
were preformed as described in Chapter 2.  Eight positive (KanR, AprS) clones 
were fermented as described and found to produce practically identical sets of 
metabolites with the major product being YC-17 (3).  One of them, KpikC-2, was 
chosen for further experiments. 
Purification of YC-17.  S. venezuelae KpikC-2 was fermented under the 
12-member ring production conditions (460 mg of crude extract per 4 L culture), 
and after the separation of the crude extract on silica gel column (loaded with 











Figure 4-3: Map of the plasmid pPikC-d used for partial deletion/ replacement of 
pikC in S. venezuelae. 
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v/v of 25% NH4OH), approximately 100 mg of pure YC-17 and 200 mg of YC-17 
mixed with 20% of narbomycin were obtained.  The structure of YC-17 was 
confirmed by 300 MHz 1H NMR (in CDCl3).32 
4.2.3 Purification of DesVII-C-His Protein 
Plasmid pHC29, containing the desVII gene insert from S. venezuelae 
ligated into the NdeI and XhoI restriction sites of pET24b(+) vector, was prepared 
by Dr. Huawei Chen.  The purification protocol was designed according to the 
QIAexpressionistTM instruction manual (Qiagen) for purification of His-tagged 
proteins with Ni-NTA agarose resin.  All steps were carried out at 4 oC, and the 
collected fractions were analyzed by SDS-PAGE. 
 Cell Growth.  An overnight culture of E. coli BL21(DE3)/pHC29 was 
used to inoculate six 1 L portions (1–2 to 100 dilution) of LB medium containing 
kanamycin (25 µg/mL).  The cultures were incubated at 37 oC until the OD600 
reached 0.6–0.7 (the temperature was gradually lowered to 16 oC before the 
culture reached the desired OD600 reading).  The cultures were then induced with 
0.5 mM IPTG and further incubated at 16 oC for 16–18 h.  The cells were 
harvested by centrifugation (5,000 g, 10 min) and used immediately in the next 
step. 
Crude Extract.  Cell pellet (typically 28 g) was re-suspended in 90 mL of 
lysis buffer (50 mM sodium phosphate, 300 mM NaCl, 10% glycerol, 5 mM 
imidazole, pH 8.0) containing 0.5 mM PMSF.  Lysozyme was added to the 
concentration of 1 mg/mL, and the resulting suspension was incubated on ice for 
30 min.  The cells were disrupted by sonication in 10 sec burst for 36 times with a 
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20 sec cooling period between each blast.  Cell debris was removed by 
centrifugation (16,000 g, 4 oC, 30 min).  The resulting supernatant was used in the 
next step, and a sample of the pellet was kept for SDS-PAGE analysis. 
Purification Using Ni-NTA Agarose.  To the crude extract, 10 mL (bed 
volume of resin) of Ni-NTA resin pre-washed with lysis buffer was added, and 
the mixture was incubated with a slow agitation at 4 oC for 3 h.  The suspension 
was loaded into the column and the flow-through fraction was collected.  The 
resin was sequentially washed with 50 mL lysis buffer containing 5 mM 
imidazole, 50 mL lysis buffer containing 15 mM imidazole, and 100 mL lysis 
buffer containing 30 mM imidazole.  The bound protein was eluted with an 
elution buffer containing 250 mM imidazole (except for imidazole concentration, 
composition is the same as in the lysis buffer).  The desired fractions, as detected 
by SDS-PAGE, were pooled and dialyzed against three changes of 1 L of 50 mM 
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Figure 4-4: SDS-PAGE of purified DesVII-C-His (lane 1, major band of 
approximately 47 kDa) and partially purified DesVIII-2 (lane 2, 
described in Section 4.2.18).  Lane M is the molecular weight 
marker: bovine serum albumin, 66 kDa; chicken egg ovalbumin, 
45 kDa; rabbit glyceraldehyde-3-phosphate dehydrogenase, 36 kDa; 
bovine carbonic anhydrase, 29 kDa, bovine trypsinogen, 24 kDa; 









Tris-HCl buffer (pH 8) containing 10% glycerol.  The purified protein was 
concentrated (precipitated particles removed by centrifugation), aliquotted into 
0.5 mL portions, flash frozen with liquid nitrogen, and stored at –80 oC (Figure 4-
4, lane 1).  The presence of the desired protein was confirmed by a Western blot 
analysis with the primary anti-polyhistidine antibody as described above.  Typical 
yields of purified DesVII-C-His were around 100 mg/L of culture. 
4.2.4 Native Molecular Weight Determination of DesVII-C-His 
The native molecular weight of DesVII-C-His was determined using 
FPLC equipped with Superdex 200 HR 10/30 column according to a procedure 
recommended by the column manufacturer, Amersham Biosciences.  Standards 
and samples were isocratically eluted using 50 mM sodium phosphate, pH 7, 
0.15 M NaCl at 0.5 mL/min.  The following protein standards (Sigma MW-GF-
200) were injected into FPLC (250 µL each): cytochrome c (12.4 kDa, 4 mg/mL), 
carbonic anhydrase (29 kDa, 6 mg/mL), bovine serum albumin (BSA, 66 kDa, 
10 mg/mL), alcohol dehydrogenase (150 kDa, 10 mg/mL), and β-amylase 
(200 kDa, 8 mg/mL).  Blue dextran (2000 kDa, 250 µL of 2 mg/mL) was used to 
determine the void volume of the column.  DesVII-C-His injected has a 
concentration of 4 mg/mL (250 µL). 
4.2.5 Preliminary Glycosyltransferase Activity Assay 
The composition of the assay mixture was developed by Dr. Lishan Zhao 
including: 50 mM Tris-HCl (pH 7.5), 5 mM MgCl2, 2 mM TDP-D-desosamine 
(22), 0.5 mM 10-deoxymethynolide (65, from 20 mM stock in ethanol), and 
20% v/v protein component (DesVII-C-His or DesVII-C-His and various protein 
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crude extracts) in a total volume of 100 µL.  The mixture was gently vortexed and 
incubated at 29 oC with shaking for about 2 h.  The products and the remaining 
acceptor substrate were extracted from the incubation mixture with 100 µL 
chloroform, and the organic extract was spotted on a TLC plate (10–20 µL per 
spot).  TLC was performed as described in the Section 4.2.2. 
4.2.6 Preparation of Protein Crude Extracts from S. venezuelae and 
S. venezuelae KdesVIII-92 Mutant 
Cell Growth.  The medium used for growing S. venezuelae KdesVIII-92 
mutant contained 50 µg/mL of kanamycin.  Spore suspensions of each strain 
(100 µL) were inoculated into 50 mL of a supplemented minimal medium33 with 
some modifications22 as described below.  Each of the solutions, with the 
exception of trace element solution and (NH4)2SO4 (which were filter sterilized), 
was separately autoclaved, then the solutions were mixed in the following order: 
deionized H2O (31.4 mL), PEG6000 (10% w/v, 50 mL), MgSO4•7 H2O (24 g/L, 
2.5 mL), TES buffer (0.25 M, pH 7.2, 10 mL), a mixture of NaH2PO4 and 
K2HPO4 (50 mM each, 1 mL total volume), glucose (50% w/v, 2 mL), Antifoam 
289 (1 mL), trace element solution (ZnSO4•7 H2O, FeSO4•7 H2O, MnCl2•4 H2O, 
CaCl2•2 H2O, NaCl, 100 mg/L each, 0.1 mL total volume), casamino acids 
(20% w/v, 1 mL), and (NH4)2SO4 (1.5 M, 1 mL).  Cultures were grown with 
vigorous shaking (350 rpm) at 29 oC for approximately 70 h.  Proteins were 
isolated according to the literature procedure34 with some modifications. 
Protein Isolation and Ammonium Sulfate Precipitation.  Cells were 
harvested by centrifugation (27,000 g, 4 oC, 10 min) and pellet was washed with 
30 mL of 0.5 M NaCl, 50 mM potassium phosphate (pH 7.2), then 15 mL of 
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50 mM potassium phosphate (pH 7.2).  The cells were resuspended in 5 mL of a 
disruption buffer (50 mM potassium phosphate, pH 7.2, 10% v/v glycerol, 2 mM 
DTT) and disrupted by sonication (12 cycles of 20 sec burst with a 10 sec cooling 
interval between bursts).  The lysate was cleared by centrifugation (27,000 g, 
4 oC, 20 min) resulting in the recovery of 4.5 mL of supernatant.  Ammonium 
sulfate (1.6 g) was added slowly to the supernatant while stirring on ice.  The 
protein precipitate was collected by centrifugation (as above) to give the 0–60% 
ammonium sulfate fraction.  To the remaining supernatant 1.1 g of ammonium 
sulfate were added.  The solution was adjusted to pH 4 with acetic acid and stirred 
for another 70 min.  Centrifugation of this solution as above resulted in the 60–
90% ammonium sulfate fraction.  Pellets were resuspended in 0.75 mL of the 
disruption buffer and dialyzed against the same buffer.  The resulting viscous 
yellowish solutions were frozen in liquid nitrogen, stored at –80 oC, and later used 
in the glycosyltransferase assays as above. 
4.2.7 Expression of desVII in S. lividans: 1st Attempt 
Preparation of pIJ702 DNA.  Strain S. lividans/pIJ702 (ATCC 35287) was 
purchased from ATCC as freeze-dried pellet and used for the plasmid isolation.  
Plasmid DNA isolation from S. lividans proved to be difficult, but a small 
quantity of pIJ702 was eventually obtained through alkaline lysis and potassium 
acetate precipitation based on a modified literature protocol.22 
Specifically, tryptic soy broth (TSB) medium (50 mL) was inoculated with 
the frozen culture of S. lividans/pIJ702 (0.5 mL) and incubated with vigorous 
shaking at 29 oC for approximately 72 h.  Cells were harvested by centrifugation, 
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and the pellet was washed with 10% sucrose and resuspended in 3.2 mL of 
TEGLR (25 mM Tris-HCl pH 8, 10 mM EDTA pH 8, 50 mM glucose, 1 mg/mL 
lysozyme, 5 µg/mL pre-boiled RNase A).  After incubation at 37 oC for 
approximately 30 min, 6.4 mL of 0.2 N NaOH, 1% SDS was added.  The 
suspension was mixed immediately by several inversions and incubated at 20 oC 
for 20 min.  To the resulting lysate the following reagents were added: 4.8 mL of 
3 M potassium acetate (pH 4.8) and 0.48 mL of acid phenol/chloroform (5 g 
phenol, 5 mL chloroform, 1 mL H2O, 5 mg 8-hydroxy quinoline).  The lysate was 
mixed immediately by inversion, incubated on ice for 5 min, and centrifuged for 
15 min at 12,000 g, 4 oC.  The aqueous phase was transferred to a fresh tube; 
DNA was precipitated with 8.64 mL of isopropanol and recovered by 
centrifugation (15 min, 12,000 g, 4 oC).  DNA pellet was washed with 6 mL of 
70% ethanol, redissolved in 3.2 mL of TE buffer (10 mM Tris-HCl, 1 mM EDTA, 
pH 8), and extracted four times with 3.2 mL of phenol : chloroform : isoamyl 
alcohol (25 : 24: 1, pH 6.5) and once with 3.2 mL of chloroform.  To the aqueous 
layer (1.6 mL) the following reagents were added: 0.16 mL of sodium acetate 
(3 M, pH 5.2) and 3.52 mL of ethanol.  DNA pellet was recovered by 
centrifugation as above, washed with 2 mL of 70% ethanol, and redissolved in 
0.6 mL of TE buffer at 4 oC overnight.  The resulting viscous solution contained 
pIJ702 plasmid DNA (as confirmed by restriction enzyme digestion and agarose 
gel electrophoresis) contaminated with small quantities of genomic DNA.  It was 
used in later experiments as the source of pIJ702. 
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Cloning desVII in pIJ702.  The fragment containing desVII, des7-Sl-C-
His, was designed to incorporate histidine tag at the C-terminus of the produced 
DesVII.  It was prepared by PCR using cosmid pLZ4 as the template and the 
following primers: des7-Sl-forward (5′-GGCCGCATGCGCGTCCTGCTGAC-3′) 
and des7-Sl-reverse-His (5′-GCGCAGATCTCAGTGGTGGTGGTGGTG-
GTGCCGGGCGTC-3′).  Underlined are the SphI and BglII restriction sites, 
respectively; nucleotides encoding the six histidine residues are shown in bold.  
This fragment was ligated into the SphI-BglII restriction sites of pIJ702, and the 
resulting construct was used to transform protoplasts of S. lividans 1326. 
Published procedures were followed for the preparation of S. lividans 
1326 protoplasts22 transformation and selection.21  For transformation, fresh 
PEG 1000 and three different ratios of T buffer to PEG (2:1, recommended 3:1, 
and 4:1) were used.  Strain S. lividans 1326 transformed with pIJ702 was a 
positive control, and the same strain with no DNA added during transformation 
was a negative control.  Transformants were plated onto R2YE plates,22 incubated 
at 30 oC for 20 h, and then overlaid with a thiostrepton solution (200 µg/mL of 
agar). 
Selection of the S. lividans/desVII-Sl-C-His/pIJ702 Clones.  Colonies 
became visible after several (5 to 7) days at 30 oC, from which 20 colonies were 
picked and streaked on R2YE agar containing thiostrepton (20 µg/mL) in slanted 
tubes.  The tubes were incubated at 30 oC for several days, and a piece of the agar 
was used to inoculate 5 mL portions of TSB media containing thiostrepton 
(10 µg/mL).  The resulting culture was grown for several days.  Several attempts 
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were made to isolate DNA of desVII/pIJ702 plasmids from the above 
S. lividans/desVII/pIJ702 cultures for analysis.  Unfortunately, no or very low 
yields of DNA were produced since no or little desired bands were visible on 
agarose gel after the digestion. 
To check for protein production, fresh cultures of transformants were 
grown as above, and cell pellets were collected by centrifugation followed by re-
suspension in a sonication buffer #2 (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 
1 mM DTT).35  After sonication (three pulses, 20 sec each), proteins were 
separated by SDS-PAGE and blotted onto the HybondC Extra membrane.  
Detection using anti-His primary antibody, alkaline phosphatase conjugate and 
NBT/BCIP substrates failed to identify a visible band for any of the 20 clones. 
4.2.8 Expression of desVII in S. lividans: 2nd Attempt 
Plasmid pSB01was designed for the expression of desVII in S. lividans.  
Unlike desVII/pIJ702, it has the desVII gene cloned downstream to melC1 of 
pIJ702 as opposed to replacing it.  Vector pUC119 was used as the base for the 
construct to enable cloning in E. coli rather than Streptomyces.  Kanamycin 
resistance marker, neo, was also introduced to improve selection of transformants 
in S. lividans. 
Preparation of Plasmid pSB01.  The design of the expression plasmid is 
shown in Figure 4-5 (Route A).  The melC1 fragment used contains not only the 
melC1 sequence but also the region between melC1 and melC2 present in the 
original S. antibioticus sequence.  The desVII fragment contains the sequence 
coding for the C-terminal His6 tag which was introduced as part of the PCR 
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primer.  Vector pIJ702 contains thiostrepton resistance gene.  All cloning steps 
were done in E. coli DH5α, and ampicillin was used as a selection marker at the 
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Figure 4-5: Strategy for constructing pIJ702/melC1/desVII plasmid for desVII 
expression in S. lividans. 
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Fragment melC1 was amplified by PCR using melC1-forward (5′-
GCGCGGCATGCCGGAACTCAC-3′, SphI site is underlined, start codon of 
melC1 is shown in bold) and melC1-reverse (5′-GCGCGCATATGCGGG-
TGCTC-3′, NdeI site is underlined, start codon of melC2 is shown in bold) as 
primers, and vector pIJ702 as the template.  Fragment desVII was amplified by 
PCR using des7-Sl-up2 (5′-GGCCCATATGCGCGTCCTGCTGAC-3′, NdeI site 
is underlined, start codon of desVII is shown in bold) and des7-Sl-C-His2 (5′-
GCGCAAGCTTCAGTGGTGGTGGTGGTGGTGCCGGGCGTC-3′, HindIII site 
is underlined, residues encoding histidine tag are italicized, stop codon is shown 
in bold) as primers and cosmid pLZ4 as the template.  The ends of these 
fragments were freed by a digestion with an appropriate pair of restriction 
endonucleases.  The three-way ligation of melC1/SphI, NdeI and desVII/NdeI, 
HindIII in the SphI-HindIII restriction sites of pUC119 was not successful.  
Therefore, an alternative path (Route B, Figure 4-5) was undertaken. 
To avoid the three-way ligation step (it has lower efficiency than the two-
way ligation and, without a marker, it is hard to select for a three-way ligation 
product) desVII/NdeI, HindIII fragment was first cloned into the pET28b vector.  
The 1.66 kb HindIII-SphI fragment of the desVII-Sl-C-His/pET28b plasmid was 
then cloned into pUC119, and the SphI-NdeI fragment of the resulting 
pUC119/desVII was replaced with melC1/SphI, NdeI to generate the desired 
pUC119/melC1/desVII plasmid, which is also the anticipated product of the 
three-way ligation (Figure 4-5). 
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Plasmid pUC119/melC1/desVII and vector pIJ702 were both digested 
with SphI and subjected to the T4 DNA ligase catalyzed reaction.  Ampicillin-
resistant clones resulting from the ligation between pUC119/melC1/desVII and 
pIJ702 were observed.  The desired clone with the correct orientation of pIJ702 
relative to pUC119/melC1/desVII was selected based on its BamHI digestion 
pattern.  The identity of the clone pUC/pIJ/melC1/desVII was confirmed by DNA 
sequencing. 
The fragment containing kanamycin resistance gene, neo/XbaI, EcoRI was 
then cloned into the pUC/pIJ/melC1/desVII plasmid.  Fragment neo was 
amplified by PCR from plasmid pDes1-d1 (Chapter 2) using the following 
primers: 1neomycin (5′-CGCGTCTAGATACCTACAGCGTGAGC-3′, XbaI site 
is underlined) and 2neo2 (5′-CGCGGAATTCCCACGAATTAGCC-3′, EcoRI 
site is underlined).  The resulting plasmid, pSB01, confers resistance to ampicillin 
in E. coli and to kanamycin and thiostrepton in Streptomyces strains.  pSB01 was 
used in later experiments. 
Expression of desVII in S. lividans TK64.  Plasmid pSB01 was used to 
transform the protoplasts of S. lividans TK64 (ATCC 69441) as described above.  
Transformants were selected by overlaying R2YE plates containing transformed 
protoplasts with soft nutrient agar22 supplemented with kanamycin to bring the 
final concentration of antibiotic in the agar to 50 µg/mL.  Thirteen positive 
colonies (KanR) were propagated on R2YE plates containing kanamycin 
(50 µg/mL) and thiostrepton (5 µg/mL).  The clones were inoculated in 5 mL of a 
modified GYM medium (per 1 L: 4.0 g glucose, 4.0 g yeast extract, 10.0 g malt 
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extract, pH 7.2)36, 37 containing kanamycin (50 µg/mL) and thiostrepton 
(5 µg/mL) and grown at 29 oC for 72 h. 
Aliquots of GYM cultures (0.5 mL) were taken and DNA was isolated 
using QIAprep kit from QIAgen (200 µg/mL of lysozyme was added to the P1 
resuspension buffer).  The isolated DNA was subjected to PCR analysis using 
des7-Sl-up2 and des7-Sl-C-His2 primers.  The reactions of five of the clones 
produced the expected 1.3 kb fragments, therefore confirming the presence of the 
pSB01 plasmid. 
The cultures of the four positive clones were harvested by centrifugation, 
cell pellet was resuspended in SDS-PAGE sample buffer, and supernatant was 
concentrated 5-fold using Microcon YM-30.  Both pellet and supernatant were 
analyzed using SDS-PAGE.  All of the supernatant fractions contained a band at 
approximately 47 kDa (expected size of His6-tagged DesVII is 47.2 kDa) 
indicating the presence of DesVII-C-His.  There was no such band visible from 
the pellet fractions. 
Concentrated supernatant fractions were used as the protein component in 
the glycosyltransferase assay (as described above) using 10-deoxymethynolide 
(65) and TDP-D-desosamine (22) as substrates in the presence of and Mg2+ and 
Mn2+ metal ions.  The extent of the reaction was evaluated by TLC analysis. 
4.2.9 Purification of Sfp Protein 
The expression plasmid containing Bacillus subtilis sfp gene, pET29-Sfp, 
was kindly provided by Dr. Christopher Walsh, Harvard Medical School.  It 
consists of a 0.7 kb sfp gene (Accession Number X63158)38 cloned into the NdeI-
 180
XhoI sites of the expression vector pET29b(+).  It allows the production of Sfp 
fused with a C-terminal His6 tag. 
 Cell Growth.  The expression plasmid pET29-Sfp was used to transform 
E. coli BL21, and the resulting strain was grown at 37 oC overnight in LB 
medium supplemented with kanamycin (50 µg/mL).  The overnight culture was 
diluted 100 fold in 3 L of LB medium (35 µg/mL of kanamycin) and incubated at 
37 oC until OD600 reached 0.4.  The production of Sfp was induced with 0.16 mM 
IPTG, and the cells were incubated at 18 oC for 16 h.  The cells were harvested by 
centrifugation (5,000 g, 10 min) and used immediately in the next step. 
Sfp Purification.  Crude protein extract (from 20 g of cell pellet) 
preparation and purification of Sfp by Ni-NTA affinity chromatography were the 
same as described for the purification of DesVII-C-His, with the only exception 
being that no protease inhibitor, PMSF, was used this time.  The desired protein 
fractions, as detected by SDS-PAGE, were pooled and dialyzed against 40 mM 
potassium phosphate buffer (pH 7.2) containing 20% glycerol.  The identity of the 
protein was confirmed by the Western blot analysis with an anti-histidine 
detection system.  The purified protein was concentrated, aliquotted, flash frozen 
with liquid nitrogen, and stored at –80 oC.  Protein was estimated to be >95% pure 
(SDS-PAGE), and its concentration was determined to be 45 mg/mL by the 
Bradford assay.  The yield of the purified Sfp was 75 mg/L of culture. 
4.2.10 Purification of apo-ACP5 
Construction of E. coli Strain Producing ACP5 domain of PikAIII PKS of 
S. venezuelae.  The DNA fragment containing the region coding for ACP5 was 
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amplified by PCR from BamHI-digested S. venezuelae genomic DNA using 
forward primer 5′-GCCGCATATGACGGTGTCCCGTCCCAGCCTTC-3′ and 
reverse primer 5′-GCGCAAGCTTGGTGTTACGGGGGCCGAGAGCCAT-
CCGGATCAG-3′ (restriction sites NdeI and HindIII, respectively, are 
underlined).  This fragment was cloned into the NdeI-HindIII sites of pET24b(+).  
The resulting plasmid, ACP5-2/pET24b, was used to transform E. coli BL21. 
Purification of ACP5-C-His.  Strain E. coli BL21/ACP5-2/pET24b was 
grown overnight in LB medium (kanamycin, 50 µg/mL).  The overnight culture 
was used to inoculate 6 L of LB medium (kanamycin, 35 µg/mL), grown at 37 oC 
until OD600 reached 0.75, and the production of ACP5-C-His was then induced 
with 1 mM IPTG.  After incubation at 37 oC for an additional 4 h, cells were 
harvested by centrifugation and ACP5-C-His was purified using Ni-NTA agarose 
as described above for DesVII-C-His purification with the following 
modifications.  Lysis buffer was 20 mM Tris-HCl (pH 8), 0.2 M NaCl, and 
1.5 mM imidazole.  After the incubation with the protein crude extract, Ni-NTA 
resin was extensively washed with the lysis buffer.  The weakly bound proteins 
were then washed out with a lysis buffer containing 20 mM imidazole.  Finally, 
bound ACP5-C-His was eluted using a lysis buffer containing 300 mM imidazole.  
The fractions containing the desired protein (23.6 kDa) were combined and 
dialyzed against 50 mM Tris-HCl (pH 8) buffer containing 10% glycerol (Figure 
4-6, lane 1). 
ACP5-C-His was further purified by anion exchange chromatography 
using FPLC equipped with a MonoQ HR 10/10 column.  Proteins were loaded on 
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the column with buffer A (50 mM Tris-HCl, pH 8, 10% glycerol) at 3 mL/min 
over 4 column volumes and then eluted with the gradient 0–40% of buffer B 
(buffer A plus 1 M KCl) in buffer A over 20 column volumes.  Fractions 
containing ACP5-C-His (at approximately 220 mM KCl) were pooled and 
desalted using Centriprep YM-10 until approximately 40 mM KCl remained.  
They were flash frozen with liquid nitrogen and stored at –80 oC (Figure 4-6, 
lane 2).  Protein concentration was 15 mg/mL, and the overall yield of pure ACP5-
C-His was 10 mg/L of culture. 
4.2.11 Model Reaction for Acyl-phosphopantetheinylation of apo-ACP5 
General.  Assays were carried out according to the published procedure 
with minor modifications.39  Radiolabeled acetyl coenzyme A [acetyl-3H] from 
ICN Biochemicals was received as 0.1 mCi/mL solution in 0.01 M sodium acetate 
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Figure 4-6: SDS-PAGE illustrating purification of ACP5.  Lane 1: protein 
sample after Ni-NTA column, lane 2: ACP5 after MonoQ 
purification.  Lane M is the molecular weight marker and bands are 
as in Figure 4-4 with an additional band of bovine aprotinin 
(6.5 kDa). 
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(pH 5) and stored at –20 ºC.  It exhibits approximately 1–2% decomposition per 
month under these conditions. 
Radioassay Procedure.  A typical assay of 100 µL contained 50 mM Tris-
HCl (pH 7.0), 5 mM MgCl2, 5 mM DTT, and 40 mM NaCl.  To this mixture were 
added 3 µL of 0.64 mM apo-ACP5-C-His (in 50 mM Tris-HCl, pH 8, 10% 
glycerol, final concentration 19.2 µM), 5 µL of 35.34 µM (1.77 µM, 
2.83×103 µCi/µmol) acetyl [3H]-CoA solution, and 1 µL of 20 µM Sfp (in 50 mM 
potassium phosphate, pH 7.5, 10% glycerol, final concentration 0.2 µM).  
Reaction mixtures were vortexed before and immediately after the addition of Sfp 
and incubated at room temperature for periods of 0.5, 1, 1.5, 2, 4 and 6 min.  Two 
control samples, one without Sfp and one without ACP, were prepared and 
incubated for 2 min.  The reactions were quenched by adding 800 µL of 10% 
TCA; then 50 µL of 10 mg/mL BSA solution was added as a carrier.  Samples 
were centrifuged, and the pellet was washed twice with 10% TCA.  Pellets were 
resuspended in 100 µL of formic acid, a scintillation liquid was added, and the 
samples were counted.  Readings of disintegrations per minute (DPM) were 
converted to the unit of mole product by the equality, 2.22×106 DPM = 1 µCi 
radioisotope and the specific activity of the compound used (µCi/µmol). 
4.2.12 Purification of TE-1 and TE-2 Proteins 
Construction of Expression Plasmids pTE-C-His and pTE(2)-C-His.  The 
fragments to be inserted in the expression vector, te-1 and te-2, were amplified by 
PCR from the S. venezuelae genomic DNA digested with HindIII.  Primers TE-b1 
(5′-GCCGCATATGTTCCGCGCCCTGTTCCGG-3′) and TE-b2 (5′-GCGC-
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AAGCTTCTTGCCCGCCCCCTCGAT-3′) were used to amplify the te-1 
fragment (restriction sites NdeI and HindIII, respectively, are underlined); and 
primers TE-b3 (5′-GCCGCATATGTCCGGGGCCGACACCGGCG-3′, 
restriction site NdeI is underlined) and TE-b2 – for the te-2 fragment.  After 
digestion with NdeI and HindIII, te-1 and te-2 were separately cloned into the 
same restriction sites of the pET24b(+) vector.  The resulting plasmids, pTE-C-
His and pTE(2)-C-His, were used to transform the competent cells of E. coli 
BL21. 
 Affinity Purification of TE-1 and TE-2.  The overnight cultures of strains 
E. coli BL21/TE-1 and E. coli BL21/TE-2 were inoculated into 1 L of LB 
medium containing 35 µg/mL of kanamycin (1 to 100 dilution) and grown at 
37 oC until OD600 reached 0.6.  The production of TE was then induced by the 
addition of IPTG to a final concentration of 50 µM, and cells were grown at 16 oC 
for an additional 17 h.  The preparation of the crude protein extract and the 
purification of TE by nickel affinity chromatography followed the same 
procedures as described for DesVII-C-His purification (Section 4.2.3).  Proteins 
eluted with a buffer containing 250 mM imidazole were dialyzed against 50 mM 
Tris (pH 8) containing 10% glycerol, concentrated, and stored at –80 oC. 
 Assay of TE Activity.  The reaction mixture of 50 µL contained 50 mM 
Tris-HCl (pH 9) or 50 mM sodium phosphate (pH 8) and 1 mM 10-
deoxymethynolide (65).  The amount of TE used varied from 0.5 to 2 µM.  The 
reaction mixtures were incubated at 29 oC for up to 16 h and the remaining 10-
deoxymethynolide was extracted with chloroform.  The success of the 
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transformation was judged by TLC based on the consumption of the substrate as 
compared to the control which lacks TE.  No reaction was discernible under the 
assay conditions using different preparations of TE. 
4.2.13 Construction and Characterization of S. venezuelae KTE Mutant 
Generation of Disruption Plasmid pTE-K.  Disruption plasmid pTE-K was 
generated from plasmid pDesVIII-K (Chapter 2) by the replacement of EcoRI, 
XbaI fragment sug-u with a portion of pikAIV, fragment KTE.  This replacement 
effectively results in deletion of part of desVIII plus a region upstream to desVIII.  
The fragment KTE was amplified by PCR from the BamHI-digested 
S. venezuelae genomic DNA using primers KTE-1 (5´-GGCCGAATTC-
CTTCACCCACTTCATCGAG-3´, EcoRI restriction site is underlined) and KTE-
2 (5´-GCGCTCTAGATCA[GTG][GTG][GTG][GTG][GTG][GTG]GAAGGA-
GGTGCTGAG-3´, XbaI restriction site is underlined, stop codon is in bold, and 
histidine codons are in square brackets).  Fragment KTE was then digested with 
EcoRI and XbaI and cloned into the respective sites of pDesVIII-K. 
 Homologous Recombination and Screening for Double Crossover 
Mutants.  E. coli S17-1 was transformed with the resulting pTE-K plasmid and 
used as a donor strain for the conjugal transfer to the wild type S. venezuelae as 
described in Chapter 2.  After an antibiotic selection, plasmid curing and replica 
screening, two strains with the desired phenotype (KanR, AprS) were obtained.  
They were grown in 25 mL of TSB medium containing 50 µg/mL kanamycin for 
48 h at 29 oC, and their genomic DNA was isolated using the Kirby mix.21 
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Genomic DNA of the mutants and the wild type S. venezuelae was 
digested with PstI, separated by agarose gel electrophoresis, and transferred to a 
nylon membrane using standard procedures.21  DIG-labeled probes were prepared 
using PCR DIG Probe Synthesis Kit from Roche (Palo Alto, CA).  Plasmid pTE-
K was employed as the template along with the following primers to amplify the 
target genes: KTE-1 and KTE-2 for KTE (see above), des8-d1 and des8-d2 for 
desVIII, and 1neomycin and 2neomycin for neo (see Chapter 2 for the sequences 
of the last four primers).  Membranes were probed with DIG-labeled fragments 
and hybridized DNA fragments were visualized using NBT/BCIP colorimetric 
detection as described in Roche’s “DIG User’s Manual”. 
Analysis of Macrolide Production by KTE Mutants.  Both mutant strains, 
KTE-1 and KTE-2, were grown in the 12-membered ring macrolide production 
medium, and the production of macrolides was analyzed by TLC (Chapter 2).  
Alternatively, SCM medium was also used for 12-membered macrolide 
production.  The recipe per 1 L included: 15 g soluble starch, 20 g of soytone, 
0.1 g CaCl2, 1.5 g of yeast extract, 10.5 g of MOPS, adjusted to pH 7.2.40  For the 
production of 14-membered macrolides, PGM medium was used except that 
CaCl2 was replaced by CaCO3.  The ingredients per 1 L included: 10 g of glucose, 
10 g of glycerol, 10 g of peptone, 5 g of beef extract, 5 g of NaCl, 2 g of CaCO3, 
adjusted to pH 7.3.30  For the growth of KTE mutant, the medium contained 
kanamycin (50 µg/mL).  It was inoculated with a spore suspension of the strain 
for small scale cultures (0.001 dilution) or a 2-day old TSB culture for large scale 
growth (0.01 dilution).  A culture of the wild type S. venezuelae was grown in 
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parallel as the control.  The cultures were grown at 29 oC for 2-4 days and then 
centrifuged.  Supernatant was extracted with chloroform for TLC analysis, and 
proteins of the cell pellet were isolated on some occasions.   
Analysis of Proteins in KTE-2.  The wild type S. venezuelae and its KTE-2 
mutant strain were grown in a supplemented minimal medium (Section 4.2.6), 
SCM, or PGM medium (25 to 100 mL scale) as described above.  Crude proteins 
were isolated using the procedure outlined in Section 4.2.6 and analyzed by SDS-
PAGE or the Western blot hybridization.  Three different detection systems were 
used for Western blot: (i) mouse anti-His primary antibody, anti-mouse IgG 
antibody which is alkaline phosphatase conjugated, NBT/BCIP colorimetric 
detection (procedure as above); (ii) mouse anti-His primary antibody, anti-mouse 
IgG antibody which is alkaline phosphatase conjugated, chemiluminescent 
detection (WesternBreeze® kit from Invitrogen); (iii) single antibody 
INDIATMHisProbeTM-horseradish peroxidase (HRP) conjugate and SuperSignal® 
West Pico chemiluminescent substrate (SuperSignal® West HisProbeTM kit from 
Pierce, Rockford, IL).  For the chemiluminescence detection, after incubation 
with the substrate solution, the membrane was exposed to the film for a period 
varying from 30 s to 5–10 min and then developed. 
Crude extracts were also separated on Ni-NTA agarose using the 
procedure outlined for DesVII-C-His purification in Section 4.2.3.  Fractions from 
Ni-NTA column were again subjected to SDS-PAGE and Western blot analyses. 
Alternatively, the cultures were grown in 200 mL of TSB medium 
(inoculated with 0.5 mL of a 24 h-old TSB seed culture, to which kanamycin was 
 188
added for the growth of KTE-2) for 19 h, followed by protein extraction and 
fractionation by solubility using partial bacterial proteome extraction kit 
ProteoExtractTM from Calbiochem (EMD Biosciences, Inc, San Diego, CA).  The 
fractions were analyzed by SDS-PAGE and WesternBreeze® Western blot. 
4.2.14 Preparation and Macrolide Production Analysis of desVIII/KTE, 
te/KTE, and te+desVIII/KTE S. venezuelae Strains 
S. venezuelae desVIII/KTE.  Plasmid pDesVIII (Chapter 2) was used to 
complement S. venezuelae KTE-2 and to generate S. venezuelae desVIII/KTE 
mutant (KanR, AprR) using the procedures described in Section 2.2.9. 
Construction of Expression Plasmid TE-a/pAX702.  The fragment of 
S. venezuelae DNA containing the TE domain was cloned into the EcoRI-NsiI 
sites of the Streptomyces expression vector pDHS702.  Vector pDHS702 contains 
pikAI promoter and confers resistance to thiostrepton.41  Fragment TE-a was 
amplified by PCR from the S. venezuelae genomic DNA digested with HindIII.  
Forward primer TE-a1 (5′-GCCGGAATTCTAAGC[GGAAG]ACCACACCCAG-
[ATG]TTCCGCGCCCTGTTC-3′) contains EcoRI restriction site (underlined), 
stop codon (bold), and DNA sequence preceding pikAIV (small caps) with the 
putative ribosome binding site (RBS) [GGAAG] and pikAIV start codon [ATG], 
followed by the 5′-terminal te sequence.  Reverse primer TE-a2 (5′-GCGC-
ATGCATTCACTTGCCCGCCCCCTCGAT-3′) contains the NsiI restriction site 
and the 3′-terminal sequence of te, including the stop codon TGA (bold).  
Expression plasmid TE-a/pAX702 was used to transform E. coli S17-1, and the 
resulting strain was the donor strain for the conjugation experiments. 
 189
 S. venezuelae te/KTE and te+desVIII/KTE.  Plasmid TE-a/pAX702 was 
separately introduced into the S. venezuelae strains KTE-2 and desVIII/KTE 
through a conjugal transfer using E. coli S17-1 as the donor strain, which was 
transformed with this plasmid as previously described (Section 2.2.9).  The 
resulting strains were propagated in a medium containing kanamycin and 
thiostrepton (50 µg/mL each) for te/KTE and kanamycin, apramycin and 
thiostrepton (50 µg/mL each) for te+desVIII/KTE. 
 Macrolide Production Analysis.  All three strains, desVIII/KTE, te/KTE, 
and te+desVIII/KTE, together with the wild type control strain were each grown 
at 29 oC in a seed medium (5 mL) supplemented with the appropriate antibiotics 
for 48 h.  A 0.3 mL seed culture from each 2-day culture was inoculated into 
15 mL vegetative media and grown for additional 48 h.  The cultures were 
harvested by centrifugation.  The supernatant was adjusted to pH 9.5 and 
extracted with chloroform.  The chloroform fractions were concentrated and 
analyzed by TLC as described before. 
4.2.15 Feeding S. venezuelae Mutants with 10-Deoxymethynolide (65) 
The antibiotics required for selective growth of the mutants were used in 
the growth media at concentrations of 50 µg/mL.  Portions of 5 mL seed medium 
were inoculated with 10 µL of strains’ spore suspensions, and the resulting 
mixture was incubated at 29 oC for 48 h.  Seed cultures (2 mL) were then 
transferred into 100 mL of vegetative medium and grown for 31 h.  Stock of 10-
deoxymethynolide (65, 100 mM in ethanol) was added to the vegetative cultures 
to the final concentration of 50 µM, and the cultures were incubated for additional 
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48 h.  Cells were removed by centrifugation, supernatant adjusted to pH 9.5, and 
extracted with an equal volume of chloroform.  The solvent was evaporated and 
crude products redissolved in 2.5 mL of chloroform.  Crude products (5 µL) were 
then analyzed by TLC as described above. 
4.2.16 Simultaneous Expression of pikAV and desVIII: DesVIII-1 
Construction of Expression Plasmid pikAV-desVIII/pET24b.  DNA 
fragment containing pikAV and desVIII was amplified by PCR using cosmid pLZ4 
as the template and des8pik-up1 (5′-GCCGCATATGACCGACAGAC-3′, the 
NdeI) and des8pik-down1 (5′-GCGCAAGCTTGGAGCTGCTGAC-3′, the 
HindIII restriction site is underlined) as primers.  This fragment was cloned into 
the NdeI-HindIII restriction sites of the expression vector pET24b(+).  The 
resulting plasmid pikAV-desVIII/pET24b was used for transformation of E. coli 
BL21. 
Purification of DesVIII.  The protocols used for the growth of the 
recombinant E. coli strain containing the expression plasmid pikAV-
desVIII/pET24b (6 L culture), the preparation of protein crude extract, and the 
nickel affinity chromatography were the same as described in Section 4.2.3.  
Since no binding to Ni-NTA agarose was achieved, the flow-through fraction was 
further subjected to anion exchange chromatography on DEAE Sepharose CL-6B 
resin. 
The sample was loaded onto a DEAE column pre-equilibrated with the 
loading buffer (50 mM potassium phosphate, pH 7.5, 15% glycerol) at 4 oC.  
Proteins were then eluted using a linear gradient between equal volumes (1 L) of 
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the loading buffer containing 0.2 M KCl and 0.8 M KCl.  The fractions of about 
15 mL were collected, and those containing proteins (as judged by UV A280 
readings) were further analyzed by SDS-PAGE.  Fractions 3–8 containing PikAV 
as the major component and fractions 21–26 containing DesVIII-1 were 
separately combined and dialyzed against the loading buffer.  The pooled sample 
of DesVIII-1 contained about 30% DesVIII-1 (43 kDa) as judged by SDS-PAGE; 
the remaining impurities were mostly of higher molecular weight proteins. 
4.2.17 Optimized Glycosyltransferase Activity Assay and Preparative TLC 
The optimized assay composition was as follows (in the order of addition): 
water (enough to bring the total volume to 50 µL), 50 mM Tris-HCl (pH 9), 
6 mM MgCl2, 1 mg/mL BSA, 1 mM 10-deoxymethynolide (65) (from 50 mM 
stock in ethanol), 0.8 mM TDP-D-desosamine (22), 5 µL of DesVII-C-His 
(100 mg/mL, 2 mM), and 5 µL of DesVIII (undetermined concentration).  When 
the effect of DesVIII concentration was studied, only 1-2 µL of DesVII-C-His and 
up to 9 µL of DesVIII were used to keep 20% v/v ratio of the added protein 
solution in the total assay cocktail so as to limit the amount of glycerol in the 
assay.  The protein portion was substituted with the same amount of buffer in the 
control reactions.  The mixture was vortexed and incubated at 29 oC with shaking 
from 2 to 19 h.  To monitor the extent of the reaction, a 20 µL aliquot of each 
reaction mixture was extracted with an equal volume of chloroform, and the 
organic extract was spotted on TLC plate.  TLC was performed as described in 
the Section 4.2.2. 
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 The preparative TLC was used to isolate reaction product.  The reaction 
was carried out in 100 µL scale overnight and extracted with 100 µL of 
chloroform.  Extracts of all samples were applied on a Polygram Sil G/UV254 
plate (4×8 cm, thickness 0.25 mm) and developed in the solvent system described 
above.  Strips of the TLC plate were cut off and visualized with vanillin stain to 
determine the location of the desired compound.  The silica coating at the same 
area on the remaining unstained portion of the plate was scraped off, and the 
compounds were eluted with three 300 µL portions of methanol.  Methanol was 
evaporated; the residue redissolved in 30 µL of methanol and submitted to a high-
resolution mass spectroscopy analysis by the chemical ionization technique in the 
positive ion mode.  The results were as follows: calculated [M+H]+ for 
C25H44NO6 454.3169, found 454.3161. 
4.2.18 Purification of DesVIII-2 Under Denaturing Conditions 
Cloning and Expression.  Gene desVIII was amplified by PCR using pLZ4 
cosmid as the template and des78-His-up (5′-GCCGCATATGACCGACGACC-
TGAC-3′, the NdeI restriction site is underlined) and des8pik-down1 (Section 
4.2.16) as primers.  The fragment was cloned into the NdeI-HindIII restriction 
sites of pET24b(+), and the resulting plasmid, pDesVIII-C-His, was used to 
transform E. coli BL21 (or E. coli NovaBlue in a separate experiment). 
 The purification protocol was designed according to the 
QIAexpressionistTM instruction manual (Qiagen) for the purification of histidine-
tagged proteins.  The overnight culture of E. coli BL21/pDesVIII-C-His was 
inoculated into 4 L of LB medium containing 25 µg/mL kanamycin (1 to 50 
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dilution) and grown at 37 oC until OD600 reached 0.5.  The production of DesVIII-
2 was induced by 1 mM IPTG, and incubation was continued at 37 oC for 
additional 5 h.  Cells were harvested by centrifugation, cell pellet was 
resuspended in 50 mL of the lysis buffer (50 mM sodium phosphate, pH 8, 0.3 M 
NaCl, 10% glycerol, 5 mM imidazole, 0.4 mM PMSF) in the presence of 
1 mg/mL lysozyme and incubated at 4 oC for 30 min.  Cells were disrupted by 
sonication, and the supernatant was removed after centrifugation.  Pellet was 
washed by the lysis buffer, and proteins were solubilized in 40 mL of Buffer B 
(100 mM sodium phosphate, 10 mM Tris, 8 M urea, pH 8) at room temperature 
for 1 h.  Cell debris was removed by centrifugation, and crude proteins were 
subjected to the nickel affinity purification under denaturing conditions. 
 Under denaturing conditions, DesVIII-2 did not bind to the nickel resin; 
instead it was found in all fractions in equal amounts.  Therefore, it was dialyzed 
against the lysis buffer with three changes (500 mL each), clarified by 
centrifugation, and incubated with Ni-NTA resin (10 mL bed volume) overnight 
at 4 oC.  It was then subjected to a routine purification as described in 
Section 4.2.3.  The fractions collected were dialyzed against 50 mM Tris-HCl, 
pH 8, 10% glycerol, and concentrated until a precipitate began to appear.  A 
further concentration led to a significant protein precipitation: thus, only 
approximately 1 mg/mL DesVIII-2 sample was obtained.  SDS-PAGE of 
DesVIII-2 (43.6 kDa) is shown in Figure 4-4 (lane 2).  Western blot analysis 
confirmed the presence of a polyhistidine tag in the purified DesVIII. 
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4.2.19 Purification of DesVIII-3 
Cloning and Expression.  Gene desVIII was amplified by PCR using pLZ4 
cosmid as the template and des78-His-forward (Section 4.2.18) and des8-reverse 
(5′-GCGCAAGCTTCAGGAGCTGCTGACCG-3′, the HindIII restriction site is 
underlined) as primers.  This fragment was cloned into the NdeI-HindIII 
restriction sites of pET28b(+), and the resulting plasmid, pDesVIII-N-His, was 
used to transform E. coli BL21. 
 The overnight culture of E. coli BL21/pDesVIII-N-His was inoculated into 
3 L of LB medium containing 25 µg/mL kanamycin (1/50 dilution) and grown at 
37 oC until OD600 reached 0.5.  The production of DesVIII-3 was induced by 
0.5 mM IPTG, and incubation was continued at 16 oC for additional 21 h.  Cells 
were harvested by centrifugation.  The cell pellet was resuspended in 50 mL of a 
lysis buffer (50 mM sodium phosphate pH 8, 0.3 M NaCl, 10% glycerol, 5 mM 
imidazole, 0.4 mM PMSF) with 1 mg/mL lysozyme and incubated at 4 oC for 
30 min.  Cells were disrupted by sonication, and the supernatant was collected 
after centrifugation. 
Purification Using Affinity, Ion Exchange and Size Exclusion 
Chromatography.  The above crude extract was subjected to the nickel affinity 
chromatography as described in Section 4.2.3.  Despite the fact that the presence 
of a histidine tag in DesVIII-3 was confirmed by the Western blot analysis, this 
fusion protein failed to bind to the resin.  Therefore, in the following protein 
preparations the crude extract was prepared as above except that 50 mM sodium 
phosphate, pH 8, 1 mM DTT, 0.1 mM PMSF was used as the lysis buffer.  Crude 
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extract was loaded onto a DEAE Sepharose CL-6B column and washed with 
50 mM potassium phosphate, pH 8, 1 mM DTT, 0.1 mM PMSF.  Bound proteins 
were then eluted using a linear gradient between equal volumes (0.5 L) of a 
loading buffer containing no KCl and 1 M KCl.  Fractions of about 8 mL were 
collected throughout the elution, and the ones containing proteins (as judged by 
UV A280 readings) were further analyzed by SDS-PAGE. 
 The selected DEAE fractions were pooled, concentrated, and loaded onto 
a Sephacryl S200 HR column equilibrated with the running buffer.  Proteins were 
isocratically eluted with 25 mM Tris-HCl, pH 7.5, 125 mM NaCl, 1 mM DTT, 
and fractions analyzed by UV-vis and SDS-PAGE as described above. 
4.2.20 Purification of DesVIII-4 via Fusion with Maltose Binding Protein 
Cloning and Expression.  The expression vector MalE-pET was provided 
by Peng Gao.  The desVIII gene was cloned into the NdeI-HindIII sites of the 
MalE-pET vector using the same insert fragment as for the pDesVIII-N-His 
plasmid.  The depiction of the resulting plasmid pDesVIII-MalEpET is shown in 
Figure 4-7.  It was used to transform the expression host E. coli BL21. 
An overnight culture of E. coli BL21/pDesVIII-MalEpET was used to 
inoculate 6 L of LB medium containing kanamycin (25 µg/mL), and the cells 
were grown at 37 oC until OD600 reached 0.5–0.6.  The temperature was then 
lowered to 18 oC.  The production of the protein was induced with 0.3 mM IPTG 
for 15 h.  The cells were harvested by centrifugation, and the cell pellet (35–40 g) 
frozen at –80 oC for 1 h to facilitate cell lysis. 
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Purification of DesVIII-4 Protein.  Cell pellet prepared in the previous 
step was thawed and resuspended in 150 mL of the lysis buffer (50 mM sodium 
phosphate pH 8, 0.3 M NaCl, 10% glycerol, 5 mM imidazole) containing 0.3 mM 
PMSF and 1 mg/mL lysozyme.  After incubation on ice for 30 min, cells were 
disrupted by sonication (36 pulses of 10 sec sonication with 20 sec cooling 
intervals between pulse), and cell debris was removed by centrifugation. 
Crude extract was incubated with 20 mL of Ni-NTA resin (bed volume) at 
4 oC for 2 h, and the matrix was loaded into an empty column.  After the removal 
of the flow-through, weakly bound proteins were eluted with 200 mL of the lysis 
buffer, followed by 150 mL of the lysis buffer containing 15 mM imidazole, and 
100 mL of the lysis buffer containing 30 mM imidazole.  Bound proteins were 
then eluted with the lysis buffer containing 250 mM imidazole, and the fractions 
containing the desired protein (88.9 kDa), as judged by SDS-PAGE, were 










Figure 4-7: Expression plasmid pDesVIII-MalEpET used for the production of 
MalE-DesVIII fusion protein.
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added to the pooled fractions to a concentration of 15 µg/mL, and the solution 
was dialyzed against 1 L of 50 mM sodium phosphate, pH 8, 0.1 M NaCl, 10% 
glycerol with two changes of buffer overnight. 
The complete digestion of MalE-DesVIII was run concurrently with 
dialysis overnight and confirmed by the presence of two major bands, 42.2 kDa 
for DesVIII-4 and 46.7 kDa for MBP (MalE), on SDS-PAGE.  The dialyzed 
solution was incubated with Ni-NTA resin as in the previous step.  Proteins were 
first eluted with 15 mM imidazole and followed by an elution with 250 mM 
imidazole.  The fractions containing MBP (250 mM imidazole) were discarded, 
and the flow-through and 15 mM imidazole fractions containing DesVIII-4 were 
combined and dialyzed against the same dialysis buffer as above.  While the 
major protein component is DesVIII-4, this sample still contains some MBP and 
the fusion protein as indicated by the Western blot analysis. 
M       1
 
Figure 4-8: SDS-PAGE of purified DesVIII-4 (lane 1, major band of 
approximately 42 kDa).  Lane M is prestained molecular weight 
marker and bands are as follows: E. coli MBP-β-galactosidase, 
175 kDa; E. coli MBP-paramyosin, 83 kDa; bovine glutamic 
dehydrogenase, 62 kDa; rabbit aldolase, 47.5 kDa; rabbit 
triosephosphate isomerase, 32.5 kDa; bovine β-lactoglobulin A, 









After the dialysis, DesVIII-4 was concentrated and loaded onto an 
amylose column (15 mL bed volume).  Unbound DesVIII-4 was eluted with 
25 mM Tris-HCl, pH 8, 0.1 M NaCl, 10% glycerol, concentrated, and stored in 
the same buffer (Figure 4-8).  The fractions eluted with 20 mM maltose contained 
MBP.  The concentration of DesVIII-4 is 5.5 mg/mL as estimated by the Bradford 
assay and it is free of MBP and the fusion MalE-DesVIII according to the 
Western blot.  A preliminary native molecular weight determination by size 
exclusion chromatography (as in Section 4.2.4) resulted in several peaks.  The 
major one corresponds to 56.8 kDa, and the second major peak is the aggregated 
protein which was eluted with the void volume. 
4.2.21 Large Scale DesVII/DesVIII Assay and Product Purification 
To confirm the structure of DesVII product, a large scale reaction was ran 
as above (Section 4.2.17) with 50 µmol of 65, 54 µmol of 22, 0.36 µmol DesVII-
C-His, and approximately 0.2–0.3 µmol DesVIII-4 in a total volume of 17 mL of 
50 mM Tris-HCl buffer (pH 9) for 9 h.  The products were extracted twice with 
an equal volume of chloroform; the combined organic layers were evaporated; 
and the residue was dried under vacuum.  NMR spectra (1H, 13C and COSY) of 
the resulting product (25 mg, 55 µmol) were taken.  They were in good agreement 
with the previously reported spectral data.32, 42 
1H NMR (500 MHz, CDCl3) of YC-17 (3): δ 6.75 (1H, dd, J = 16.0, 
5.5 Hz, 9-H), 6.43 (1H, dd, J = 15.5, 1.5 Hz, 8-H), 4.95 (1H, ddd, J = 8.5, 6.0, 
2.5 Hz, 11-H), 4.25 (1H, d, J = 7.5 Hz, 1′-H), 3.59 (1H, d, J = 10.5 Hz, 3-H), 3.49 
(1H, dqd, J = 12.0, 6.0, 2.0 Hz, 5′-H), 3.25 (1H, dd, J = 10.0, 7.0 Hz, 2′-H), 2.86 
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(1H, dq, J = 10.0, 6.5 Hz, 2-H), 2.62 (1H, dqq, J = 12.5, 7.0, 1.0 Hz, 10-H), 2.54 
(2H, 2 sets of m, 3′-H and 6-H), 2.31 (6H, s, NMe2), 1.71 (2H, m, 5a-H and 12a-
H), 1.69 (1H, m, 4′ax-H), 1.56 (1H, m, 12b-H), 1.46 (1H, ddd, J = 14.0, 12.5, 
4.0 Hz, 5b-H), 1.41 (3H, d, J = 7.0 Hz, 2-Me), 1.26 (1H, m, 4′eq-H), 1.23 (3H, d, 
J = 6.0 Hz, 5′-Me), 1.22 (1H, m, 4-H), 1.19 (3H, d, J = 7.0 Hz, 6-Me), 1.10 (3H, 
d, J = 6.5 Hz, 10-Me), 1.01 (3H, d, J = 6.5 Hz, 4-Me), 0.91 (3H, t, J = 7.5 Hz, 12-
Me). 
13C NMR (125 MHz, CDCl3): δ 205.29 (C-7), 175.20 (C-1), 146.83 (C-9), 
126.00 (C-8), 105.00 (C-1′), 85.81 (C-3), 73.68 (C-11), 70.35 (C-2′), 69.42 (C-5′), 
65.94 (C-3′), 45.11 (C-6), 44.10 (C-2), 40.27 (NMe2), 37.85 (C-10), 34.12 (C-5), 
33.51 (C-4), 29.71 (C-4′), 25.17 (C-12), 21.14 (5′-Me), 17.70 (6-Me), 17.40 (4-
Me), 16.06 (2-Me), 10.30 (12-Me), 9.58 (10-Me). 
The sample isolated from a large scale reaction contained a small amount 
of aliphatic impurity displaying signals as following 1H NMR: δ 0.83 (m), 1.3 (t 
and m), 2.35 (broad d) and 13C NMR: δ 28.57).  Further purification of this 
compound using silica gel chromatography led to the recovery of only 3.5 mg of 
pure 3. 
4.2.22 HPLC Assay of DesVII/DesVIII Activity 
Reactions in 50 or 100 µL scale were carried out to assay the 
DesVII/DesVIII activity as previously described for the TLC assays.  The protein 
components were removed from the reaction mixture by filtering through a 
Microcon YM-10 centrifugal device.  The filtrate was then chromatographed on 
an HPLC reverse phase analytical C18 column (4.5×250 mm, 5 µm).  Either 
 200
Econosil C18 (Alltech, Deerfield, IL) or Microsorb-MV C18 (Varian, Palo Alto, 
CA) was used, both showing similar elution profiles.  Data summarized in Table 
4-2 was obtained using Microsorb-MV C18 column.  Two alternative solvent 
systems were used for elution with flow rate of 1 mL/min.  The detector was set at 
235 nm. 
1. Using Ammonium Acetate Buffer.  Compounds were eluted isocratically 
with 50% acetonitrile in 0.057 M ammonium acetate.  In this system, the retention 
time for 65 was 6.4 min and that for the product 3 (as a broad peak) fluctuated 
between 17.5 and 19.0 min, depending on its concentration when Econosil C18 
column was used. 
2. Using Triethylamine Buffer.  The previously reported solvent 
composition was used.43  Buffer A was 0.014 M triethylamine adjusted to pH 3 
with trifluoroacetic acid (TFA), and buffer B was acetonitrile.  Compounds were 
eluted with 26% B for 14 min, followed by 26–60% B gradient over 11 min, and 
then 60–100% B gradient over 10 min.  This system gave better peak shape for 
the glycosylated compounds when Microsorb-MV C18 column was used.  The 
retention times obtained under these conditions are shown in Table 4-2. 
4.2.23 Far Western Blot Analysis of DesVII-DesVIII Interactions 
The standard procedure was followed for Far Western blot analysis of 
protein interactions.44  The sample containing the untagged DesVIII protein, 
DesVIII-1 (Section 4.2.16) was separated on SDS-PAGE, and proteins were 
transferred to Hybond-C Extra nitrocellulose membrane as described for Western 
blot (Section 4.2.1).  After blocking and washing with appropriate buffers, the 
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membrane was exposed to 10 mL of a probe dilution buffer containing His6-
tagged DesVII (40 µg/mL) at 4 oC for approximately 16 h.  The membrane was 
then washed in PBS buffer44 and probed with an anti-histidine antibody using 
SuperSignal® West HisProbeTM kit from Pierce (Section 4.2.13).  
Chemiluminescence detection was used. 
4.3 RESULTS AND DISCUSSION 
4.3.1 Place of DesVII Among Other Glycosyltransferases 
The desVII gene product was first assigned as the desosaminyltransferase 
in the methymycin/pikromycin pathway based on its sequence similarity to other 
known glycosyltransferases.18  It shares high sequence similarity to a number of 
glycosyltransferases involved in the biosynthesis of macrolide antibiotics, such as 
OleG1 and OleG2 of the oleandomycin pathway in S. antibioticus (50.5% and 
53.5% identity, respectively),45 TylM2 of the tylosin pathway in S. fradiae (51.8% 
identity),46 and EryCIII of the erythromycin pathway in S. erythraea (50.7% 
identity) (Figure 4-9).47  DesVII also exhibits varied sequence similarity to GtfA, 
GtfB, and GtfC of the chloroeremomycin (101) pathway, GtfD and GtfE of the 
vancomycin (100) pathway in Amycolatopsis orientalis (18.8–20.9% identity),8 
and NovM of the novobiocin (102) pathway in Streptomyces spheroides (32.6% 
identity).11 
It should be noted that during the course of the study we discovered that 
the nucleotide sequence originally deposited in the GenBank (accession number 
AF079762) is missing a fragment coding for the protein residues 136 through 149 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































AAC68677) does contain this fragment (Figure 4-9, underlined).  Also, we 
discovered that the nucleotide sequence in the GenBank contains C (codon CAT) 
rather than T (codon TAT) at position 1784 (in the nucleotide sequence 
AF079762), which translates to a His rather than a Tyr at position 104 in the 
protein sequence (AAC68677) (Figure 4-9, underlined).  This misassignment was 
confirmed by DNA sequencing.  Thus, DesVII should be corrected to have Tyr-
104 in its sequence, consistent with many other homologous glycosyltransferases 
containing an aromatic amino acid residue, usually tyrosine, at this position. 
According to the CAZy database (Carbohydrate-Active enZYmes), 
DesVII has been placed in the glycosyltransferase family GT1.  This family of 
proteins contains, among others, many inverting glycosyltransferases involved in 
the biosynthesis of secondary metabolites, including macrolides (e.g., tylosin, 
erythromycin, oleandomycin, spinosin), aromatic polyketides (e.g., daunorubicin, 
novobiocin, urdamycin, mithramycin), and nonribosomal peptides (e.g., 
vancomycin, chloroeremomycin).48-50  This classification is primarily based on 
the similarities in amino acid sequence, and it is useful for deducing structural and 
mechanistic insights, such as whether it is an inverting or a retaining glycosyl-
transferase, how it evolutionarily related to other glycosyltransferases, and 
possible folds of its three-dimensional structure. 
A complementary system for classification of glycosyltransferases has 
also been developed based on the known X-ray structures of several such 
proteins.51  According to this system, all of the diverse glycosyltransferases can be 
assigned to one of the two superfamilies or protein folds, GT-A and GT-B.52, 53  
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Members of the GT-A superfamily include SpsA,54 LgtC,55 bovine α-1,3-
galactosyltransferase,56 bovine β4GalT1,57 rabbit GnT1,58 and human β-1,3-
glucuronyltransferase,59 while those belonging to superfamily GT-B include 
bacteriophage T4 β-glucosyltransferase BGT,60 MurG,61 and GtfB.62  Based on 
the amino acid sequence alignment of DesVII with glycosyltransferases with 
known tertiary structures, DesVII should be a member of the superfamily GT-B.  
This superfamily is extremely diverse and consists of prokaryotic and eukaryotic 
enzymes with various donor and acceptor substrates.  Most of the prokaryotic 
enzymes that glycosylate secondary metabolites belong to this superfamily.  
Although there are only four published crystal structures of the GT-B superfamily 
members to date, BGT, MurG, GtfB, and most recently GtfA,63 all of them 
contain a two-domain structure with the active site located in the deep cleft 
between the two domains.  The N-terminal domain binds the acceptor, and the C-
terminal domain binds the sugar donor.  Unlike the GT-A superfamily members, 
the GT-B superfamily enzymes lack a conserved DXD metal ion binding motif 
for binding the sugar-nucleotide, since the majority of the GT-B superfamily 
members are not metal-dependent.  Instead, it is proposed that the Rossmann-like 
motif of the C-terminal domain is part of the binding site for the sugar donor 
substrate.53  The two-domain structure of GT-B glycosyltransferases is believed to 
be the determinant controlling the structural diversity of the final products. 
The closest homologue of DesVII with a known crystal structure is GtfB 
(19.8% identity), catalyzing the attachment of a glucose residue to the 
vancomycin aglycone (Figure 4-1).  The analysis of GtfB crystal structure and 
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site-directed mutagenesis revealed that its residue Asp332 likely plays a role as 
the general base in the glycosyl transfer reaction.  This residue is strictly 
conserved among the macrolide glycosyltransferases, including DesVII (Figure 4-
9), and is expected to have the same function in their respective catalytic 
mechanisms. 
4.3.2 Disruption of desVII in S. venezuelae 
To verify the assigned function of desVII gene, a S. venezuelae KdesVII 
mutant, in which desVII gene is replaced by the thiostrepton resistance gene, was 
constructed as described in Chapter 2 following a literature procedure.19  The 
disruption plasmid pDesVII-K2 (derived from the pKC1139 vector) was 
constructed, and its sequence was verified by another member of our group, 
Charles Melançon.  It was used for a homologous recombination between the 
donor strain, E. coli S17-1 which is the host of this plasmid, and the wild type 
S. venezuelae.  Double-crossover mutants were selected based on their phenotype 
as apramycin sensitive (AprS, indicates the departure of pKC1139 containing 
desVII gene) and thiostrepton resistant (ThioR, confirms the incorporation of 
thiostrepton resistance gene in place of desVII in the chromosome).  The resulting 
mutant, KdesVII-2, was fermented as described in Chapter 2 using the 12-
membered ring fermentation conditions,64 and its macrolide production was 
compared to that of the wild type S. venezuelae using TLC. 
As expected, KdesVII-2 mutant did not produce any glycosylated 
macrolides.  Only aglycone, 10-deoxymethynolide (65), and its hydroxylated 
derivatives, methynolide (74) and neomethynolide (75), were detected.  This 
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result confirmed that DesVII is indeed the glycosyltransferase responsible for the 
desosaminylation of 10-deoxymethynolide (65). 
4.3.3 Preparation of DesVII Substrates and Product 
One of the obstacles to study the glycosyltransferases involved in the 
biosynthesis of secondary metabolites is the difficulty of obtaining their 
substrates.  I am greatly indebted to our research group members, current and 
former, for the chemical and enzymatic syntheses of TDP-D-desosamine (22), 
TDP-D-mycaminose (25), TDP-β-L-rhamnose (109), and TDP-α-L-rhamnose 
(108), which are donor substrates or potential substrates of DesVII (see 
Section 4.2). 
Acceptor substrate, 10-deoxymethynolide (65), was isolated from the 
fermentation broth of S. venezuelae KdesI-80 mutant, which lacks a key enzyme 
to complete the desosamine biosynthesis leading to the accumulation of aglycone 
(Chapter 2).29  The medium optimized for a 12-membered ring macrolide 
production was used in this case.64  An alternative substrate, 14-membered 
narbonolide (64), was provided by a group member Dr. Haruko Takahashi by 
fermenting the same mutant, KdesI-80, under the 14-membered macrolide 
production conditions. 
To facilitate the analysis of the DesVII reaction, a sample of one of its 
products, YC-17 (3), was needed.  YC-17 is a substrate of P450 hydroxylase, 
PikC, also known as PicK, that converts YC-17 into methymycin and 
neomethymycin via hydroxylation at C-10 or C-12 position, 
respectively.31, 32, 65, 66  PikC also catalyzes the hydroxylation of narbomycin (5) at 
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C-12 position to give pikromycin (4).  Inactivation of the pikC gene should result 
in the accumulation of YC-17 (3) (or narbomycin (5) under different conditions) 
in the S. venezuelae cultures.31 
The isolation of YC-17 (3) from the fermentation broth of S. venezuelae 
mutant AX906 has been reported in an early collaborative effort with Professor 
David Sherman.31  The strain S. venezuelae AX906 was supplied to us by 
Professor Sherman.  Despite the fact that the strain has the correct phenotype 
(KanR, cell shape is also as expected for S. venezuelae), we failed to detect any 
methymycin- or pikromycin-related macrolide products in the fermentation broth 
of this mutant.  Multiple attempts were made; sixteen individual colonies were 
isolated, but none of them produced the desired macrolide compound.  Therefore, 
we decided to use a different approach. 
It was reported that the addition of the monooxygenase inhibitor, 
xanthotoxin, to the cultures of S. venezuelae could force the accumulation of 10-
deoxymethynolide (65).40  We expected that some amount of YC-17 (3) may also 
be produced under this condition.  Unfortunately, when xanthotoxin was added to 
S. venezuelae culture in a vegetative media, no YC-17 (3) was detected in the 
chloroform extracts by TLC analysis.  But the amounts of methymycin (1) and 
neomethymycin (2) were significantly reduced as compared to culturing in the 
absence of the inhibitor (estimated to be about 20% of that produced in the control 
reaction).  An additional component, identified to be 10-deoxymethynolide (65), 
was also detected.  It is possible that the presence of an inhibitor has some effect 
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on the upstream genes or gene products involved in the sugar biosynthesis or 
attachment. 
In order to overcome the problem of obtaining YC-17 (3), we opted to 
prepare a pikC mutant by ourselves.  The S. venezuelae mutant in which the pikC 
gene was replaced with kanamycin resistance gene (neo) was generated using a 
homologous recombination between disruption plasmid pPikC-K and the genomic 
DNA of the wild type strain.  Unlike AX906 mutant in which pikC was disrupted 
by insertional inactivation via double crossover, the KpikC-2 strain has pikC 
disrupted through a deletional inactivation, namely, 1,127 bp fragment of pikC 
gene (out of 1,251 bp total) is replaced with neo.  KpikC-2 produced YC-17 (3) as 
the major product in a vegetative medium (approximately 300 mg from 4 L 
culture), with the second major component being narbomycin (5, 40 mg, not 
purified).  A sufficient amount of YC-17 (3) (100 mg) was obtained from the 
separation of the crude extract by silica gel chromatography. 
4.3.4 Purification of DesVII-C-His Protein 
4.3.4A Purification of DesVII-C-His Protein 
A former member of our group Dr. Lishan Zhao made the first attempt to 
detect DesVII activity as glycosyltransferase using the crude extracts of E. coli 
BL21 containing pHC29.  The plasmid pHC29 was originally prepared by another 
former group member Dr. Huawei Chen by cloning the desVII gene into the NdeI-
XhoI restriction sites of pET24b(+). 
In this study, plasmid pHC29 was used to transform the expression host 
E. coli BL21.  Upon the induction with IPTG, DesVII-C-His was produced by 
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E. coli BL21/pHC29.  It was purified using affinity chromatography with Ni-NTA 
agarose to near homogeneity, and the resulting protein was stored in 50 mM Tris-
HCl buffer (pH 8) supplemented with 10% glycerol as 25 or 100 mg/mL solution.  
Attempts to further purify DesVII-C-His using FPLC equipped with MonoQ or 
Superdex columns led to a significant loss of the protein due to precipitation and, 
therefore, were abandoned. 
4.3.4B Native Molecular Weight Determination of DesVII-C-His 
The composition of the native DesVII-C-His was determined using gel 
filtration chromatography on Superdex 200 HR 10/30 column.  Fitting to the 
calibration curve constructed using protein molecular weight markers, a molecular 
weight of approximately 108 kDa for DesVII-C-His was deduced.  Thus, the 
native DesVII-C-His is likely a homodimer under the experimental conditions 
(calculated molecular weight of the monomer is 47.5 kDa).  It should be noted 
that a significant amount of protein (estimated 25%) eluted as an aggregated 
fraction with a molecular weight of approximately 1,379 kDa. 
4.3.4C Attempts to Refold DesVII-C-His 
One possible reason that the early experiments to detect DesVII activity 
were unsuccessful is due to the misfolding of DesVII during protein synthesis.  To 
test this contention, we decided to try to refold DesVII-C-His by denaturing it first 
and then renaturing it while it is still bound to the resin.67  However, this attempt 
failed due to the protein precipitation upon the addition of the renaturing buffer 
and was later abandoned.  Therefore, a protein sample of DesVII-C-His obtained 
as described above was used for further studies. 
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4.3.5 Possible Problems and Solutions to Detect DesVII Activity 
Dr. Lishan Zhao made the first attempt to detect DesVII activity as a 
glycosyltransferase, however, he was unsuccessful to show the activity of the 
enzyme.  Several reasons are conceivable for the absence of DesVII activity 
reported by Dr. Lishan Zhao. 
1. Inappropriate assay conditions were used.  Dr. Zhao had tried many 
modifications, such as using different buffers (potassium phosphate or Tris-
HCl), different pH (6.2, 7.0, 8.1, or 9.0), different divalent metal cations 
(MgCl2 or MnCl2), and different organic solvent for the preparation of 
aglycone stock solution (ethanol or DMSO).  The introduction of additional 
components, such as BSA at 1 mg/mL or Triton X-100 at 0.2% v/v, was also 
attempted.  However, none of these changes seemed to improve the assay 
outcome.  Thus, a more systematic check of assay conditions may be 
necessary. 
2. DesVII is in an inactive form.  It may be misfolded during expression or 
denatured during purification.  Since the denaturing/renaturing attempt 
described above was unsuccessful, other procedure to refold the purified 
protein will be tested.  Using an in vitro E. coli transcription/translation 
system to produce DesVII, or to express desVII in the S. lividans host may 
also be worth a try. 
3. The postulated acceptor substrate of DesVII may be incorrect.  The fact that 
purified DesVII failed to couple TDP-D-desosamine to the putative 
macrolactone substrate, 10-deoxymethynolide (65), has prompted us to 
 211
consider a new hypothesis in which a linear polyketide attached to the acyl 
carrier protein (ACP) domain of the methymycin polyketide synthase, 
instead of 10-deoxymethynolide (65) itself, may be the true substrate of 
DesVII.  This hypothesis is clearly provocative and needs to be tested. 
4. An additional protein component may be required for a successful glycosyl 
transfer.  As mentioned in Chapter 1, the originally proposed function of 
desVIII is to code for a tautomerase in the TDP-D-desosamine biosynthesis.  
It later became apparent that the tautomerization step is not necessary for the 
formation of TDP-D-desosamine (Chapter 2).68  However, desVIII 
disruption experiments demonstrated that DesVIII is indeed essential for the 
biosynthesis of methymycin/neomethymycin and most likely participates in 
the desosaminylation of aglycone step(s).  The initial efforts to examine 
whether it has any effect on DesVII activity will be described in this section.  
The in-depth study of DesVIII involvement in glycosylation will be 
presented later in this chapter. 
4.3.5A Co-expression of desVII and desVIII in E. coli 
In order to test the hypothesis of whether DesVIII is required for DesVII 
activity, attempts were made to clone and express desVIII and desVII genes 
together in E. coli.  These genes are located next to each other on the chromosome 
of S. venezuelae, desVIII upstream of desVII.  They are in frame and are separated 
by a 147-bp stretch of DNA.  The amplification of a 2,562-bp fragment of pLZ4 
cosmid containing both genes proved to be an obstacle.  No desired DNA product 
was obtained in PCR reaction when different annealing temperatures and DNA 
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polymerases (Pfu or Advantage cDNA polymerases) were used.  After several 
attempts this strategy was abandoned. 
4.3.5B Glycosyltransferase Assay with DesVII-C-His 
The recipe of this assay was developed by Dr. Lishan Zhao as described in 
Section  4.2.5.  The protein used was DesVII-C-His (pure or crude) with varied 
concentration.  The negative controls contained the same volume of the protein 
dialysis buffer in place of DesVII-C-His.  No product was detected by TLC after 
two hours of incubation at 29 oC under the assay conditions. 
4.3.5C Assays Using Crude Protein Extracts of Wild Type S. venezuelae and Its 
KdesVIII-92 Mutant 
Since no activity was detected with DesVII-C-His alone, crude protein 
extracts of the wild type S. venezuelae and its KdesVIII-92 mutant were also 
added to the assay mixture to determine whether additional components are 
required for activity.  Crude extracts of each strain were partially purified by 
ammonium sulfate fractionation.  Two fractions precipitated with 0–60% and 60–
90% ammonium sulfate were collected.  These fractions were added to the assay 
mixture either as the protein component alone (10–20% v/v) or together with 
DesVII-C-His.  The chloroform extracts of the incubated assay mixtures (2 h, 
29 oC) were examined by TLC analysis. 
In addition to the unreacted substrate, 10-deoxymethynolide (65), the 
production of a new compound was observed when the 60–90% ammonium 
sulfate precipitate fraction from either wild type or mutant S. venezuelae was 
used, with or without the addition of DesVII-C-His.  This new compound is more 
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polar than 65 with an Rf value expected for YC-17 (3).  However, the same 
compound was also detected when just the disruption buffer was added to the 
assay mixture.  This compound must therefore be a decomposition product of 10-
deoxymethynolide (65) and is likely resulted from a Michael addition of DTT at 
the C8-C9 double bond conjugated to the ketone moiety in 65.  The structure of 
this Michael adduct was confirmed by 1H NMR.  No other products were 
detected. 
4.3.5D Expression of desVII in S. lividans: 1st Attempt 
Expression of Streptomyces genes in S. lividans proved to be useful in 
many cases when proteins could not be produced or properly folded in E. coli.  
Therefore, we attempted to express desVII in S. lividans 1326. 
The gene desVII was cloned in the plasmid vector pIJ702 routinely used 
for the expression of genes in Streptomyces lividans.22, 36  Vector pIJ702 contains 
thiostrepton resistance (ThioR) marker and melanin operon (melC) of 
S. antibioticus, but the latter is disrupted when desVII is inserted.  The construct 
based on the pIJ702 vector was designed to have DesVII fused with a C-terminal 
histidine tag (desVII-Sl-C-His) when expressed.  The transformation of S. lividans 
1326 protoplasts with this construct resulted in the formation of thiostrepton-
resistant colonies phenotypically similar to S. lividans 1326, i.e. covered in white 
spores and producing dark purple pigment.  However, the S. lividans control 
strain without the plasmid also produced a lower, but still significant, number of 
colonies.  The isolation of the plasmid DNA from the selected clones for agarose 
gel analysis was not successful.  The analysis of crude proteins isolated from 
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these clones using anti-histidine detection system did not result in any visible 
bands on the Western blot.  Thus, no DesVII-C-His fusion protein was produced. 
The difficulties with this approach result from the use of pIJ702 vector.  
Since it cannot be used to transform E. coli, all the steps after ligation have to be 
performed in S. lividans.  Therefore, isolation of the constructed plasmid was 
more problematic.  Since the negative control strain also produced a few 
background colonies, it was difficult to tell whether the selected clones contained 
the plasmid (pIJ702 with or without the insert), and if they did, whether these 
plasmids were the correct ones.  Thus, we decided to take a different approach to 
express desVII in S. lividans, where we could verify the constructs before 
introducing them into the host. 
4.3.5E Expression of desVII in S. lividans: 2nd Attempt 
A new strategy was developed for desVII expression in S. lividans.  First, 
pUC119 vector will be incorporated into the pIJ702 vector to simplify cloning 
procedures and verification of the resulting constructs.  This pUC119 portion in 
this hybrid vector can be later excised, and the resulting plasmid self-ligated prior 
to the transformation of S. lividans.  Second, in this construct, desVII will be 
cloned downstream of the melC1 gene in the pIJ702 vector, instead of replacing it 
as in the previous experiment.  Gene melC1, in addition to melC2, in the pIJ702 
plasmid is derived from the melC operon of S. antibioticus.  While melC2 
translates into tyrosinase MelC2, the protein encoded by melC1 is involved in the 
activation and secretion of MelC2.69  Together, MelC1 and MelC2 are necessary 
for the production of melanin pigment.  Thus, incorporation of desVII 
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downstream of melC1 to replace melC2 should result in the secretion of DesVII 
by S. lividans.  This would significantly simplify the analysis of proteins produced 
by S. lividans. 
The plasmid pSB01, derived from the pIJ702 vector harboring pUC119 
fragment, melC1, desVII, and the kanamycin resistance marker neo, was 
constructed.  It was used to transform the protoplasts of S. lividans TK64, and the 
transformants were selected based on their resistance to kanamycin.  The success 
of transformation was confirmed by PCR analysis of the DNA preparations from 
selected clones.  The extracellular (supernatant from the centrifuged culture) and 
cell proteins (pellet) were analyzed by SDS-PAGE.  A band of approximately 
47.2 kDa was observed in the supernatant fractions, implicating the presence of 
DesVII-C-His protein in these fractions. 
The glycosyltransferase assay was performed as described above, with the 
addition of the concentrated extracellular fractions.  TLC analysis of the 
chloroform extract from the reaction mixture revealed the presence of unreacted 
substrate 10-deoxymethynolide (65) in the mixture but no YC-17 (3) product.  
Evidently, protein expression in S. lividans did not provide  active DesVII, at least 
when tested under the above assay conditions. 
4.3.5F Production of DesVII Using in vitro Transcription/Translation System 
In search for active form of the glycosyltransferase DesVII, the production 
of DesVII by Rapid Translation System (RTS) which uses E. coli lysate for gene 
overexpression in vitro was also attempted.  We used plasmid pHC29 as the 
template for transcription in this experiment.  In fact a gene cloned into any of the 
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pET vectors can be used, since the pET vector satisfies all of the requirements for 
DNA templates of this system. 
Template for the synthesis of green fluorescent protein (GFP) was used as 
the positive control.  After proper incubation, GFP was produced in the positive 
control (by Western blot analysis and fluorescence at UV365); however, no 
product was detected by SDS-PAGE or the Western blot analysis when pHC29 
was used as the template.  Attempts to purify (or concentrate) DesVII sample 
using Ni-NTA agarose failed to yield the expected protein.  Therefore, RTS did 
not solve the problem to obtain DesVII.  Consequently, this strategy was 
abandoned. 
4.3.5G Summary 
This section summarized our initial attempts to detect glycosyltransferase 
activity of DesVII.  Significant efforts were directed to the production of active 
DesVII by various systems or methods.  These include using E. coli and 
S. lividans as host cells, using E. coli extracts as protein source in assays, and 
refolding the purified DesVII to renature the protein.  We have also tested crude 
protein extracts of S. venezuelae and its KdesVIII mutant as possible sources of 
glycosyltransferase activity.  This test was also carried out in the presence of 
purified DesVII.  However, none of these attempts were successful.  Reflecting 
upon the setbacks of these experiments, we have come up with a fundamentally 
different hypothesis regarding the chemical nature of the acceptor substrate of 
DesVII.  Our efforts to test this hypothesis are the subject of the following 
section. 
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4.3.6 New Hypothesis: Glycosylation Catalyzed by DesVII Occurs Prior to 
the Detachment of Polyketide Chain from PKS 
4.3.6A Background and Strategy 
It has been widely accepted that the substrates for a macrolide glycosyl-
transferase include an NDP-sugar donor and a macrolactone acceptor.  In the case 
of DesVII, they are TDP-D-desosamine (22) and 10-deoxymethynolide (65).  
Enough evidence has been accumulated supporting sugar in its NDP- form as a 
substrate for all glycosyltransferases.  In fact, the amino acid sequence of known 
macrolide glycosyltransferases all contain an NDP-binding domain.  The identity 
of the aglycone substrate, however, has never been established by any in vitro 
study. 
We eliminated the methynolide (74) and neomethynolide (75) as possible 
substrates since it has been shown that hydroxylation of macrolide happens after 
the glycosyl transfer step (Section 1.5).  While 10-deoxymethynolide (65) would 
be the most reasonable acceptor in DesVII-catalyzed reaction, the failure of 
DesVII to achieve the coupling of TDP-D-desosamine to 65 under our assay 
conditions imposed serious challenge to the above assumption.  We then 
considered the linearized form of 65 with the carboxyl group exposed or 
substituted in coenzyme A (CoA) thioester or other ester forms as the aglycone 
substrate.  This hypothesis, however, would involve a considerable modification 
of the well-studied polyketide biosynthesis, particularly, the cyclization step by 
the thioesterase (TE) domain of polyketide synthase.  It is thus more probable that 
the aglycone substrate is the linear form of 10-deoxymethynolide (65) which is 
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still attached to the acyl carrier protein (ACP) domain of PKS prior to being 
cleaved by the TE domain through a cyclization reaction. 
This postulation is not without a precedent, since it is somewhat analogous 
to the N-acylation of one of the Nε amino group of asparagine (Asn1) of the 
growing nonribosomal peptide chain tethered to the peptidyl carrier protein (PCP) 
domain of the mycosubtilin nonribosomal peptide synthetase (NRPS) cluster.  It is 
thought that the attached acylating β-amino-acyl-C18 chain is generated from a 
fatty acid myristate via the catalyses of several other domains of NRPS and is 
transferred onto Asn by the action of the condensation (C) domain.70  In contrast 
to the mycosubtilin case, in the NRPS clusters of other N-acylated nonribosomal 
peptides the corresponding acyltransferase is not a part of the cluster.71(p.214) 
Accordingly, our hypothesis is that DesVII catalyzes the glycosylation at 
C-3 hydroxyl group of the growing polyketide chain attached to ACP5 domain of 
PikAIII PKS (23, Figure 4-10), followed by TE catalyzed cyclization, resulting in 
the production of 12-membered YC-17 (3).  Chain extension catalyzed by another 
condensation unit prior to cyclization would lead to the formation of the 14-
membered narbomycin (5).  It is also possible that both hexaketide and 
heptaketide, attached to ACP5 and ACP6, respectively, can be glycosylated by 
DesVII.  The glycosylated polyketide chain is then transferred to the serine 
residue of TE domain, cyclized by macrolactonization, and subsequently released. 
To test this hypothesis we set out to (i) generate the linear form of 10-
deoxymethynolide (65) in its CoA thioester form (104); (ii) attach it to the 
recombinant apo-ACP5 domain via the action of phosphopantetheinyl transferase 
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Sfp; (iii) incubate the resulting holo-ACP5 (105) with DesVII under glycosylation 
conditions; (iv) treat the glycosylated product 106 with recombinant TE or an 
entire polyketide synthase PikAIV to cyclize the macrolactone.  If our hypothesis 
is correct, this scheme, summarized in Figure 4-10, would result in the production 
























































































Figure 4-10: Experimental strategy to test the new hypothesis about DesVII 
acceptor substrate. 
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4.3.6B Preparation of Sfp 
The Bacillus subtilis Sfp protein is part of the biosynthetic machinery 
responsible for the formation of lipopeptide antibiotic surfactin.38  It activates the 
apo-forms of peptidyl carrier protein (PCP) domains of surfactin synthetase by 
transferring the 4′-phosphopantetheinyl (Ppant) moiety of CoA to the serine 
residue conserved in all PCPs, resulting in their respective holo-forms.72  The 
thiol moiety of the Ppant linker is then loaded with a specific amino acid via 
acylation to form a thioester bond.  The loaded amino acid is then used in 
subsequent nonribosomal peptide synthesis.  Unlike other Ppant transferases 
(PPTases), Sfp can modify a wide variety of proteins including not only PCP 
substrates but also aryl carrier protein (ArCP) domain and ACP domain.  It is also 
very flexible in regards to its CoA substrates.  Sfp was shown to recognize not 
only CoA but also its acyl thioesters, such as acetyl, propionyl, butyryl, hexanoyl, 
isobutyryl, isovaleryl, acetoacetyl, benzoyl, and phenylacetyl thioesters,73 as well 
as CoA aminoacylated by various amino acids.74 
The crystal structure of the Sfp-CoA complex provides an explanation of 
Sfp’s ability to use diverse CoA substrates.75  It clearly shows that the 
pantetheinyl residue of CoA is flexible and is exposed to the solvent, and it makes 
no interactions with Sfp.  The 3′-phospho-5′-ADP moiety of CoA on the other 
hand is buried in the binding pocket and makes contacts with Sfp necessary for 
binding of the substrate.  Therefore, it is reasonable to expect that Sfp is able to 
convert apo-ACP5 into holo-ACP5 acylated with hexaketide (105). 
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The gene sfp from B. subtilis was expressed in E. coli BL21 as a C-
terminal His6 fusion protein using expression plasmid pET29-Sfp kindly provided 
by Dr. Christopher Walsh.  Sfp (27.1 kDa) was purified to near-homogeneity 
using Ni-NTA affinity chromatography.  It was later used in the radioassays with 
ACP5 and labeled acetyl-CoA. 
4.3.6C Preparation of apo-ACP5 
Acyl carrier protein domain ACP5 is a part of module 5 of methymycin/
pikromycin PKS PikAIII (Figure 1-16).  Its role in the biosynthesis of pikromycin 
is to serve as the reaction site for the 5th chain extension reaction.  After 
condensation, the hexaketide chain attached to its serine residue through Ppant 
linker is transferred to the keto synthase (KS) domain KS6 and then condensed 
with ACP6-linked methylmalonyl unit in the 6th chain extension reaction.  The 
resulting heptaketide is transferred to the TE domain of module 6, were 
cyclization takes place and subsequently the 14-membered macrolideproduct is 
released.  When a truncated version of module 6 lacking the N-terminal section of 
KS6 is produced by S. venezuelae, the hexaketide is transferred to TE directly 
from the ACP5 domain.76  Alternatively, the hexaketide may also be first 
transferred to ACP6 without chain extension and then to TE.77  Either way, the 
final cyclization product is a 12-membered macrolide.  In order to test the new 
glycosylation hypothesis, we decided to produce a histidine-tagged ACP5 in 
E. coli and to phosphopantetheinylate it with acyl-CoA using Sfp enzyme.  Its 
competence as a substrate for DesVII will then be tested in reaction with TDP-D-
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desosamine (22).  The resulting adduct, if there are any, will be treated with TE 
(as a part of PikAIV) to release the final product. 
 Since PKS domains are components of a large protein molecule encoded 
by a single ORF rather than by separate ORFs, care must be taken when deciding 
on the boundaries of the separate domains for heterologous expression.  The study 
done by Sherman and co-workers where ACP5 domain was used as a part of 
hybrid PKS and retained its activity78 helped us to design an expression plasmid 
ACP5-2/pET24b for the production of individual ACP5. 
ACP5-2/pET24b containing the fragment of pikAIII coding for the last 228 
amino acids of PikAIII PKS was used for the production of ACP5 (23.6 kDa) in 
E. coli BL21.  Although, it was reported that the E. coli PPTases are capable of 
priming foreign ACP and PCP domains, the catalytic efficiency is low.73  Hence, 
short induction times should result in the production of the majority of ACP in its 
apo form.  Since our goal was to obtain apo-ACP5, we harvested ACP5-producing 
cultures 3 to 4 h after the induction with IPTG at 37 oC.  The protein was purified 
to near-homogeneity using affinity (Ni-NTA agarose) and anion exchange 
(MonoQ) chromatography and used in the model radioactive assays with Sfp and 
labeled acetyl-CoA. 
4.3.6D Model Reaction: Synthesis of Acetyl-holo-ACP5 
To verify that Sfp is capable of priming apo-ACP5, we first tested whether 
radioactively labeled acetyl CoA [acetyl-3H] can be recognized as the second 
substrate by Sfp.  A radioassay developed by Walsh et al.39 with minor 
modifications was used.  Figure 4-11 shows a representative example of the Sfp 
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radioassay data.  We found that the reaction is complete within 2 min after the 
addition of Sfp, despite the fact that only 50% of the radioactivity added is present 
in the protein pellet.  It appeared that only 50% of the acetyl CoA was used.  This 
may be an indication that a significant amount of ACP5 used in the assay was in 
the holo form.  When ACP5-C-His obtained from the culture induced by IPTG for 
16 h at 24 oC was used, the conversion rates were even lower (5–10%), indicating 
that the majority of ACP5 produced by cells which were harvested late was in its 
holo form.  Another reason for the low yield of the modified protein might be a 
slow decomposition of acetyl CoA in the stock solution over the time, resulting in 
the lower amounts of substrate than assumed in the assay mixture. 
Nevertheless, this model assay demonstrated that Sfp is capable of adding 









































Figure 4-11: Radioassay: representative Sfp reaction progress data.  First two 
bars are for negative control reactions without Sfp and without 
ACP5-C-His, respectively, incubated for 2 min.  The last bar is the 
labeled substrate (same amount as in the assay mixtures) in the 
scintillation cocktail.
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CoA substrate specificity of Sfp reported by other researchers,73, 74 we expect that 
104 (Figure 4-10) may also be used as a substrate by Sfp. 
4.3.6E Preparation of Acyl-CoA Substrate 22 for Sfp Reaction 
The chemical synthesis of the linear polyketide 103 is a challenging task 
due to its complex structure containing six stereogenic centers.  Thus, we planned 
an alternative approach to generate 104 from the readily available 10-
deoxymethynolide (65).  This approach involves opening the macrolactone by 
chemical hydrolysis of the ester linkage, selectively activating carboxylic acid by 
the condensation with isobutyl chloroformate, and coupling it with CoA.  
However, the hydrolysis of the ester linkage was unsuccessful despite multiple 
attempts.  In fact, the double bond conjugated to the ketone which constitutes a 
Michael acceptor is more reactive toward the base under some of the conditions 
tried.  Group member Dr. Chai-Lin Kao has nearly completed an alternative 
multistep chemical pathway to make compound 103 from 65.  The results of his 
work will be reported elsewhere. 
4.3.6F Purification of TE Domain 
To probe the “Linear substrate hypothesis” a heterologously expressed TE 
domain was produced.  Early experiments have shown that the TE domain is 
capable of catalyzing the in vitro hydrolysis of the thioester linkage in N-
acetylcysteamine derivatives of polyketides, and it can also catalyze in vitro 
lactonization of unnatural polyketides attached to the ACP domain when fused to 
an appropriate PKS module.79  It has also been demonstrated that the excised 
epothilone TE domain catalyzes an efficient cyclization of the N-acetylcysteamine 
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thioester of the linear epothilone.80  Therefore, it is reasonable to expect that the 
purified TE domain can promote the release of polyketide, glycosylated or not, 
from DesVII-treated 105 (106).  It is our hope that a cyclization catalyzed by TE 
will also take place resulting in the formation of YC-17 (3) or 10-
deoxymethynolide (65).  However, it is possible that, in our system, hydrolysis 
may prevail over lactonization and a linear polyketide will be released.  In any 
case, the release of polyketide from ACP will facilitate its characterization.  It 
should be mentioned that TE of epothilone PKS can catalyze hydrolysis of cyclic 
epothilone C to its linear form, seco-epothilone C.80  If the same is true for the 
methymycin case, the purified TE can potentially be used as a more convenient 
means to prepare the linear 10-deoxymethynolide substrate 103. 
Purification of TE Domain of Methymycin PKS.  The fragment of 
S. venezuelae DNA containing the TE domain was amplified by PCR and cloned 
into the expression vector pET24b(+).  Since TE is a component of the PikAIV 
and its boundary is not well defined, two plasmids were constructed, pTE-C-His 
and pTE(2)-C-His, for the production of two versions of TE of different length 
with C-terminal His6 tag.  The insert of pTE-C-His encodes TE-1 (contains 288 
C-terminal amino acids of PikAIV plus 13 amino acids to introduce His6 tag), and 
that of pTE(2)-C-His encodes TE-2 (299 amino acids of PikAIV).  Both proteins 
were overproduced in E. coli BL21 and purified using nickel affinity 
chromatography.  While the purified TE-1 (32.2 kDa) was a nearly homogenous 
protein as shown by SDS-PAGE, the purification of TE-2 (33.1 kDa) was not 
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very successful, and TE-2 was isolated as a major component contaminated with 
other proteins. 
Both TE-1 and TE-2 were assayed towards hydrolysis of 10-
deoxymethynolide (65).  No visible depletion of 65 under the assay conditions 
was detected by TLC analysis.  Therefore, it is apparent that TE does not catalyze 
hydrolysis of macrolide under the conditions tested.  Nevertheless, it may still be 
useful in the hydrolysis of polyketide thioesters. 
4.3.6G Generation and Characterization of Mutants Lacking TE Domain 
Since obtaining 103 proved to be difficult, we opted for generating ACP-
linked polyketide using an alternative in vivo approach.  Specifically, our plan 
involves the replacement of the fragment of DNA encoding the TE domain of 
PikAIV, TEII (PikAV), and DesVIII in the genome of S. venezuelae with a 
fragment containing the kanamycin resistance gene, preceded by a DNA portion 
encoding for His6 tag.  Such a mutant, KTE, would lack the ability to synthesize 
and/or attach TDP-D-desosamine (the effect of desVIII disruption) and would also 
be unable to cyclize and release the hexapolyketide moiety attached to ACP5 or 
ACP6 domains (TE function).  PikAIV PKS of such a mutant will be truncated at 
the C-terminus and fused with a polyhistidine tag to facilitate the detection and 
purification of this protein.  The attachment of a heptaketide chain to its ACP6 
domain is also possible when the strain is grown under the 14-membered ring 
production conditions. 
The detection of PikAIV mutant in the crude extracts of S. venezuelae 
KTE will be performed using Western blot analysis with an anti-polyhistidine 
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antibody, following a similar procedure reported by Xue et al.76  However, the 
anticipated low yield of PikAIV may impose a problem for its purification.  In 
addition, precautions must be taken to avoid accidentally removing the polyketide 
chain during the purification.  It was our hope that a sufficient amount of the 
heptaketide-PikAIV adduct could be purified using Ni-NTA resin.  It could then 
be used as a substrate in the glycosylation assays. 
Despite the fact that we could not obtain the expected heptaketide-PikAIV 
adduct, S. venezuelae mutant KTE generated here, as well as its derivatives 
complemented with other genes, were important to our understanding of the 
glycosylation biosynthetic step as shown later in this section. 
Preparation of KTE Mutant of S. venezuelae.  The functional TE domain 
of PikAIV, defined by Tsai and coworkers, is shown in Figure 4-12 
(underlined).81  The C-terminal portion of pikAIV deleted in this study contains 
three catalytic residues of TE.  The site of deletion begins at Gln1142 as indicated 
by an arrow.  The ORF pikAV encodes thioesterase type II, TEII, whose function 
remains elusive, but unlikely plays a direct role in the polyketide biosynthesis.  It 







Figure 4-12: Underlined C-terminal portion of PikAIV is TE according to Ref. 81 
with a catalytic triad (Ser1196, Asp1224, His1316) shown in bold.  
Symbol ↓ indicates the beginning of the chromosomal region 
removed in the KTE mutant of S. venezuelae. 
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was deleted in our experiment mainly to simplify the cloning procedures.  
Removal of desVIII would disrupt the glycosylation step as discussed in 
Chapter 2.   
The mutant was generated through a homologous recombination between 
the disruption plasmid pTE-K and chromosomal DNA of the wild type 
S. venezuelae as previously described.  The presence of the desired mutation in 
two strains with the expected phenotype (KanR, AprS), KTE-1 and KTE-2, was 
confirmed by a Southern blot hybridization analysis using DIG-labeled KTE, 
“desVIII”, and neo fragments.  A hybridization of mutant DNA with KTE and 
“desVIII” probes resulted in the bands of approximately 6.9 and 4.7 kb, 
respectively, while a hybridization of wild type DNA resulted in 12.8 kb band 
with both probes.  Only the mutant DNA contains a fragment hybridizing with the 
S. venezuelae wild type
pikAIII pikAIV
pikAV
desVIII desVII desVI desR
PstI (703)
PstI (3358) PstI (16120)
pikAIII desVII desVI desRpikAIV-mutant neo
PstI (703)
PstI (3358)






Figure 4-13: Chromosomal regions of interest in S. venezuelae wild type and KTE 
mutant.  Restriction endonuclease PstI was used for digestion of the 
genomic DNA, and the corresponding restriction sites are shown.  
The annotated fragments complementary to the DIG-labeled probes 
used for Southern hybridization are shown in bold.
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neo probe (6.9 kb), and no such fragment is present in the chromosome of wild 
type S. venezuelae.  These observations are consistent with the replacement of the 
C-terminal portion of pikAIV and the entire pikAV and desVIII in the chromosome 
of S. venezuelae as depicted in Figure 4-13. 
As expected, no macrolide compounds were produced by KTE-1 and 
KTE-2 under either the 12- or 14-membered ring production conditions. 
Analysis of Proteins in KTE-2 Mutant.  Crude proteins were obtained from 
the KTE-2 mutant grown in a supplemented minimal medium and compared to 
the crude protein fraction of wild type S. venezuelae using SDS-PAGE and 
Western blot analysis.  No apparent difference between the crude proteins isolated 
from these strains was detected.  This result is not too surprising since PikAIV is 
likely a minor component of the proteome.  In contrast, Western blot analysis 
with anti-polyhistidine detection is expected to highlight at least one, and possibly 
two, bands among KTE-2 proteins.  One band should be approximately 
121.0 kDa, corresponding to the mutated PikAIV-C-His.  The other should be 
99.5 kDa, representing the mutated PikAIV-C-His truncated at the N-terminal KS6 
domain.  Having a phosphopantetheinyl linker would add 340 Da to this number, 
and the attachment of a hexaketide tail would add an additional 297 Da.  To our 
disappointment, no bands of the indicated sizes were detected.  In fact, the 
Western blot looked identical for both wild type and the KTE-2 proteomes. 
Further efforts were made to facilitate the detection of PikAIV-C-His.  For 
example, different conditions were used for culturing the strains.  Growth in the 
SCM medium, used for the 12-membered ring production, is expected to give a 
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major band of 99.5 kDa, while in the 14-membered ring production medium, 
PGM, a major band of 121 kDa is expected.  TSB medium, generally not used for 
secondary biosynthesis stimulation, was also tried.  Cultures were grown for a 
long period of time, up to four days, and the crude protein fractions were partially 
purified using Ni-NTA agarose to simplify protein detection.  A partial bacterial 
proteome extraction kit ProteoExtractTM was also used to separate crude proteins 
based on their solubility properties.  To increase the sensitivity of the Western 
blot analysis, chemiluminescence detection was used in place of the routine 
colorimetric detection.  However, despite numerous attempts, no PikAIV-C-His 
was detected in the KTE-2 mutant strain. 
Complementation of KTE-2 with desVIII.  S. venezuelae KTE-2 was used 
as a host for the expression of desVIII using the Streptomyces-E. coli shuttle 
plasmid DesVIII/pAX617, which contains desVIII gene as an insert (see 
Chapter 2).  The reintroduction of desVIII is expected to restore the desosamine 
biosynthesis and attachment in the host cells, while the macrolactone release 
would still be precluded due to the truncation of the C-terminal region of PikAIV 
and the deletion of PikAV.  This strain was constructed to check whether a 
glycosylated polyketide can be detected to be attached to the ACP domain as 
predicted by the “Linear substrate hypothesis”.  While the incubation failed to 
produce positive results, the generated strain, desVIII/KTE, was found, as 
expected, to be deficient in macrolide production. 
Expression of te in KTE-2 and in desVIII/KTE Strains.  Gene te, which 
encodes TE-1, was expressed in the S. venezuelae KTE-2 and desVIII/KTE 
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strains using Streptomyces-E. coli shuttle vector pDHS702.  The resulting strains, 
te/KTA and te+desVIII/KTE, were fermented under the 12-membered ring 
production conditions, and their macrolide products were analyzed by TLC.  The 
results are summarized in the second column of Table 4-1.  The expression of te 
in KTE-2 restores the production of aglycone, 10-deoxymethynolide (65), and the 
expression of both te and desVIII in KTE-2 re-establishes the biosynthesis of 
methymycin (1) and neomethymycin (2).  These results demonstrated that, except 
for TE and DesVIII, all other components of the methymycin biosynthetic 
machinery are intact in the KTE-2 mutant. 
4.3.6H Challenge to the “Linear Substrate Hypothesis”: Feeding Experiments 
The evidence contradicting the “Linear substrate hypothesis” came from 
feeding experiments.  Three S. venezuelae strains, KTE-2, desVIII/KTE, and 
te+desVIII/KTE, were grown under the 12-membered ring production conditions, 
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then 10-deoxymethynolide (65) was added to the cultures and the growth was 
continued.  A TLC analysis of the macrolides produced by these cultures revealed 
that (65) is taken up by these S. venezuelae cells and is modified by the enzymes 
of these strains.  Figure 4-14 shows the TLC of the macrolide products and Table 
4-1 (third column) provides a summary of the results.  First, feeding of 65 
(spot A) to KTE-2 led to its partial conversion to the hydroxylated aglycones, 
methynolide (74, B) and neomethynolide (75, C).  This observation clearly 
indicated the cellular uptake of the aglycone and the subsequent modification by 
PikC.  No glycosylated products were detected, since glycosylation apparatus was 
not restored.  On the other hand, feeding of 65 (A) to desVIII/KTE and 
te+desVIII/KTE resulted in its conversion to the same compounds as produced by 
wild type, methymycin (1, D) and neomethymycin (2, E).  The fact that in the 
 
Figure 4-14: TLC analysis of macrolide production by S. venezuelae mutants fed 
with 10-deoxymethynolide.  Strains are as follows: KTE-2 (lane 1), 
desVIII/KTE (2), te+desVIII/KTE (3), wild type (4). 
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desVIII/KTE case where TE has been deleted the system is still capable of 
glycosylating 65, strongly suggests that TE is not required for glycosylation when 
65 is available to the cell.  Therefore, the macrolactone, 10-deoxymethynolide 
(65), must be the substrate for the glycosyltransferase, DesVII.  This result is 
inconsistent with the “Linear substrate hypothesis”. 
4.3.7 Optimization of DesVII Assay Conditions 
As it became apparent that 10-deoxymethynolide (65) and TDP-D-
desosamine (22) are indeed substrates for DesVII, we again turned our attention 
to search for the missing ingredients or special conditions for the glycosyl-
transferase activity.  The first test was to run the assay using a series of Tris 
buffers at different pH (5, 6, 7, 8, 9) with DesVII-C-His purified from E. coli.  A 
TLC analysis revealed the formation of a new product in trace amount, as 
compared to the control without DesVII, at pH 8 and 9.  This product has Rf value 
similar to that of YC-17 (3).  The yield of this product, although significantly 
higher at pH 9 than 8, was very low and did not improve after extending the 
incubation time to 19 h.  The amount of the product was not sufficient for any 
further analysis except by TLC. 
Several changes to the original assay composition (Section 4.2.5) were 
also made in a hope of achieving better conversion.  For instance, to improve the 
stability of the proteins, BSA was added to the assay mixture at 1 mg/mL.  Since 
the enzyme activity is often inhibited by the presence of organic solvent, the 
concentration of 10-deoxymethynolide ethanol stock solution was increased from 
20 to 50 or 100 mM so as to minimize the volume of ethanol stock necessary for 
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the assay mixture.  Also, the concentration of 10-deoxymethynolide (65) in the 
assay mixture was raised from 0.5 to 1 mM to ensure the supply of the aglycone 
substrate.  Meanwhile, the concentration of TDP-D-desosamine (22) was altered 
from 2 to 0.8 mM to prevent any substrate inhibition toward DesVII.  Incubation 
time at 29 oC was also varied from hours to days to push for maximum 
conversion.  While, based on the analysis of other glycosyltransferases, DesVII is 
not expected to require any cofactors, the addition of common cofactors, such as 
PLP, PMP, FMN, FAD, NADH, and NADPH, was nevertheless attempted.  None 
of these changes resulted in a noticeable improvement of DesVII activity. 
4.3.8 Involvement of DesVIII in Glycosyl Transfer by DesVII 
To check whether DesVIII is needed for the glycosyltransferase activity of 
DesVII, a sample of DesVIII was needed.  Dr. Lishan Zhao had tried to express 
desVIII in E. coli BL21 using a pET expression system, but no expression was 
detected.  Attempt was also made to express dnrQ as a replacement for desVIII, 
since DnrQ can complement DesVIII activity in vivo (Chapter 2).  Unfortunately, 
our efforts to produce DnrQ in E. coli as C- and N- terminal His6 tag fusions 
resulted in low yields of proteins which failed to bind Ni-NTA agarose.  Thus, the 
main focus of our research on this subject was directed to improve the 
heterologous expression of desVIII and to purify the corresponding protein by 
different methods.  The results are described below. 
4.3.8A Simultaneous Expression of pikAV and desVIII 
It was found by Reynolds, Sherman and coworkers that the deletion of 
687 bp of the 843 bp pikAV in S. venezuelae leads to a strain unable to glycosylate 
 235
polyketide aglycones.82  The authors suggested that the deleted region contains a 
transcription unit essential for the expression of the des genes, desVIII, desVII, 
and desVI.  Although it is likely that this unit may only be required for gene 
expression in Streptomyces strains, we decided, for the sake of precaution, to 
include pikAV in our expression system when express desVIII in E. coli.  It should 
be noted that the pikAV and desVIII genes are translationally coupled, meaning 
that the stop codon of pikAV, TGA, overlaps with the start codon of desVIII, 
GTG. 
Genes pikAV and desVIII were cloned as a single DNA fragment in the 
pET24b(+) vector, and the resulting plasmid, pikAV-desVIII/pET24b, was used 
for the expression in E. coli BL21.  Two protein bands of approximately 32 and 
43 kDa were clearly visible on SDS-PAGE of the isolated crude extracts, 
indicating the presence of PikAV and DesVIII-C-His (abbreviated DesVIII-1 later 
in text), respectively.  However, DesVIII-1 failed to bind to the nickel affinity 
resin.  It was determined later by Western blot analysis that DesVIII-1 protein 
does not contain a histidine tag.  DNA sequencing confirmed that there is a stop 
codon immediately flanking the C-terminus of desVIII, possibly due to a frame-
shift in the pET24b vector used in this cloning.  A DEAE anion exchange 
chromatography was used to purify this protein.  Thus, a crude but enriched 
DesVIII-1 sample was obtained that was used in the subsequent activity assays.  
Due to the presence of many contaminants, the concentration of DesVIII-1 in this 
sample was not determined. 
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4.3.8B DesVIII Significantly Improves the Yield in Glycosyltransferase Assay 
The crude sample of DesVIII-1 was added as a new component to the 
optimized glycosyltransferase assay discussed above.  The extent of the reaction 
was monitored by TLC.  After 2 h incubation, a slight improvement in the YC-17 
yield was noted in the reactions where DesVIII-1 was present as compared to the 
incubation without DesVIII-1.  More significant improvement was found when 
the incubation was continued for 19 h.  Under this condition, almost all of the 
substrate was converted to the product (>90% as estimated by TLC) in the assay 
mixture containing DesVIII-1, whereas only approximately 5% of 10-
deoxymethynolide (65) was converted to YC-17 (3) in the absence of DesVIII-1.  
Further extension of incubation time did not visibly change the substrate/product 
ratio in either case.  A preparative TLC was used to isolate the reaction product, 
which was verified to be YC-17 by mass spectroscopy using a chemical ionization 
technique.  The structure of the product was later confirmed by NMR analysis of 
the product obtained from a large scale incubation.  The 1H and 13C NMR data are 
in excellent agreement with published spectra, unequivocally proving it to be YC-
17 (3).42, 32 
 The results of this assay have allowed us to define the necessary 
conditions for DesVII activity.  Two important discoveries are: first, DesVIII 
must be included in the assay mixture in addition to DesVII, and second the 
reaction should be buffered to pH 9.  However, a sample of pure DesVIII was 
needed to further investigate its involvement in the reaction. 
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4.3.8C Improvement of DesVIII Purification Method 
Purification of DesVIII with C-terminal His6 tag.  Gene desVIII was 
cloned into pET24b(+) and the resulting clone, pDesVIII-C-His, was used to 
transform E. coli BL21.  The protein, DesVIII-C-His (DesVIII-2, 43.6 kDa), was 
clearly over-produced by E. coli after the addition of IPTG, however, it was 
produced mainly as inclusion bodies.  Some attempts were made to adjust the 
expression conditions in order to obtain a soluble DesVIII-2.  These included 
using different E. coli colonies, different media (LB and 2×YT), different IPTG 
concentrations, different induction times and temperatures.  None of these 
changes improved the protein solubility.  The expression in E. coli NovaBlue 
strain did not produce any desired protein at all. 
 The insoluble DesVIII-2 protein pellet was collected and solubilized in a 
buffer containing 8 M urea.  The denatured but soluble DesVIII-2 was subjected 
to nickel affinity purification.  This method yielded an impure protein sample of 
DesVIII-2 (approximately 1 mg/mL of DesVIII-2, Figure 4-4, lane 2).  The 
attempts to further purify this sample by FPLC with MonoQ or Superdex columns 
or concentrate it led to protein precipitation.  When the DesVIII-2 sample was 
used in the glycosyltransferase activity assay it, like DesVIII-1, was effective to 
significantly increase the yield of the product, as compared to the controls in 
which DesVIII-2 was absent. 
 Purification of DesVIII with N-terminal His6 tag.  In order to generate an 
N-terminal His6-tagged protein, desVIII was cloned into the pET28b(+) vector.  
The resulting plasmid, pDesVIII-N-His, was used to transform the expression host 
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E. coli BL21.  To our delight, this strain over-produced DesVIII-N-His (DesVIII-
3) in soluble form.  Western blot analysis confirmed that DesVIII-3 contains a 
histidine tag.  However, DesVIII-3 can not bind to the nickel affinity resin.  
Despite numerous attempts, we failed to purify DesVIII-3 using different affinity 
(cobalt-containing TALON), ion exchange (DEAE), or size exclusion (Sephacryl) 
resins. 
 The activity of DesVIII-3 was evaluated during the protein purification 
attempts.  It dropped significantly after each step, possibly due to the prolonged 
incubation at 4 oC.  The recovery of DesVIII-3 was also quite low after each 
column run, probably due to the protein precipitation upon loading onto the 
column. 
 Purification of DesVIII Fused to Maltose Binding Protein.  A useful 
expression vector was developed by a member of our group, Peng Gao.  Using 
this vector, MalE-pET, the protein of interest is expressed in fusion with maltose 
binding protein (MBP).  The MalE-pET plasmid is derived from the pET vectors 
family and contains gene malE, coding for MBP, followed by the sequences for 
the His10 tag, Tev protease cleavage site, and the restriction endonuclease 
recognition sites.  A gene cloned into the NdeI-HindIII sites of such a plasmid 
would be expressed in E. coli host having MBP and His10 tag at its N-terminus.  
MBP would direct the proper folding of the downstream protein, and the fusion 
can be purified by a nickel affinity chromatography.  It can then be cleaved by 
Tev protease whose cleavage site, Glu-X-X-Tyr-X-Gln/Ser↓, is located after the 
His10 tag and right before the start of the protein of interest.  The desired protein 
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can then be separated from MBP using a second affinity column.  Among many 
advantages of this method is that the final protein will not contain any tags and 
will have a sequence identical to that of the native protein (with the exception of 
the first amino acid being valine instead of methionine in the case of DesVIII). 
 The desVIII gene was cloned into the MalE-pET vector, and the resulting 
construct, pDesVIII-MalEpET, was used for the expression in E. coli BL21.  The 
fusion protein, MalE-DesVIII (88.9 kDa), was overproduced and present in the 
soluble fraction.  It binds to Ni-NTA agarose well, and is a major component of 
the imidazole elution fractions although other protein impurities are also present.  
The fraction containing the partially purified fusion protein, together with DesVII, 
was found to be active in the glycosyltransferase assay.  Upon digestion with Tev 
protease, the 88.9 kDa band disappeared, and two major bands, 42.2 kDa for 
DesVIII-4 and 46.7 kDa for MBP, were visible on SDS-PAGE.  Purification by a 
second nickel affinity column resulted in the removal of most of MBP.  The 
remaining trace of MBP was removed using an amylose affinity column. 
We were able to concentrate DesVIII-4 to approximately 5.5 mg/mL 
before the formation of precipitate became visible.  Despite the presence of minor 
impurities, this purification technique produces the best DesVIII sample in terms 
of purity (Figure 4-8).  The DesVIII-4 protein is active in the glycosyltransferase 
assay.  A preliminary estimation of the native molecular mass of DesVIII-4 by 
size exclusion chromatography gave a value of 57 kDa, which is consistent with a 
monomeric composition. 
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4.3.8D Substrate Preferences in DesVII/DesVIII-Catalyzed Reaction 
Having obtained purified and active DesVII-C-His and DesVIII-4 
proteins, we could now investigate the substrate preference of this catalytic pair.  
We tested a number of donor and acceptor substrates available to us.  The reaction 
products in the incubation mixture were first detected by TLC and then purified 
by preparative TLC or HPLC followed by high-resolution mass spectroscopy 
analysis (CI, positive mode). 
Two alternative HPLC solvent systems were used, both employing a 
reverse phase C18 analytical column.  Traditionally, we eluted macrolide 
compounds using isocratic 30–70% acetonitrile in 0.057 M ammonium acetate.  
This solvent works well for aglycones or when the sugar moiety of the macrolide 
does not possess an amine functionality.  However, we discovered that peaks 
become broad, and the retention time fluctuates for the macrolides containing 
amino sugars under the above elution conditions.  It was later found that the 
solvent system developed for the separation of tylosin derivatives works better.43  
In this method, compounds are eluted with a gradient of acetonitrile in 0.014 M 
triethylamine, with its pH adjusted to 3 with trifluoroacetic acid.  The compounds 
were analyzed by TLC or MS after the removal of the solvent. 
Figure 4-15 depicts the aglycone and sugar nucleotide substrates tested in 
the assay with DesVII/DesVIII catalytic pair.  The isolated hybrid products are 
also shown.  Figure 4-16 shows HPLC traces for the assay mixtures with the 
corresponding peaks labeled.  It should be pointed out that the reactions shown in 
































R1=H, R2=H (10-deoxymethynolide, 65)
R1=OH, R2=H (methynolide, 74)

























































R1=H, R2=H (YC-17, 3)
R1=OH, R2=H (methymycin, 1)




















Figure 4-15: Macrolide aglycones and sugar nucleotides tested as substrates in the 
DesVII/DesVIII assay.  The products of reactions are also shown.
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illustrate the differences in retention times of substrate and product.  Complete 
consumption of the aglycone was observed in most cases when sufficient amount 
of donor sugar nucleotide was added.  Table 4-2 provides a summary of all the 
substrates tested and the high resolution MS and HPLC data of the isolated 
products. 
As expected, DesVII/DesVIII pair was capable of adding desosamine onto 
natural acceptors, 10-deoxymethynolide (65) and narbonolide (64) to yield natural 
products 3 and 5, respectively.  It was also able to desosaminylate hydroxylated 
aglycones 74 and 75 to yield methymycin (1) and neomethymycin (2), 
respectively.  These observations are interesting, since it has been established that 
in S. venezuelae glycosylation precedes hydroxylation in the final tailoring steps 
Minutes 






































Figure 4-16: Representative HPLC traces for the reactions catalyzed by 
DesVII/DesVIII with the following substrates: A.  10-
deoxymethynolide (65) and TDP-D-desosamine (22), B.  65 and 
TDP-D-mycaminose (25), C.  methynolide (74) and 22, D.  tylactone 
(47) and 22, E. 47 and 25. 
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(Section 1.5).  Therefore, our results indicate that DesVII/DesVIII pair is fairly 
flexible with respect to the side chains of the aglycone substrate. 
We were unable to detect any product when 15-methyl-6-deoxy-
erythronolide B (107), a methylated analog of erythromycin precursor 6-deoxy-
Table 4-2:  Summary of Glycosylation Reactionsa 
Aglycone Acceptors 
 








































ND ND ND NP NP 













90 NP ND ND ND ND ND 
a Substrates and products are numbered as in Figure 4-15.  b HPLC retention time 
(HPLC conditions are described in Section 4.2.22).  c Results of a high-resolution 
CI+ MS.  d Calculated [M+H] values.  e No product detected.  f Not determined. 
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erythronolide B (15, Figure 1-10), was used as the acceptor substrate.  Just like 
narbonolide (64), this compound is a 14-membered macrolactone, but differs from 
64 by having a hydroxyl group at C-3, instead of a keto group, additional methyl 
groups at C-10 and C-15, and the absence of a double bond at C10-C11.  Any of 
these structural variations may have contributed to the lack of recognition in the 
glycosyl transfer reaction. 
Because tylactone (47) contains two potential glycosylation sites, 3-OH 
and 5-OH, two different singly glycosylated products could be generated in our 
experiment.  Since mass spectroscopy was used to determine the chemical nature 
of the products, it is impossible to distinguish whether 112 and 48 are 
glycosylated at 3-OH or 5-OH positions.  However, it is clear that only one sugar 
is attached in both cases, and a single product is generated in each reaction.  It 
should be pointed out that the natural product, tylosin (13), made by S. fradiae, 
has a mycaminose attached at 5-OH position of tylactone, and 48 is likely an 
intermediate in the tylosin biosynthetic pathway (Figure 1-11).  Compound 112 
was previously reported by Gaisser and coworkers.83  In their study, the authors 
used a mutant of S. erythraea, erythromycin producer, capable of biosynthesizing 
TDP-D-desosamine and TDP-L-mycarose but lacking the necessary glycosyl-
transferases for their attachment and the entire polyketide synthase machinery.  
To this mutant was introduced a plasmid carrying the gene encoding the glycosyl-
transferase of tylosin biosynthesis, TylM2, (Fig. 1-11).  After feeding the mutant 
strain with tylactone, 5-desosaminyl-tylactone (112, desosaminylated at 5-OH) 
was detected in the fermentation broth, and its structure was confirmed by NMR 
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spectroscopy.83  Taking into consideration the results obtained by Gaisser and 
coworkers83 and the fact that narbonolide is also desosaminylated at 5-OH, it is 
likely that our product is also the 5-desosaminyl-tylactone (112). 
We also found that DesVII/DesVIII is able to utilize TDP-D-mycaminose 
(25) with approximately the same efficiency as its natural substrate, TDP-D-
desosamine (22).  This finding is not surprising since these two compounds only 
differ in the presence of an additional C-4 hydroxyl group in mycaminose.  Our 
previous in vivo experiments have already demonstrated S. venezuelae’s ability to 
accept various biosynthetic intermediates of desosamine, including the ones 
substituted at C-4: D-quinovose29 and 4-amino-4,6-dideoxy-D-glucose.68 
Only TDP-β-L-rhamnose (109) and not TDP-α-L-rhamnose (108) is a 
substrate for DesVII/DesVIII, and the yield of the glycosylated product 79 is 
significantly lower than those of the desosaminylated and the mycaminosylated 
compounds.  The in vivo incorporation of L-rhamnose into macrolides in 
S. venezuelae mutant has been reported by our group.84 
The fact that TDP-D-glucose (110) is not a substrate in our assay is not a 
total surprise.  This compound is an important precursor in many primary and 
secondary metabolite pathways and is abundant in the cell.  The fact that it has 
never been detected as a part of a naturally occurring macrolide structure indicates 
that it is not a substrate for this type of glycosyltransferases.  To our best 
knowledge, there is only one example in which glucose is attached to a macrolide 
moiety.  The discovery was made by Gaisser and coworkers, where mutant 
S. erythraea deficient in macrolide glycosyltransferases was able to glucosylate 
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exogenous tylactone to produce 5-O-glucosyl-tylactone.83  However, the identity 
of the responsible glycosyltransferase remains unknown.  In contrast, glucose is a 
common donor substrate for the glycosyltransferases catalyzing glycosylation of 
macrolide antibiotics as a part of the organism’s resistance mechanism 
(Chapter 3).  However, these glycosyltransferases catalyze bond formation 
between two glycosyl moieties rather than between glucose and the macrolide 
acceptor. 
Because D-quinovose is a substrate of DesVII, we expected that UDP-D-
xylose (90) may be recognized by DesVII/DesVIII as well.  However, this was 
not the case.  It is possible that DesVII/DesVIII has a strict preference for TDP 
over UDP nucleotide.  But it cannot be excluded that the absence of the methyl 
group at C-5 of xylose may also be a determining factor. 
Several of the compounds produced in this study, including 79, 111, and 
112, have not yet been found as natural products.  Out of these, 111 is a novel 
compound, which has never been reported.  The results presented here 
demonstrate that DesVII/DesVIII pair can catalyze coupling of various aglycone 
and sugar derivatives that are not their natural substrates.  Due to the limitation in 
the selection of both acceptor and donor substrates, no correlations can be made at 
this point to define the structural elements of the substrates necessary for 
recognition by the catalyst(s).  Nevertheless, the development of an in vitro 
system greatly simplifies such structure activity relationship studies.  More 
importantly, the data collected in the presented work, combined with the previous 
 247
in vivo studies have clearly established the feasibility of glycodiversification of 
macrolides by using the glycosyltransferase systems. 
4.3.8E The Place of DesVIII Among Its Homologues 
The BLAST search of the protein database led to a number of DesVIII 
homologues in bacterial genomes.  On the top of the list are thirteen proteins (at 
the time of writing, including DesVIII) whose catalytic functions are associated 
with the biosynthesis of glycosylated secondary metabolites in bacteria, for the 
most part streptomycetes.  The majority of them have been assigned as 
tautomerases or 3,4-isomerases, just as DesVIII was speculated initially.  
Generally, they are charged with the biosynthesis of a specific sugar unit in each 
respective pathway.  They all have an end-to-end similarity to P450 hydroxylases 
but lack the P450 signature motif, including the heme-ligating invariant cysteine 
residue.   
These DesVIII homologues are followed by a large number of authentic 
bacterial P450 enzymes which have a typical P450 signature motif and an 
                        390                ↓        420 
     P450, B. subtilis  TRSP---NPHLSFGHGHHVCLGSSLARLEAQ 
     P450, M. ulcerans  TRANA--NRHLAFSGGRHFCLGAALARVEGE 
    P450, G. violaceus  TRVD---NRHLAFGDGIHHCFGGPLARVEGQ 
     P450, C. watsonii  QRS----NRNLPFGGGIHFCLGAFLARLQGQ 
       P450, M. leprae  DRPS---SRHLAFAVGSHFCLGAALARLEAT 
    DesVIII, S. venezu  ARPDA--AAHLALHPAGPYGPVASLVRLQAE 
    DnrQ, S. peucetius  DRPRSPGFTHMALAGRDHLGLVAPLVRVQCT 
    EryCII, S. erythra  DRPD---ADRALSAHRGHPGRLEELVTALAT 
             Consensus   R     N HLAFG G H CLGASLARLEA  
Figure 4-17: Alignment of selected DesVIII homologues and bacterial 
cytochrome P450 enzymes.  Shown in bold is the bacterial P450 
signature motif: F G X G X H/R X C L G/A with the heme-ligating 
cysteine marked with ↓.  These features are absent in DesVIII, 
DnrQ, and EryCII. 
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invariant cysteine residue.  Protein sequence alignment of these P450 enzymes 
(only those more similar to DesVIII were selected) with DesVIII and its 
“tautomerase” homologues (Figure 4-17) shows that, despite an overall 30–40% 
sequence identity with DesVIII, these two groups of enzymes are clearly 
different.  Figure 4-18 depicts a phylogenetic tree illustrating the degree of 
sequence similarity between DesVIII and its closest homologues among 
“tautomerases” and P450s.  It is apparent that the degree of sequence homology 
between different DesVIII homologues shows correlation with the structure of the 
acceptor substrate being glycosylated, whether it is a macrolide or an aromatic 
polyketide, and whether it has sugar moieties attached to it already.  This is 
consistent with the fact that DesVIII, and most likely its homologues, are involved 




















































































































































Figure 4-19 A: Structures of the macrolide compounds discussed in the text and 
the relevant portions of their biosynthetic gene clusters. 
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 There is little biochemical data available on the specific function of any of 
the DesVIII homologues involved in the biosynthesis of glycosylated polyketides.  
Their functions have been tentatively assigned based only on gene knockout 
experiments and/or sequence comparison.  Figure 4-19 provides the structures of 
the representative polyketides and the corresponding putative glycosyltransferases 
for each glycosylation step.  The order of glycosylations in each compound is also 
shown, when known. 
The closest DesVIII homologue, NbmC (70% identity), is a part of 
narbomycin (5) biosynthesis in Streptomyces narbonensis and presumably has the 
same function as DesVIII.43  Genes encoding MydC (42% identity to DesVIII) 
and TylM3 (34%) are found in the biosynthetic clusters of mycinamicin II (113, 
Micromonospora griseorubida)85 and tylosin (13, S. fradiae),46 respectively, and 
are involved in the biosynthesis or attachment of the first sugar moiety to the 
aglycone.  OleP1 (30%) of oleandomycin (9, S. antibioticus),45 EryCII (31%) of 
erythromycin (6, S. erythraea),47 and MegCII (29%) as well as MegDVI (35%) of 
megalomicin (114, Micromonospora megalomicea)86 biosynthetic pathways are 
involved in the attachment of sugar moieties to already glycosylated macrolides 
(Figure 4-19 A).  DnrQ (35%), SnogN (33%), AknT (33%), and RhoF (33%) are 
involved in the glycosylation of aromatic polyketides doxorubicin (115, 
S. peucetius),87 nogalamycin (116, Streptomyces nogalater),88 aclarubicin (117, 
Streptomyces galilaeus),89 and β-rhodomycin II (118, Streptomyces violaceus),90 
respectively (Figure 4-19 B). 
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Interestingly, in twelve of the thirteen cases these glycosylated metabolites 
contain an amino sugar and the DesVIII homologues are likely involved in the 
biosynthesis or attachment of the amino sugar in the respective pathways.  The 
exception is the DesVIII homologue encoded by lkm32 from the biosynthetic 
gene cluster of lankamycin in Streptomyces rochei.91  Lankamycin (not shown) 
does not contain an amino sugar moiety.  In this case, however, the identified 
gene cluster is not a part of the chromosome but part of a plasmid, which could be 


































































Figure 4-19 B: Structures of the aromatic polyketides discussed in the text and the 
relevant portions of their biosynthetic gene clusters. 
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 Another interesting feature of the pathways including a DesVIII 
homologue is the location of this homologous gene in each gene cluster.  The 
sugar biosynthetic genes found in the gene clusters of polyketide secondary 
metabolites are generally clustered, but their relative arrangement can be different 
from case to case.  The genes homologous to desVIII, however, are almost always 
followed by a glycosyltransferase gene (Figures 4-19 A and B), and each pair is 
involved in the biosynthesis or attachment of the same sugar moiety.  Out of the 
thirteen cases discussed here, the only exception is the nogalamycin gene cluster 
of S. nogalater, where desVIII homologue, snogN, is followed by snogG2 
encoding a putative C-methyltransferase.88  This, however, may be related to the 
special mode of attachment of an amino sugar moiety to an aromatic aglycone, in 
which formation of a C-C bond occurs in addition to the glycosidic coupling. 
Overall, the consecutive arrangement of desVIII and desVII, and in many 
other cases, can be considered a general trend.  Recognition of this pattern is 
useful in the assignment of gene functions in other biosynthetic clusters or in the 
prediction of the structures of unidentified secondary metabolites. 
 Because of the likely connection between the presence of desVIII 
homologues in the biosynthetic gene clusters and amino sugars in the produced 
compounds, it is tempting to assume that DesVIII homologues are specifically 
required for the transfer of amino sugars.  However, our in vitro experiments 
demonstrate that DesVII/DesVIII pair can also catalyze the attachment of L-
rhamnose, and the glycosyl transfer is undetectable in the absence of DesVIII.  It 
is conceivable that DesVIII and its homologues are coevolved with the 
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corresponding “DesVII” to catalyze the amino sugar transfer.  This protein pair 
works synergistically even when a neutral sugar is used as an alternative 
substrate. 
However, there exist some glycosyltransferases involved in the attachment 
of amino sugars in the biosynthesis of secondary metabolites that are not 
accompanied by a DesVIII equivalent.  These include GtfC and GtfD 
participating in the biosynthesis of vancomycin and teicoplanin, respectively, both 
of which are nonribosomal derived peptide antibiotics.9, 10  Likewise, FscMI, the 
glycosyltransferase involved in polyene macrolide antibiotic FR-008 biosynthesis 
also lacks a DesVIII equivalent.92  These exceptions may be due to the different 
mechanisms of glycosylation and/or the differences in the structures of aglycones. 
4.3.8F Role of DesVIII in Glycosylation Reaction: Initial Studies 
It is evident from the results discussed above that the glycosyl transfer 
reaction requires DesVII, and the presence of DesVIII substantially increases the 
glycosyl transfer efficiency.  However, DesVIII is not absolutely required for 
glycosyl transfer, since low conversion of glycosylation is still possible in its 
absence under alkaline conditions.  Because DesVII performs the actual chemical 
reaction of glycosyl transfer in methymycin/pikromycin biosynthesis, the role of 
DesVIII in this process, although identified as being important, is not immediately 
apparent.  Our attempts to investigate its function were hampered by the 
difficulties encountered in obtaining pure DesVIII sample.  Therefore, only 
preliminary results and qualitative trends of its characterization are reported here. 
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Probing Protein-Protein Interactions between DesVII and DesVIII.  In our 
search of appropriate assay conditions, we observed that increasing the amount of 
DesVIII with the constant amount of DesVII resulted in the increase in the % 
conversion (See Figure 4-21 for an example showing such a trend).  In order to 
determine an optimal molar ratio of DesVII to DesVIII it is important to establish 
that there is an interaction between DesVII and DesVIII.  Two different methods 
were used to probe protein/protein interactions. 
Size exclusion chromatography was performed on individual DesVII and 
DesVIII proteins, and the DesVII/DesVIII mixture.  The FPLC trace of 
DesVII/DesVIII mixture is practically superimposed to the individual traces of 
DesVII and DesVIII, and no protein peak with a molecular mass corresponding to 
the sum of these two proteins (at least 90 kDa, depending on subunits’ ratio and 
number) was detected.  However, the results were complicated by the fact that 
significant amounts of DesVIII was in the aggregated state.  Therefore, even 
though there exists no obvious interaction between DesVII and DesVIII proteins, 
the results are not conclusive. 
The Far Western blot analysis is another method employed to probe the 
DesVII/DesVIII interaction.  In this experiment, untagged DesVIII-1 was first 
separated by SDS-PAGE and transferred to a nitrocellulose membrane.  The 
membrane was then exposed to the solution containing DesVII-C-His, washed, 
and probed with an anti-histidine antibody.  The detection of a chemiluminescent 
band on the membrane would indicate the presence of a ternary complex between 
antibody, DesVII-C-His, and the immobilized DesVIII-1.  Unfortunately, despite 
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many attempts, no such band was detected.  Therefore, this experiment also failed 
to show the interaction between DesVII and DesVIII.  It is possible that transfer 
of DesVIII to the membrane in the presence of methanol irreversibly changed its 
conformation or the conformation of the crucial recognition motifs.  It is also 
possible that during the transfer, blocking or the washing steps, DesVIII simply 
denatures, since, as it has been before, DesVIII tends to form inclusion bodies 
during purification.  Therefore, this method might also be unreliable in 
determining protein interaction in our system. 
The data obtained here do not support the protein-protein interaction 
hypothesis between DesVII and DesVIII.  However, none of the methods used 
was completely reliable.  It should be mentioned that using a yeast two-hybrid 
system, a member of our group, Allen Yu, has obtained preliminary results 
indicating the existence of interaction between DesVII and DesVIII in vivo. 
Speculation of the Roles of DesVIII in Glycosyl Transfer. 
Hypothesis 1: DesVIII Serves as DesVII-reactivating Enzyme.  
Preliminary observation showed that when nearly full consumption of the 
aglycone was achieved in the presence of DesVIII and sufficient amount of sugar 
substrate; the control reaction without DesVIII only resulted in approximately 5% 
conversion of aglycone into a glycosylated product.  Prolonged incubation did not 
improve the yield of the product in the absence of DesVIII.  We estimated that the 
amount of the product generated in the absence of DesVIII is roughly twice that 
of the amount of DesVII (two equivalents per DesVII monomer).  It appears that 
only single turnover happens when DesVII acts alone.  It is therefore possible that 
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DesVII is inactivated after each turnover and needs to be re-activated by an 
additional component, DesVIII. 
On the basis of the protein sequence analysis and the anomeric 
configuration of sugar donors and glycosylated products, DesVII is clearly an 
inverting glycosyltransferase.  Figure 4-20 A shows the established mechanism 
for this group of enzymes.  Similar to other glycosyltransferases of the GT-B 
superfamily, DesVII does not possess a DXD metal binding motif found in 
members of the GT-A superfamily.  In the enzymes of the GT-A superfamily this 
motif is used to coordinate a divalent metal, usually magnesium, which in turns 
stabilizes the leaving diphosphate group of the nucleotide. 
We speculate that in DesVII reaction, perhaps the leaving nucleoside 
diphosphate, upon its displacement by a hydroxyl group of the acceptor substrate, 
is transferred to an acceptor residue of DesVII (Figure 4-20 B).  It may remain 




























Figure 4-20: Mechanisms for inverting glycosyltransferases: (A) generally 
accepted mechanism; (B) proposed mechanism for DesVII reaction. 
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Support for this hypothesis comes from an interesting observation that the 
intensity of the TDP peak (retention time approximately 2.5 min, Figure 4-16) in 
HPLC trace of the DesVII/DesVIII reaction is higher when the amount of DesVIII 
is increased.  Preliminary data illustrating the dependence of the intensity of the 
TDP peak in an HPLC chromatogram and the extent of conversion (% conversion 
calculated from the integrations of the substrate (65) and product (3) peaks on the 
HPLC chromatogram) on the amount of DesVIII is shown in Figure 4-21.  In the 
absence of DesVII, the dependence of the TDP peak intensity on the amount of 
DesVIII exists as well (not shown).  These finding may indicate that DesVIII is 
somehow involved in the release of TDP from DesVII or directly from the donor 






































Figure 4-21: The dependence of % conversion (diamonds) and release of TDP 
(squares) on the amount of DesVIII in the DesVII/DesVIII assay.  
Release of TDP is estimated from the HPLC chromatogram as the 
ratio of the integration of peaks at 2.5 min to the sum of the peaks 
corresponding to 65 and 3.  The DesVII concentration is constant. 
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It should be noted that the DesVIII sequence does not contain a putative 
nucleotide binding domain, at least not a known one.  Thus, this proposal, 
although plausible, is largely speculative.  Additional information is definitely 
needed to determine its merit. 
Hypothesis 2: DesVIII Protects Amino Group of Sugar Moiety from 
Oxidation by P450 Enzymes.  It has been shown that the dimethylamino group of 
an unusual sugar in macrolide antibiotics, e.g. desosamine in erythromycin (R-
NMe2, where R is the remainder of sugar appendage), undergoes oxidation by 
P450 enzymes during drug metabolism in patient’s body (mainly in liver).1  The 
resulting nitrososugar (RNO) is a reactive species and binds strongly to the heme 
group of P450, forming an inactive complex.  This leads to interference with the 
metabolism of other drugs by hepatic P450s.93 
We speculate that DesVIII has evolved from P450 enzymes and has 
inherited their affinity to amino sugars of polyketides but lost the catalytic activity 
as a monooxygenase.  Therefore, it can bind amino sugars, perhaps either as a free 
compound or as a part of an antibiotic, and protects them from oxidation by 
functional P450s of the bacterium until the biosynthetic product is excreted from 
the cell.  It has been reported that hepatic P450 prefers to bind an unprotonated 
dimethylamino group,94 and this is consistent with our observation of 
DesVII/DesVIII activity at alkaline pH. 
 To probe this hypothesis, we decided to analyze the effect of P450 
enzymes on the DesVII/DesVIII activity.  A microsome preparation of human 
hepatic cytochrome P450 CYP3A4 isozyme was selected for the study.  This 
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isoform has a high affinity for macrolide antibiotics but can also oxidize other 
xenobiotics, such as testosteron and nifedipine.  Most membrane-bound enzymes, 
including cytochrome P450, are associated with microsomes.  The microsome 
preparations used in this study are derived from insect cells and also contained 
rabbit cytochrome P450 reductase.  Generally, in order to observe cytochrome 
P450 monooxygenase activity, an NADPH or an NADPH generating system has 
to be added to the assay.  However, since the binding property, not the 
monooxygenase activity, of P450 is probed in our study, no NADPH or NADPH 
generating system is needed. 
 In our experiments, microsomes were added to the DesVII/VIII assay as 
described in Section 4.2.17.  Due to the low abundance of the P450 enzyme in the 
microsome preparation, the concentration of P450 in the assay (0.13 µM) was 
lower than those of DesVII (10.5 µM) and DesVIII (7.8 µM), although the 
microsome portion constituted 17% of the assay volume.  The preliminary data 
showed some improvement in the degree of conversion from 65 to 3 (Table 4-3).  
This observed improvement was marginal in the presence of DesVIII but nearly 
doubled in the absence of DesVIII. 
 
Table 4-3:  The Effect of Cytochrome P450 on Glycosylationa 
Entry DesVIII-4 P450 % Conversion 
1 + – 93 
2 + + 99 
3 – – 4 
4 – + 10 
a The assays were run as described in Section 4.2.17 and analyzed by HPLC.  
DesVII was present in all reactions. 
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 In order to increase the amount of P450 in the assay, in a separate 
experiment, a purified human recombinant cytochrome P450 CYP3A4 enzyme 
was used (2.5 µM, concentrations of DesVII and DesVIII were as above).  
Unfortunately, there was no effect on the glycosyl transfer by this preparation of 
cytochrome P450.  Clearly, a more thorough examination of the effects of the two 
preparations of cytochrome P450 on the glycosylation reaction is necessary.  It is 
possible that variations of components other than cytochrome P450 in the 
microsomal preparation are affecting the results, most likely the components of 
the phospholipid membranes.  Preparations of P450 from other sources should 
also be tried. 
Hypothesis 3: DesVIII, as P450 Enzymes, Is Membrane Associated.  
Another explanation for the synergistic effect of DesVIII on DesVII activity, 
based on the sequence homology between DesVIII and P450 enzymes, is their 
shared affinity to membranes.  The results of the experiments described above 
suggest that phospholipids in microsomal preparations may be responsible for 
increasing the efficiency of the glycosyl transfer.  Aglycones are poorly soluble in 
water and likely bind to lipid membrane rather than circulate freely in the 
cytoplasm of the cell.  It is possible that DesVIII brings aglycone substrate, 
DesVII, and sugar donor together to facilitate the glycosyl transfer.  This 
hypothesis could also explain the tendency of DesVIII to aggregate during protein 
purification.  Although DesVIII does not have an obvious membrane binding 
domain, it may have a hydrophobic surface in its three-dimensional structure.  To 
probe this hypothesis more experiments must be conducted.  These should include 
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the effects of phospholipids and detergents on the glycosylation by DesVII alone 
and in the presence of DesVIII. 
4.4 CONCLUSIONS 
This chapter describes the investigation into the glycosylation reaction in 
the biosynthesis of macrolide antibiotics by S. venezuelae.  This study resulted in 
the purification of a recombinant glycosyltransferase DesVII, the development of 
the optimal assay conditions for the glycosyl transfer reaction, and the production 
of a few new hybrid macrolides carrying unnatural sugars.  The most significant 
discovery is the necessary requirement of an additional protein component, 
DesVIII, in the glycosyl transfer reactions.  The role of DesVIII is still elusive and 
several plausible hypotheses are suggested here.  Further exploration is necessary 
to substantiate or debunk these hypotheses.  The substrate specificity of 
DesVII/DesVIII pair was also studied. 
 This study demonstrated, for the first time, the in vitro activity of a 
glycosyltransferase involved in the biosynthesis of macrolide antibiotics.14  The 
discovery of the involvement of DesVIII in the catalysis provided evidence 
indicating the DesVII/DesVIII pair as a unique glycosylation system not reported 
before.  The presence of homologous desVII/desVIII gene pairs in other 
polyketide biosynthetic clusters points toward a more general existence of such a 
system.  This information is essential for future applications of 
glycodiversification of secondary metabolites in a combinatorial approach. 
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mRNA Messenger ribonucleic acid 
NAD+ Nicotinamide adenine dinucleotide 
NADH Nicotinamide adenine dinucleotide, reduced form 
NADPH Nicotinamide adenine dinucleotide phosphate, reduced 
NBT Nitro blue tetrazolium 
NDP Nucleoside diphosphate 
NMR Nuclear magnetic resonance 
NRPS Nonribosomal peptide synthetase 
OD600 Optical density at 600 nm 
ORF Open reading frame 
PCP domain Peptidyl carrier protein domain 
PCR Polymerase chain reaction 
PIKS Pikromycin polyketide synthase 
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TFA  Trifluoroacetic acid 
ThioR Thiostrepton resistant 
TLC Thin-layer chromatography 
TSB Tryptic soy broth 
TTP Thymidine triphosphate 
UDP Uridine diphosphate 
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